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Summary 
Cytochrome P450 (CYP) 3A is the most important subfamily of drug-metabolizing enzymes 
in humans. It exhibits broad substrate specificity and is responsible for metabolizing more 
than 50% of the currently marketed drugs, as well as endogenous substances and 
environmental chemicals. A huge number of studies on CYP3A-mediated drug metabolism 
in humans have demonstrated that the CYP3A activity exhibits marked interindividual 
variability, rendering the dosing and the therapeutic use of many CYP3A substrates difficult, 
especially those with narrow therapeutic ranges. Furthermore, a number of clinical drug-
drug interactions have been ascribed to the induction and/or inhibition of CYP3A.  
Assessing the functional CYP3A activity (phenotyping) might therefore be of clinical 
relevance to predict enzyme inhibition or induction and, as a consequence, to predict 
unwanted therapeutic outcomes such as lack of therapeutic efficacy or potentially harmful 
response due to sub-therapeutic or (severe) toxic drug levels. 
 
Several methods for CYP3A phenotyping have been published in the past, showing that 
Midazolam (MDZ) is the most suitable probe drug available at present. However, these 
methods were using either therapeutic doses of MDZ, which may cause adverse reactions, 
or, if employing lower doses, were not able to quantify the two hydroxy-metabolites. In order 
to avoid these problems, the aim of the first project (Chapter 3) was to develop a sensitive 
and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the 
quantitative determination of MDZ and two of its metabolites, 1´-hydroxymidazolam (1´-
OHMDZ) and 4-hydroxymidazolam (4-OHMDZ), in human plasma using liquid-liquid 
extraction and a stable isotope derivative as internal standard. The validation data showed 
excellent results for all the parameters studied. The analytical method has been 
successfully applied to a pharmacokinetic study, showing that MDZ and, to our knowledge 
for the first time, both hydroxy-metabolites can be determined precisely in samples obtained 
in vivo following the administration of a single sub-therapeutic oral MDZ dose (2 mg). The 
method appears therefore to be useful for low-dose CYP3A phenotyping in plasma, 
resulting in minimized adverse reactions, but larger studies are needed to proof this 
assumption. 
 
So far, CYP3A phenotyping with MDZ is based on the determination of the MDZ clearance, 
necessitating serial blood samples. Although the more recently proposed single point 
methods in plasma are less invasive, the use of oral fluid as a non-invasive matrix may be 
advantageous for assessing the CYP3A activity. Since MDZ is extensively bound to plasma 
Summary 
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proteins (96%), concentrations of free drug are expected to be very low in oral fluid and 
therefore extremely sensitive analytical methods would be required. Chapter 4 presents the 
development and validation of an LC-MS/MS method which allows for the first time the 
simultaneous determination of MDZ and two of its metabolites in human oral fluid. In a 
single subject pharmacokinetic study it has been shown that the assay is suitable for 
analyzing oral fluid samples after the administration of a therapeutic MDZ dose. MDZ oral 
fluid concentrations were roughly two orders of magnitude lower as compared to plasma. 
However, it could be shown that the kinetics of plasma and oral fluid are comparable with 
each other, resulting in a satisfactory correlation for MDZ (R2=0.972). Therefore, the method 
seems to be useful for assessing the CYP3A activity in oral fluid. 
 
To definitely confirm the results obtained in chapter 4, a randomized, two way cross-over 
study was conducted (Chapter 5) using the previously described analytical methods. Our 
main goal was to compare midazolam kinetics between plasma and saliva and to find out 
whether saliva is suitable for CYP3A phenotyping. Therefore, eight healthy subjects were 
treated with 2 mg midazolam intravenously (iv) or 7.5 mg orally (po) under basal conditions 
and after CYP3A induction with rifampicin. Our investigation demonstrated that under basal 
conditions and iv administration, midazolam and 1′-hydroxymidazolam (plasma, saliva), 4-
hydroxymidazolam and 1′-hydroxymidazolam-glucuronide (plasma) were detectable. The 
correlation between the midazolam concentrations obtained in plasma and saliva, both 
under basal conditions and after induction, was significant. After treatment with rifampicin, 
the AUC of midazolam had decreased significantly. After po administration and basal 
conditions, midazolam, 1′-hydroxymidazolam and 4-hydroxymidazolam were detectable in 
plasma and saliva. Similar to iv administration, there was a significant linear correlation 
between MDZ plasma and saliva concentration, indicating that the kinetics of MDZ can be 
reliably assessed also in saliva. After treatment with rifampicin, the AUC of midazolam and 
1′-hydroxymidazolam had decreased significantly. The results of the study also showed that 
after treatment with rifampicin, 1´-OHMDZ undergoes extensive glucuronidation, resulting in 
a decrease of 1´-OHMDZ AUC, instead of the expected increase. This is most likely due to 
an induction of UDP-glucuronosyltransferases by rifampicin. In conclusion, we provided 
evidence that MDZ and 1´-OHMDZ can be determined reliably in saliva, that the 
concentrations in saliva correlate well with those in plasma and that MDZ kinetics in saliva 
may be a useful tool to differentiate between constitutive and induced CYP3A activity. 
Therefore, saliva appears to be a suitable matrix for non-invasive CYP3A phenotyping using 
midazolam as a probe drug. 
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Chapter 6 describes a case report were we present a patient with refractory focal 
nonconvulsive status epilepticus who was treated with very high doses (up to 4 mg/min) of 
intravenous midazolam, phenytoin, carbamazepine, and other antiepileptics. From the 
literature it was known that the half-life of midazolam can increase at high dosage. 
Therefore, the kinetics of midazolam (MDZ), 1´-hydroxymidazolam, and 4-
hydroxymidazolam were assessed at steady state (dosage 1 mg/min) and after stopping the 
treatment. The results showed that the total body clearance of MDZ and intrinsic hepatic 
clearance at steady state were both 5 to 10 times higher than after normal therapeutic 
doses, demonstrating hepatic CYP3A induction. Despite the high body clearance, we 
observed a substantially prolonged terminal half-life of midazolam, mainly due to an 
extraordinarily large volume of distribution caused by saturation of protein binding. The free 
fraction of MDZ at steady state was much higher as compared to normal therapeutic doses. 
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1 Introduction 
1.1 General introduction: Drug biotransformation 
During lifetime, most of us are exposed to a wide variety of drugs (and xenobiotics). Most of 
these pharmacologically active substances are lipophilic and require an enzymatic 
biotransformation into more polar derivatives before elimination can take place. The major 
organ for drug metabolism is the liver. Other sites include epithelial cells of the 
gastrointestinal tract, kidneys, lungs, and the skin. 
Drug biotransformation reactions can be classified into two phases, phase I and phase II.  In 
phase I, polar functional groups (e.g. hydroxyl groups) are either introduced or unmasked, 
which results in (more) polar metabolites of the original drug. Typical phase I reactions are 
oxidation, reduction or hydrolysis. If the metabolites of phase I reactions are sufficiently 
polar, they may be readily excreted at this point. Phase II involves the conjugation of the 
parent drug or its more polar phase I metabolite(s) with an endogenous substrate (such as 
glucuronic acid, sulphate, an amino acid, acetate or glutathione) rendering it more water 
soluble to assist excretion. Figure 1 shows the different phase I or II enzymes and their 
relative contribution on total drug metabolism. 
 
 
Figure 1. Drug metabolising enzymes in human: The relative contribution on total drug metabolism is 
estimated by the relative size of each section (Evans and Relling, 1999).  
Phase I enzymes (modification of function groups, left): ADH: alcohol dehydrogenase; ALDH: 
aldehyde dehydrogenase; CYP: cytochrome P450; DPD: dihydropyrimidine dehydrogenase; NQO1: 
NADPH quinone oxidoreductase or DT diaphorase. 
Phase II enzymes (conjugation with endogenous substituents, right): COMT: catechol O-
methyltransferase; GST: glutathione S-transferase; HMT: histamine methyltransferase; NAT: N-
acetyltransferase; STs: sulfotransferases; TPMT: thiopurine methyltransferase; UGTs: uridine-
diphosphate-glucuronosyltransferases. 
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As mentioned introductorily, drug biotransformation leads in general to more polar, water-
soluble metabolites that can be well excreted, resulting in the detoxification of a drug. In 
some cases however, formation of carcinogenic or toxic metabolites through 
biotransformation can also occur (toxification). Additionally, metabolism can convert inactive 
or less active xenobiotics (so-called prodrugs) into pharmacologically (more) active 
metabolites (e.g. conversion of levodopa to the active dopamine). 
Orally administered drugs are mainly absorbed by the digestive system and enter the 
hepatic circulation through the portal vein. Some drugs (e.g. propranolol) are so extensively 
metabolised by the liver that only a small amount of unchanged drug may enter the 
systemic circulation, which results in a reduced bioavailability of the drug (so-called “first-
pass effect”) (Langguth et al., 2004; Mutschler, 1996). 
 
 
1.2 Cytochrome P450 enzymes 
The cytochrome P450 (CYP) superfamiliy is the major enzyme family responsible for the 
oxidative (phase I) biotransformation of a variety of xenobiotics including drugs and 
carcinogens (Omura and Sato, 1964; Wrighton et al., 1996). Beside involvement in drug 
metabolism, CYPs also play an important role in the biotransformation of endogenous 
substrates, such as cholesterol biosythesis and metabolism, bile-acid biosythesis, steroid 
synthesis and metabolism vitamin D3 synthesis and metabolism, and retinoic hydroxylytion 
(Nebert and Russell, 2002). 
CYPs are heme-containing proteins that have been characterised in many species including 
bacteria, plants, fungi and mammals (Nebert and McKinnon, 1994). In mammalian cells, 
CYPs are predominantly localised along the membrane of the smooth endoplasmatic 
reticulum of the liver; but they are also expressed in extrahepatic tissues such as intestine, 
lungs, kidney, brain and placenta. The monooxygenases mediate oxidation reactions, 
where an incorporation of one oxygen atom from O2 into the target molecule takes place, 
while the remaining oxygen atom is reduced to water:  
R-H + O2 + NAD(P)H + H+ Æ  R-OH + H2O + NAD(P)+ 
The CYP enzymes are conveniently arranged into families and subfamilies on the basis of 
percentage homology in the amino acid sequence. Enzymes that share at least 40% identity 
are assigned to a particular family, denoted by an arabic numeral, whereas those sharing 
>55% homologies are grouped in the same subfamily, designated by a letter (Nebert et al., 
1987). Subfamilies are often further divided into isoenzymes (arabic numeral), many of 
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which have specific drug substrates. To date, at least 18 CYP gene families have been 
identified in mammals (Table 1).  
 
Table 1. Substrates and functions of human CYP gene families (Nebert and Russell, 2002) 
 
 
Three main CYP gene families, CYP1, CYP2, and CYP3, are responsible for the 
biotransformation of many drugs and xenobiotics in humans (Nelson et al., 1996).   
More than 90% of drug oxidation can be attributed to six main cytochromes: CYP1A2, 2C9, 
2C19, 2D6, 2E1 and 3A4 (Table 2).  
 
Table 2. Major human cytochrome P450 (CYP) enzymes and drug substrates 
CYP Drug substrate 
1A2 Caffeine, clozapine, phenacetin, theophylline 
2C9 Diclofenac, ibuprofen, losartan, phenytoin, S-warfarin 
2C19 Diazepam, omeprazole, propranolol, progesterone, R-warfarin 
2D6 Codeine, dextrometophan, fluoxetine, flecainide, imipramine, propaphenone, 
propranolol, sparteine 
2E1 Ethanol, halotan 
3A4(/5) Atorvastatin, erythromycin, dapson, diazepam, felodipine, midazolam, nifedipine, 
ritonavir, tacrolimus, testosterone, verapamil 
Introduction 
18 
However, these CYP enzymes are often showing an overlapping substrate specificity, so 
that one specific substrate may be metabolised by more than one enzyme (Nelson et al., 
1996).  
Among the different cytochromes, CYP3A is the most important drug-metabolising 
subfamily in humans.  
 
 
1.3 CYP3A subfamily 
Four members of the CYP3A subfamily, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, have 
been identified so far. Their genes are arranged in tandem on chromosome 7q21 (Gellner et 
al., 2001; Krishna and Shekar, 2005). Members of this subfamily are involved in many 
clinically important drug-drug interactions (Slaughter and Edwards, 1995). The wide 
substrate spectrum of CYP3A is the reason behind. 
CYP3A4 is the major phase I metabolising enzyme in humans. It exhibits broad substrate 
specificity and is responsible for metabolising more than 50% of the currently marketed 
drugs, as well as steroids and environmental chemicals. CYP3A4 also activates 
procarcinogens such as aflatoxin B1 and polycyclic aromatic hydrocarbons (Guengerich, 
1999). CYP3A4 is the major form present in the liver and the small intestine, accounting for 
30% and 70% of the total amount of CYP enzymes, respectively (Shimada et al., 1994; 
Thummel and Wilkinson, 1998). The location of CYP3A4 in the intestine and liver makes it 
well suited to play a significant role in first-pass drug metabolism. CYP3A protein amount 
and catalytic activity decreases longitudinal along the small intestine (Doherty and 
Charman, 2002). In the kidney, CYP3A4 is present in only about 30% of renal tissue 
samples. Typical substrates of this enzyme are shown in Table 2. Marked interindividual 
variations in CYP3A4 activity (up to 20-fold) are seen in the human population (Shimada et 
al., 1994; Wilkinson, 1996) which does not appear to be caused by genetic polymorphism 
(see 1.3.1.1). 
CYP3A5 was isolated from a liver cDNA library and was first termed PCN3, sharing 85% 
sequence similarity with CYP3A4 (Aoyama et al., 1989). It is a polymorphic expressed form, 
which is present in the liver of about 20% of Caucasians and in more than 50% of African-
American subjects (Daly, 2006; Kuehl et al., 2001). In individuals who express CYP3A5 in 
the liver, it represents up to 50% of the total hepatic CYP3A content. CYP3A5 is the most 
common CYP3A isoform in the human kidney and is also distributed in other organs and 
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tissues such as lung, prostate, colon or the intestine (Daly, 2006; Thummel and Wilkinson, 
1998).  
CYP3A7 was originally found in the fetal liver and accounts for between 30% and 50% of 
the total CYP content in this tissue (Shimada et al., 1996). It has been shown that CYP3A7 
is expressed in placental and endrometrial microsomes that increases dramatically from the 
first to the second trimester of pregnancy (Schuetz et al., 1993). The level of expression of 
CYP3A7 varies with gestational age and is higher in the 20-week fetus than compared to 
the fetus at 40 weeks of age, and decreases dramatically after birth (Kitada and Kamataki, 
1994; Kitada et al., 1987). It is now apparent that CYP3A7 is also expressed in adult livers 
(Koch et al., 2002). Other tissues expressing CYP3A7 in adults include intestine, 
endometrium, adrenal gland and prostate (Burk et al., 2002; Koch et al., 2002; Schuetz et 
al., 1993). 
CYP3A43 is the most recently discovered member of the CYP3A family (Domanski et al., 
2001; Gellner et al., 2001). Although the expression of CYP3A43 in fetal as well as in adult 
liver is low, there is significant extrahepatic expression, with relatively high mRNA levels 
being observed in the prostate and testis (Gellner et al., 2001; Westlind et al., 2001). 
CYP3A43 is expressed at 0.1% and 2% of the levels of CYP3A4 and CYP3A5 (Westlind et 
al., 2001). 
 
1.3.1 Factors which may influence the CYP3A activity 
Currently, most medications are dosed based upon the assumption that each individual in 
the general population metabolises drugs at approximately the same rate. However, it has 
been demonstrated that the activities of CYP enzymes show marked interindividual 
variations (up to the 100 fold for CYP3A activity) (Lin and Lu, 2001), which may lead to 
unwanted therapeutic outcomes such as ineffectiveness or potentially harmful response due 
to sub-therapeutic or toxic drug levels.  
Many different factors may influence the hepatic and intestinal CYP3A activity which makes 
the dosing and therapeutic use of many CYP3A substrates difficult, especially those with a 
narrow therapeutic range.  
 
1.3.1.1 Genetic variability 
A genetic polymorphism, which is a monogenetic trait, expressed in at least two distinct 
phenotypes, each in a frequency >1% within a population, may account for a considerable 
variability (20-95%) in drug metabolism. The functional consequence of genetic variants 
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ranges from no effect to altered expression of the encoded protein and can thus result in 
treatment failure or toxic effects.  
Data from twin studies suggest that the interindividual differences in CYP3A activity are 
mainly (60-90%) determined by genetic factors rather than by environmental factors 
(Ozdemir et al., 2000). Several allelic variants have been characterised for CYP3A4 
(www.imm.ki.se/CYPalleles), most of them are single nucleotide polymorphisms (SNP) 
(Lamba et al., 2002). But these variants predict only to a very limited extent the observed 
wide interindividual variability of CYP3A4 activity (Eiselt et al., 2001). In general, with the 
exception of the CYP3A4*1B polymorphism (associated with progression of prostate 
cancer; frequency of 3.6%-9.6% of whites and 53%-67% of Africans), the SNPs described 
so far are too rare (<1% allele frequency) to be of clinical relevance (Krishna and Shekar, 
2005; Mathijssen and van Schaik, 2006; Tang et al., 2005; Wojnowski, 2004; Wojnowski 
and Kamdem, 2006).  
Several allelic variants have also been described for CYP3A5. The large interpopulation 
variation in CYP3A5 expression is largely due to a common SNP in the intron 3 of CYP3A5 
resulting in a non-functional protein. The non functional allele CYP3A5*3 frequency varies 
from 27% to 50% in blacks and 85% to 95% in whites. The CYP3A5*6 and CYP3A5*7 allel 
also translate into non-functional CYP3A5 protein and are found only in African populations 
and African-American (Jin et al., 2007). Only people with at least one CYP3A5*1 allele 
(wild-type) express large amounts of CYP3A5 (Daly, 2006; Kuehl et al., 2001). Kuehl et al. 
also showed that CYP3A5 represents up to 50% of total hepatic CYP3A content in some 
individuals. CYP3A5 might thus be an important contributor to interindividual and interethnic 
differences in CYP3A dependent drug metabolism. However, studies that have related 
CYP3A5 genotype to pharmacokinetics of midazolam (MDZ), a substrate of both CYP3A4 
and CYP3A5, show discrepancies in the outcome. Two studies suggest that CYP3A5*1 
heterocygotes show faster MDZ clearance than CYP3A5*3 homozygotes, while results of 
other studies indicate that the genetic variants identified so far in CYP3A4 and CYP3A5 
genes have only a limited influence on in-vivo MDZ clearance (Eap et al., 2004c; Floyd et 
al., 2003; He et al., 2005; Shih and Huang, 2002; Wong et al., 2004). Further studies are 
necessary to prove the impact of genetic variants on CYP3A mediated drug metabolism in-
vivo.  A few studies have suggested an association between CYP3A5 genotype and blood 
pressure and/or risk of hypertension; but the data were inconsistent. In a recent study, 
Langaee et al. has shown that CYP3A5 polymorphism does not appear to contribute 
importantly to blood pressure or risk of hypertension, but may influence response to calcium 
channel blockers in some populations (Langaee et al., 2007). Jin et al. has demonstrated 
that CYP3A5 plays an important role in the metabolism of verapamil in vivo, which has been 
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used clinically for the treatment of hypertention. CYP3A5 genotype is associated with 
variations in verapamil disposition and response in healthy volunteers (Jin et al., 2007). 
 
1.3.1.2 Concurrent exposure to drugs or other environmental chemicals 
A drug interaction occurs when the disposition of one drug is altered by another drug, food, 
drink or environmental chemical agent. This can lead to changes in drug metabolism which 
may affect pharmacokinetics of the drug and its clinical effects.  
Induction and inhibition of metabolising enzymes are the two main mechanisms for 
interactions between drugs. Enzyme induction usually may lead to decreased plasma drug 
concentration and reduced pharmacological effect due to an increase in drug metabolism. 
In some cases, the metabolites formed during biotransformation may be chemically 
reactive, so that enzyme induction also may result in increased toxicity caused by the 
increased production of toxic metabolites. Enzyme inhibition may lead to an enhancement 
in systemic drug exposure and therefore potentially to toxic effects. Inhibition, the most 
important mechanism for drug interactions, is especially of great importance when patients 
receive drugs with narrow therapeutic ranges.  
CYP3A activity can be inhibited and induced by a wide variety of drug substances. The 
clinically most relevant of these are listed in Table 3 (Shapiro and Shear, 2002; Sikka et al., 
2005).  
Several mechanisms of inhibition are possible. Azole antifungals, such as ketoconazole, 
act via competitive inhibition (most common inhibition mechanism) by rapid, reversible 
binding of the inhibitor to the active site of CYP3A. This type of inhibition is transient and 
normal activity returns once the inhibitor has been cleared. A well-known example is the 
interaction observed in some patients on co-administration of the antihistamine terfenadine 
and an inhibitor of CYP3A such as ketoconazole. Inhibition of this enzyme markedly 
elevates the terfenadine levels, leading to the inhibition of cardiac potassium levels and, in 
consequence, to a sometimes fatal cardiac arrhythmia (Wilkinson, 1996). Irreversible, 
mechanism-based inhibition occurs if a substrate binds to CYP3A and alters its structure 
(e.g. ethinylestradiol) (Thummel and Wilkinson, 1998). 
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Table 3. Inhibitors and inducers of CYP3A  
 
 
 
 
CYP3A induction is generally considered clinically less important than its inhibition 
because it is expected to reduce the plasma concentration of co-administerd CYP3A 
substrate drugs rather than to impair their safety (Burk and Wojnowski, 2004). However, the 
loss of efficacy also has a divesting effect on the treatment of life-threatening diseases, 
such as cancer, organtransplatation, and so on. CYP3A undergoes induction in the liver and 
also in the small intestine (Kolars et al., 1992; Schuetz et al., 1984). Enzyme induction 
refers to an increase in enzyme activity, which results usually from increased enzyme 
production through enhanced translation and transcription. One of the most effective 
inducers of CYP3A expression, both in-vitro and in-vivo, is the macrocyclic antibiotic 
rifampicin. In contrast to the immediate response of CYP inhibition, induction is a gradual 
process over time (Goodwin et al., 2002; Thummel and Wilkinson, 1998). The inducibility of 
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CYP3A expression, coupled with the remarkable versatility of CYP3A catalytic activities, 
creates the potential for drug-drug interactions. 
On the transcription regulation side, the pregnane X receptor (PXR), a member of the 
nuclear receptor superfamily, has been identified as a major regulator of CYP3A expression 
and the mediator of CYP3A induction by xenobiotics. PXR is highly expressed in the liver 
and intestine. The mechanism proposed for rifampicin (ligand of PXR) induced CYP3A 
induction is shown and explained in Figure 2 (Chen and Raymond, 2006; Goodwin et al., 
2002). CYP3A turned out to be inducible also by the constitutive androstane receptor (CAR) 
(Wojnowski, 2004). (Note: Rifampicin also acts as an inducer of P-glycoprotein (P-gp) and 
UDP-glucuronosyltransfease 1A through PXR, (Chen and Raymond, 2006)) 
 
PXR
Rif
Promotor ORF Encreasedexpression
Increased
transcription
Rif RXR
PXR RXRPXR
Rif RXRPXR
Rif
NucleusCytoplasm
 
Figure 2. Transcriptional activation of rifampicin target genes.  
Rifampicin binds with PXR in the cytoplasm (activation), which induces a conformational change 
within the receptor, and enters into the nucleus to form a heterodimer with the retinoic acid receptor 
RXR (co-activator protein). The heterodimer binds to the promoter of the target gene to activate the 
transcription of its open reading frame (ORF). 
 
 
Although the majority of CYP3A4 mediated interactions occur within the liver, the enzymes 
in the intestine may also play a significant role in this process. For instance, grapefruit juice 
has been shown to be an important dietary component inhibiting enteric CYP3A4. 
Kupferschmidt et al. has shown that the bioavailability of MDZ increased by 46% after 
ingestion of grapefruit juice (Kupferschmidt et al., 1995). 
Finally, CYP3A4 is the most important CYP3A member with regards to involvement in 
clinically significant drug interaction. CYP3A5 mediated drug metabolism is unlikely to be of 
relevance in individuals exposed to inducers (Daly, 2006). 
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1.3.1.3 Expression levels of nuclear receptors 
In human liver, high correlations have been descibed between mRNA levels of PXR and 
CYP3A4 (r2 = 0.68), between CAR and CYP3A4 (r2 = 0.89) and between CAR and PXR (r2 
= 0.71 to 0.86) (Chang et al., 2003; Pascussi et al., 2001). These observations suggest that 
the expression levels of CAR and PXR might be a major determinant in the individual 
CYP3A4 expression. PXR polymorphisms may play a role in the observed interindividual 
CYP3A variability (Hustert et al., 2001). 
 
1.3.1.4 Others 
Inflammatory bowel disease and cirrhotic liver disease are known to decrease the content 
and activity of CYP3A in these tissues (Iqbal et al., 1990; McConn et al., 2009; Morgan, 
2009; Paintaud et al., 1996). Cotreau et al. have reviewed studies on age dependent 
pharmacokinetics of CYP3A substrates and found a decreased clearance of CYP3A 
substrates in elderly people (Cotreau et al., 2005). Furthermore, aging affects many 
physiological factors that influence drug disposition, such as liver mass, liver blood flow and 
plasma protein binding (Kinirons and O'Mahony, 2004). The majority of in vivo-studies 
investigationg sex-based differences indicate that woman exhibits faster clearance for 
drugs that are CYP3A (and P-glycoprotein) substrates than men. Noumerous compounds 
have been utilized for that purpose (for review (Scandlyn et al., 2008)) (Chen et al., 2006; 
Gandhi et al., 2004). However results have been conflicting. Drugs that are only CYP3A, but 
not P-gp, substrates, did not exhibit gender dependent differences in pharmacokinetics. 
Overall, those findings suggested a sex-based differences may actually caused by P-gp 
(Cummins et al., 2002). Gorski et al. has reported a sex-related difference in the extent of 
intestinal and hepatic induction by rifampicin. Women had a significantly higher clearance 
than men, whereas men had a significantly greater induction of oral clearance than women 
(Gorski et al., 2003). During pregnancy hepatic and/or intestinal CYP3A and P-gp activities 
are increased (Hebert et al., 2008).   
 
 
1.4 Phenotyping  
Pronounced interindividual differences in drug disposition are mainly caused by differences 
in the activity of drug metabolising enzymes in the liver and the small intestine. As 
mentioned before, the variable activities have been ascribed to genetic variations, 
environmental factors and physiological factors such as inflammation or hepatic diseases. 
Patients with unusually high or low activity of metabolising enzymes might be of increased 
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risk for subtherapeutic or toxic response to many commonly used medications. Therefore, 
characterising of drug metabolising enzymes in an individual patient is important to 
maximise clinical drug safety and to minimise the occurrence of adverse drug reactions 
(Bachmann, 1996). 
Using modern techniques, such as polymerase chain reaction (PCR), single base primer 
extension or gene sequencing, genotyping allows the characterisation of many significant 
CYP genes and the identification of SNPs (Bachmann, 2002; Tribut et al., 2002). However, 
genotyping alone does not succeed to predict the variable CYP expression enough. The 
optimal method to measure the real-time activities (functional expression) of drug 
metabolising enzymes is phenotyping, where the metabolism of a specific probe-drug 
(which is ideally a simple, fast, cheap, easily to administer and detectable compound and 
which is metabolised by the enzyme of interest) is used to estimate the activity of the 
enzyme involved in its metabolism. The individual ability to metabolise this probe-drug is 
measured by determining the circulating or excreted concentrations of the drug or its 
metabolites. Although it is often more time-consuming compared to genotyping, 
phenotyping provides the most clinically relevant information because it reflects the 
combined effects of genetic, environmental and endogenous factors on the activity of CYPs. 
Criteria for the validation of probe-based phenotyping are shown in Table 4 (Bachmann, 
2002; Watkins, 1994; Zaigler et al., 2000). 
 
Table 4. Criteria used for the validation of probe-based methods for phenotyping CYP activity  
• Correlation with the activity of the target enzyme determined in human liver biopsies 
• Correlation with the content of the target enzyme determined in human liver biopsies 
• Correlation with the fractional clearance of the probe drug mediated by the target enzyme 
• Correlation with other validated phenotyping procedures for the enzyme 
• Reduction in enzyme activity in subjects treated with known inhibitors of the target enzyme  
• Increase in enzyme activity in subjects treated with known inductors of the target enzyme  
• Reduction in the in-vivo measure of enzyme activity in patients with severe liver disease  
• Marked reduction during the anhepatic phase of liver transplant phase 
• Proven in-vitro specificity of the metabolic step used 
• Reproducibility 
• Results reflect genetic polymorphism (if present) 
• Lack of dependence on confounding factors (e.g. urinary flow, creatinine clearance, activity of 
other enzymes) 
• Adherence of analytical assays for the substances to general validation criteria 
• Low invasiveness (drug well tolerable, no blood sampling, no radioactivity) 
• Technical ease of the procedure  
• Inexpensive procedure 
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Using the probe-drug approach, the activity of the specific enzyme of interest in-vivo is best 
estimated by determining the clearance of the probe. If the probe has multiple metabolic 
pathways involving several enzymes, the partial clearance corresponding to the pathway 
specifically catalysed by the enzyme phenotyped should be an appropriate measure. 
However, to determine the clearance precisely, multiple blood samples are required. In 
order to minimise sampling, metabolic ratios based on single-point measurements of the 
parent drug and its respective metabolites at an appropriate time is an alternative approach. 
If the concentrations of parent drug and metabolite measured in oral fluid or urine are 
correlated with those in plasma, the use of these non-invasive matrices could be 
advantageous (Zaigler et al., 2000).  
 
1.4.1 Phenotyping of CYP3A 
As CYP3A is the most abundant CYP enzyme in humans and is known to be responsible 
for metabolising more than 50% of the currently marketed drugs, CYP3A phenotyping has 
been the subject of numerous investigations; especially because CYP3A4 is the most 
important CYP3A member with regards to involvement in clinically significant drug 
interactions. 
The CYP3A probe is defined as any drug whose metabolism is principally or uniquely 
catalysized by CYP3A. Thus, the amount of drug’s metabolite(s) generated through CYP3A-
mediated metabolic pathway(s) can be used to reflect the level of the enzyme activity (Liu et 
al., 2007). Several CYP3A probes have been proposed so far, including midazolam, 
triazolam, testosterone, 14C-erythromycin, cortisol, dapsone, alfentanil, dextromethorphan, 
nifedipine and lidocaine (Liu et al., 2007; Streetman et al., 2000). The advantages and 
disadvantages of some probe drugs are summarised in brief in Table 5 (Streetman et al., 
2000). Unfortunately, none of these test probes meet all the criteria listed in Table 4 and, in 
addition, the correlation between the test procedures is not satisfactory (see 1.4.2)  
The erythromycin breath test and the MDZ plasma clearance seems to be the best methods 
for phenotyping CYP3A at present. These two phenotyping procedures will be described in 
more detail in the next two chapters; an excellent review of other proposed CYP3A probes 
is given by Streetman et al. or Watkins (Streetman et al., 2000; Watkins, 1994). 
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Table 5. Summary of advantages and disadvantages associated with various proposed CYP3A 
probes 
 
 
 
1.4.1.1 [14C N-methyl] erythromycin breath test (EMBT) 
The EMBT has been developed by Watkins (Watkins et al., 1989). Subjects were given a 
small dose (< 0.1μmol) of [14C] N-methyl erythromycin intravenously which undergoes N-
demethylation, mediated exclusively by CYP3A4 (not CYP3A5). Because the carbon atom 
in the cleaved methyl group largely appears in breath as 14CO2, the activity of CYP3A4 is 
reflected in the rate at which breath 14CO2 is produced (Baker et al., 1983; Watkins et al., 
1989; Wrighton et al., 1990). Currently, the EMBT uses a single 20 min breath sample for 
estimating the enzyme activity (Turgeon et al., 1994). This offers the advantage of an 
indirect but rapid measure of CYP3A4 activity. 
The EMBT has been validated according to most of the criteria given in Table 4. The results 
of EMBT phenotyping show a significant correlation with the concentration of CYP3A4 
protein from liver biopsy samples, but not with the hepatic content of other CYP proteins 
(Lown et al., 1992). The breath test has shown to predict steady-state concentrations and 
clearance of the CYP3A4 substrate cyclosporine A (Turgeon et al., 1994; Watkins et al., 
1990). Administration of the known inhibitor troleandomycin reduced the EMBT results and 
CYP3A inducers such as rifampicin increased EMBT results (Watkins et al., 1989), 
reflecting increased CYP3A activity. It is assumed that the EMBT responds predictably to 
CYP3A4 induction or inhibition and drug-drug interaction in human (DeVane et al., 2004; 
Nicandro et al., 2007). The mean EMBT results in patients with severe liver diseases is far 
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below that observed in subjects with normal liver function (Lown et al., 1992). Changes in 
volume of distribution (Vd), hepatic extraction ratio as well as protein binding can affect the 
results of EMBT (Lane and Parashos, 1986; Watkins, 1994). 
Beside the high expression of CYP3A in the liver, the small intestine is the second major 
site of CYP3A expression in humans, where the enzyme mediates the first-pass metabolism 
of orally administered drugs. The intravenous EMBT therefore reflects only hepatic CYP3A4 
activity and is not able to fully predict the metabolic fate of oral substrates. The intravenous 
administration should avoid significant metabolism by the gut. Indeed, little CO2 was 
produced during the anhepatic phase of the liver transplant operation (Watkins et al., 1992).  
Paine et al. developed an oral stable-labeled (13C) formulation of the test with regard to 
measure aggregate liver and intestinal CYP3A4 activity (Paine et al., 2002). However, the 
oral EMBT has shown to be not suitable as an in-vivo phenotyping probe. In addition, 
erythromycin is not a “pure” CYP3A probe as it has been shown to be a substrate of P-
glycoprotein (Kim, 2002; Takano et al., 1998) a drug-efflux pump localised among others in 
the intestinal wall. 
The major disadvantage of the test is that the EMBT uses radiolabeled 14C. Although the 
required doses are low, the very long half-live of 14C raises theoretical health concerns. 
 
1.4.1.2 MDZ as phenotyping probe 
MDZ is recognised as one of the preferred in-vivo probes by the Food and Drug 
Administration (FDA) and the Pharmaceutical Research and Manufacturers in America 
(Bjornsson et al., 2003).  
MDZ as CYP3A phenotyping probe has been validated by a number of different criteria 
(Table 4). MDZ is chiefly oxidised by both, CYP3A4 and CYP3A5 (Patki et al., 2003), to 
mainly 1´-hydroxymidazolam (1´-OHMDZ). Minor metabolites are 4-hydroxy- (4-OHMDZ) 
and 1´,4-dihydroxymidazolam (see also 1.5.1). A study with human liver biopsies from 
transplant recipients has demonstrated that the total MDZ clearance in-vivo (after 
intravenous MDZ application) is highly correlated with the hepatic CYP3A content in-vitro 
and with the in-vivo clearance of a known CYP3A substrate, cyclosporine A (Thummel et 
al., 1994b). Kronbach et al. have shown that the MDZ clearance correlates with the amount 
of CYP3A4 protein, recognised by mono- and polyclonal antibodies (Kronbach et al., 1989). 
In addition, validation by other criteria has been accomplished, including the finding of 
appropriate changes in MDZ clearance after pre-treatment with potent CYP3A inhibitors 
(Olkkola et al., 1993; Olkkola et al., 1994), inducers (Backman et al., 1996a; Backman et al., 
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1996b) and in patients with severe liver disease (Pentikainen et al., 1989). Moreover, MDZ 
clearance can be influenced by hepatic blood flow (Rogers et al., 2003).  
Since CYP3A is abundant in the intestine, orally administered MDZ is subject to both 
intestinal and hepatic CYP3A metabolism. In humans, it is therefore used to measure the 
total CYP3A activity. Studies during the anhepatic phase of a liver transplant operation 
(Paine et al., 1996) have shown that the small intestine contributes significantly to the first-
pass metabolism of MDZ by mucosal CYP3A. Furthermore, in S-9 fraction prepared from 
small intestine biopsies, Lown et al. found that the rate of 1´-OHMDZ formation correlates 
significantly with CYP3A protein content (Lown et al., 1994). 
In summary, MDZ possesses many of the characteristics of an ideal CYP3A probe in 
humans: it is exclusively metabolised by CYP3A4/3A5 to a primary metabolite, 1´-OHMDZ 
(Gorski et al., 1994); the short half-life allows to estimate the area under the concentration 
time-curve (AUC) and other easily measurable pharmacokinetic endpoints with sampling 
over a limited time period; its metabolism is sensitive to altered CYP3A activity (Gorski et 
al., 2003), and it is not a substrate of P-glycoprotein (Kim et al., 1999). In contrast to EMBT, 
which only measures the hepatic CYP3A4 activity, MDZ can be administered either 
intravenously to assess hepatic CYP3A activity (systemic clearance) or orally to assess 
combined intestinal and hepatic CYP3A activity (Thummel et al., 1996; Tsunoda et al., 
1999). Furthermore, no radioisotopes are required, making it to a safer approach as 
compared to EMBT.  
MDZ clearance has proven to be an effective marker for CYP3A activity; as such, it is 
widely used for predicting CYP3A-mediated drug-drug interactions (Streetman et al., 2000). 
However, there are some disadvantages in using MDZ as phenotyping probe including the 
production of sedative or amnesic effects in some subjects, the need of relatively complex 
analytical techniques and the requirement of multiple intravenous blood samples over a 
time frame of several hours, which can be inconvenient and cost-intensive. Several limited 
sampling strategies have been developed to simplify sampling and minimising costs and 
labor. A single time point measurement of MDZ plasma concentration at 4 h after 
intravenous or oral MDZ administration was suggested to represent an accurate marker of 
CYP3A phenotype under constitutive and modified states (Lin et al., 2001). Limited 
sampling models using MDZ plasma concentrations at one, two or three time points after 
intravenous administration using multiple linear regressions have shown to predict the AUC 
of MDZ (Kim et al., 2002). Several studies have assessed the usefulness of the ratio 1´-
OHMDZ to MDZ plasma concentrations to predict the CYP3A activity, but results from these 
investigations have shown inconsistencies (Eap et al., 2004b; Penzak et al., 2008; Rogers 
et al., 2002; Thummel et al., 1994b; Zhu et al., 2001). In a recently published study (Lee et 
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al., 2006), the investigators could not find any time point of 1´-OHMDZ/MDZ plasma 
concentration ratio that would accurately predict the MDZ AUC, which is, beside the 
determination of MDZ clearance, a validated marker for CYP3A activity (Streetman et al., 
2000). In addition, they have shown that limited sampling models with two (0.5 and 6 hours) 
and three (0.5, 2 and 6 hours) time points following oral administration can be used in 
healthy subjects to evaluate CYP3A baseline activity (Lee et al., 2006).  
The use of urine samples to predict in-vivo CYP3A activity would be an attractive, non-
invasive alternative to plasma sampling. Streetman et al. have investigated the utility of 
MDZ urinary metabolic ratios for assessing the CYP3A activity (Streetman et al., 2001). 
However, they found only a poor correlation to the total MDZ clearance, suggesting that 
these metabolic ratios are not an accurate measure of hepatic CYP3A activity. As MDZ is 
also metabolised by CYP3A5 (Patki et al., 2003), which is highly expressed in the human 
kidney, urine measurements can be problematic. Metabolites measured in this matrix might 
reflect not only hepatic but also in part renal CYP3A activity, which might therefore lead to 
confounding results.  
So far, no data has been published on the correlation of MDZ measured in oral fluid with 
MDZ plasma clearance or other CYP3A phenotyping probe. In comparison, for assessing 
the CYP1A2 activity in-vivo, the determination of paraxanthine/caffeine ratio in saliva has 
been shown to be highly correlated to paraxanthine/caffeine ratio in plasma and to total 
caffeine clearance (Carrillo et al., 2000; Faber et al., 2005). If the MDZ concentrations in 
oral fluid would be also significantly correlated to MDZ concentrations in plasma, the 
quantification of MDZ (and metabolites) in oral fluid may offer the possibility to conduct 
simple, non-invasive and less expensive CYP3A phenotyping. 
 
1.4.2 Problems and perspectives of CYP(3A) phenotyping 
One might expect that characterisation of CYP3A activity using any or all probe drugs ought 
to give similar results. However, the correlations made between two probe-based measures 
of CYP3A activity have, in general, been poor or controversial (Hunt et al., 1992; Kinirons et 
al., 1993; Kinirons et al., 1999; Lown et al., 1995; Stein et al., 1996; Watkins et al., 1992). 
The disappointing correlations might be due to the following phenomena: 
• Dietary factors that modify CYP3A activity 
• More than 1 binding site within the CYP3A 
• Different routes of drug administration 
• Overlapping substrate specificity of probes (ie, processing by multiple CYPs) 
• Extrahepatic processing of probes in gastrointestinal epithelium and kidney 
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• Metabolism by CYP3A5 or CYP3A7 in addition to CYP3A4 
• Co-processing of a probe by transport proteins such as P-glycoprotein 
 
Because of pronounced interindividual differences in drug disposition, optimal therapy 
requires drug administration according to each patients need. Assessing the metabolic 
capacity of an individual patient before or during drug therapy might help to find the optimal 
individual dose or to give hints at the cause of adverse events or non-response. Since in-
vitro tests suggest that different CYPs may play a role in the bioactivation of different 
environmental chemicals with carcinogenic potential, for example activation of aflatoxins 
though CYP3A4, phenotyping might be important in risk assessment, as the increased 
activity of these CYPs have been implicated in increased cancer risk (Bachmann, 1996; 
Guengerich, 1990)  
Despite the potential benefits, phenotyping of CYP enzymes is not used in routine clinical 
practice so far. More prospective studies, demonstrating the clinical benefit and/or cost-
effectiveness of phenotyping have to be done with respect to predict ineffectiveness of 
treatment and/or toxic effects.  
 
 
1.5 Midazolam 
MDZ (Figure 3) is a short-acting imidazobenzodiazepine with hypnotic, muscle-relaxant, 
anticonvulsant and anxiolytic properties. In clinical practise, it is used for the induction of 
anaesthesia, sedation and the treatment of generalised seizures and status epilepticus 
(Nordt and Clark, 1997). Compared to other benzodiazepines, it is characterised by a more 
rapid onset of clinical effects and shorter duration of action. In acidic solutions, the 
diazepine ring opens between position 4 and 5, producing a polar, water-soluble primary 
amine derivative. However, at physiological pH, the drug is completely ring-closed, resulting 
in increased lipophilicity (Dundee et al., 1984; Kanto and Allonen, 1983; Smith et al., 1981).  
 
1.5.1 Pharmacokinetics and metabolism 
Following oral administration, MDZ is absorbed rapidly from the gastrointestinal tract with 
maximum plasma concentrations occurring usually within 30-90 min (Klotz, 1989; Reves et 
al., 1985). Due to the significant first-pass metabolism in the liver and the intestinal wall, 
only 40-50% of the usually orally administered dose reaches the systemic circulation. A 
higher bioavailability was observed after the administration of a higher (40 mg) dose 
(Heizmann et al., 1983). This may be explained by the fact, that the hepatic first-pass 
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metabolism is saturable (Bornemann et al., 1985). An increased bioavailability was also 
observed in patients with liver cirrhosis due to the impaired first-pass effect (Pentikainen et 
al., 1989). After intramuscular injection, the absorption of MDZ is rapid and nearly complete 
(absolute bioavailability >90%) and the pharmacological effects usually appear within 5-15 
min. Following intravenous administration, the onset of pharmacological action occurs within 
1-5 min (Klotz, 1989). MDZ undergoes intermediate hepatic extraction. 
Midazolam has a Vd of 1-2.5 l/kg in normal healthy volunteers. The Vd of MDZ is increased 
in obese patients, elderly persons, during pregnancy and in patients with chronic renal 
failure. Approximately 96% of MDZ is bound to plasma proteins (mainly to albumin); protein 
binding of the drug is decreased in patients with chronic renal failure (Dundee et al., 1984; 
Reves et al., 1985; Vinik et al., 1983).  
As mentioned before, MDZ is extensively metabolised mainly in the liver, but also in the 
small intestine, by CYP3A (Gorski et al., 1994). The main metabolite is 1´-OHMDZ; it 
accounts for 95% of net intrinsic clearance in human liver microsomes (von Moltke et al., 
1996). This metabolite is pharmacologically active and has sedative properties equivalent to 
MDZ. 1´-OHMDZ is produced in higher concentrations following oral administration as a 
result of the first-pass metabolism. Minor metabolites are the pharmacologically inactive 4-
OHMDZ and 1´,4-dihydroxymidazolam. All metabolites undergo rapid glucuronidation, one 
of the major phase II conjugation reactions, in the liver and are then excreted into the urine 
as glucuronide conjugates (Heizmann et al., 1983; Nordt and Clark, 1997). Nearly 90% of 
an orally administered dose of radiolabeled MDZ is excreted within 24 h. In humans, urinary 
recovery of 1´-OHMDZ-glucuronide accounted for 60-70% of an administerd dose of 
[14C]midazolam (Heizmann and Ziegler, 1981). The conjugation with glucuronic acid is 
catalyzed by uridine diphosphate-glucuronosyl-transferases (UGTs), a family of enzymes, 
which transfers glucuronic acid from uridine diphosphate-glucuronic acid (UDPGA) to the 
aglycone substrate. UGT’s comprise two subfamilies, UGT1 and UGT2. Until recently, 
glucuronidation of 1´-OHMDZ was not well characterized. Zhu et al. demonstrated in vitro, 
using human liver microsomes and recombinant human UGTs, that O-glucuronidation of the 
1´-OH metabolite was catalyzed by UGT2B4 and UGT2B7. (Zhu et al., 2008) The metabolic 
pathway of MDZ is shown in Figure 3.  
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Figure 3. Metabolism of midazolam. 
 
 
Zhu et al. also reported that in addition to the 1´-OHMDZ O-glucuronide (Figure 3), a 
quaternary N-glucuronide of this metabolite has been identified from incubations of 1´-
OHMDZ in human liver microsomes. The N-glucuronidation was catalyzed by UGT1A4. 
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When MDZ was incubated with human liver microsomes (HLMs) enriched with UDPGA, a 
direct quaternary N-glucuronide of MDZ (N-2 position) was detected (Zhu et al., 2008). 
Similar results have been obtained in a recently published in vitro study (Klieber et al., 
2008). Following incubation of MDZ with HLMs supplemented with UDPGA, two metabolites 
(which could be considered as two different conformers of the same molecule), were 
identified as quaternary direct N-glucuronides of MDZ (under control conditions but also in 
the presence of ketoconazole), thus revealing an additional metabolic pathway for MDZ. 
Very recently, it could be demonstrated by Hyland et al. that direct N-glucuronidation of 
MDZ also occurs in vivo (Hyland et al., 2009). Quantification of the N-glucuronide in urine 
samples obtained from individuals receiving iv and oral MDZ has shown that this metabolite 
accounted for 1-2% of the administered dose. NMR data confirmed a conjugation on the N-
2 position and, as reported by Klieber et al. (Klieber et al., 2008) two forms of this 
glucuronide have been found. Furthermore, incubation of MDZ with recombinant human 
UGTs showed, that for MDZ N-glucuronidation, UGT1A4 was clearly favoured over 
UGT2B4 and 2B7 (>100-fold and >400-fold, respectively). From incubations with HLMs and 
recombinant human UGT enzymes, N-glucuronidation of 1´-OHMDZ and 4-OHMDZ is also 
inferred (Hyland et al., 2009). 
In-vitro studies using recombinant CYP3A4 and CYP3A5 have shown that both, rCYP3A4 
and rCYP3A5, contribute to MDZ metabolism producing 1´-OHMDZ and 4-OHMDZ (Patki et 
al., 2003). In human liver microsomes, some studies have demonstrated that the rate of 1´-
OHMDZ formation correlated well with CYP3A protein content (r=0.92) and, to a lower 
extend, with CYP3A5 content (r=0.6) (He et al., 2006). However, other studies had 
inconsistent results. Yamaori et al. found that the correlation of the rate of 1´-OHMDZ 
formation with the CYP3A5 content was higher than that with CYP3A4 content, whereas 
correlation of the rate of 4-OHMDZ formation with CYP3A5 content was similar to that with 
CYP3A4 in HLMs from Japanese subjects (Yamaori et al., 2004). 
Initial studies found that livers expressing CYP3A5 had an increased rate of 1´-OHMDZ 
formation (Gellner et al., 2001; Gorski et al., 1994). Further investigations using 
recombinant systems have also suggested that CYP3A5 is efficient in forming the 1´-OH 
metabolite compared with 4-OHMDZ and that the overall catalytic activity for 1´-OHMDZ 
formation is higher for CYP3A5 compared with CYP3A4 (Huang et al., 2004). These 
findings are also in accordance with results of an in-vitro study carried out in our laboratory. 
An in-vivo study has shown significantly higher total 1´-OHMDZ AUC / total 4-OHMDZ ratios 
in CYP3A5 as compared to poor metabolisers (Eap et al., 2004c). These results are in 
agreement with the in-vitro data showing that microsomal samples containing CYP3A5 and 
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CYP3A4 exhibit a greater ratio 1´-OHMDZ/4-OHMDZ compared with samples containing 
CYP3A4 alone (Gorski et al., 1994).  
The 1´-OHMDZ-glucuronide also appears to have sedative properties when concentrations 
are high, as has been observed in adult patients with renal failure. The accumulation of the 
1´-OHMDZ conjugate of MDZ may explain the prolonged sedation after cessation of MDZ 
(Bauer et al., 1995).  
Compared with other benzodiazepines, MDZ has a short elimination half-life (t1/2) of 1.5-3 h. 
During pregnancy, the t1/2 decreases to 30-120 min, whereas the t1/2 seems to be prolonged 
in obese patients, geriatric individuals and patients with impaired hepatic function 
(Greenblatt et al., 1984; Nordt and Clark, 1997). The elimination half-life of the 1´-hydroxy 
metabolite is approximately 1 h (Kanto, 1985). The total plasma clearance of MDZ is 5.8-9 
mL/min/kg in healthy subjects but is decreased in elderly persons (Dundee et al., 1984).  
 
1.5.2 Mechanism of action and potential adverse side effects 
MDZ binds with high specificity to a subunit of the γ-amino butyric acid (GABAA) receptors 
(which is not identical with the GABA binding site) in the central nervous system (CNS) 
which leads to the activation of these GABAA receptors. In contrast to barbiturates, which 
stimulate the GABA receptors directly, benzodiazepines act indirect by enhancing the 
inhibitory action of the neurotransmitter GABA. The binding of GABA to the receptor 
increases the flow of chloride ions into the cell, which than leads to a decreased ability of 
the cell to initiate an action potential. Therefore, the presence of GABA is required for the 
effectiveness of benzodiazepines. The effects of the benzodiazepines can be reversed by 
the specific competitive receptor antagonist flumazenil (Krähenbühl, 2003; Nordt and Clark, 
1997). 
Long-term use of MDZ may lead to addiction and to tolerance concerning the hypnotic 
effects. Furthermore, MDZ has been associated with anterograde amnesia, respiratory 
depression and cardiac arrest. Patients with hepatic or renal insufficiencies may be at risk 
for prolonged sedation. Elderly patients (age >60) have an increased risk for suffering 
adverse drug reactions because of a possible prolonged elimination half-life of MDZ. 
Synergy occurs when used in combination with anaesthetics, alcohol or other CNS 
depressants (Bauer et al., 1995; Nordt and Clark, 1997). MDZ may also interact with 
several concomitantly administered medications that may inhibit (e.g. erythromycin, azole 
antifungals, verapamil or cimetidine) or induce (e.g. carbamazepine, rifampicin or 
phenytoin) CYP3A activity  (Backman et al., 1996a; Backman et al., 1996b; Nordt and 
Clark, 1997; Olkkola et al., 1993).   
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1.6 Determination of midazolam and its metabolites 
1.6.1 Nonchromatographic techniques 
Several non-chromatographic techniques are available for the analysis of midazolam (and 
metabolites) in urine and blood/plasma. These assays are often used to provide an initial 
test or to screen biological matrices for the presence of the benzodiazepine. Numerous 
commercial kits are existing for this purpose. Midazolam and its two major metabolites can 
be detected in urine by fluorescent polarisation immunoassay (FPIA) (e.g. Abbot TDx and 
ADx) and by the enzyme immunoassay (EIA) EMIT (Fraser et al., 1991). With FPIA, MDZ 
has also been determined in plasma and blood samples (Bourget et al., 1996; Huang and 
Moody, 1995). Other methods for determining MDZ in plasma or human tissues include 
enzyme linked immunosorbent assay (ELISA) (Gorczynski and Melbye, 2001) and 
radioimmunoassay (RIA) (Dixon et al., 1982). However, these techniques are not relevant 
for the quantitative determination of MDZ and its metabolites with regard to CYP3A 
phenotyping, and will therefore not be described in more details in this work. 
 
1.6.2 HPLC and GC(-MS) analysis  
Numerous high performance liquid chromatography (HPLC) and gas chromatography (-
mass spectrometry) (GC-MS) methods have been published for the identification and 
quantitative determination of MDZ and its metabolites in different matrices.  
A suitable sample preparation is an important prerequisite for the chromatography of 
biosamples (e.g. urine, plasma, blood or oral fluid). Mostly, the isolation of MDZ and its 
metabolites has been performed by either liquid-liquid extraction (LLE) or solid phase 
extraction (SPE). As MDZ is a weakly basic drug, LLE is most commonly conducted at a 
slightly alkaline pH, where the analyte is uncharged, using for example ethyl acetate, 
acetone, chloroform, toluene, hexane, dichloromethane, butylacetate, diethyl ether or 
mixtures of them as organic phases. The general pros and cons of using either LLE or SPE 
are described by Franke and De Zeeuw (Franke and de Zeeuw, 1998).  
The most important published HPLC and GC(-MS) methods for the quantitative 
determination of MDZ and its metabolites are summarised in Table 6 and 7. 
Although HPLC has been used for decades, for the quantification of MDZ and its major 
metabolite(s), theses methodologies typically represent relatively poor sensitivity and low 
throughput. As shown in Table 6, the limit of quantification (LOQ) is either in the ng/ml or in 
the high pg/ml range. Focusing on CYP3A phenotyping, the administration of therapeutic 
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MDZ doses (about 4-7.5 mg per oral) is often required, due to the lacking sentitivity, which 
may lead to adverse drug reactions such as sedation or amnesia.  
 
Table 6. Selection of published HPLC methods 
Reference Matrix Drugs  Extraction Detection method LOQ (ng/ml) 
(Ha et al., 1993) Plasma Urine 
MDZ 
1´-OHMDZ LLE UV (245 nm) 5 
(Mastey et al., 
1994) Plasma 
MDZ 
1´-OHMDZ 
4-OHMDZ 
SPE UV (254 nm) 15 
(Lehmann and 
Boulieu, 1995) Plasma 
MDZ 
1´-OHMDZ LLE UV (215 nm) 2 
(Carrillo et al., 
1998) Plasma 
MDZ 
1´-OHMDZ 
4-OHMDZ 
LLE UV (254 nm) 7 
(Eeckhoudt et al., 
1998) Plasma 
MDZ 
1´-OHMDZ LLE UV (240/300 nm) 1 / 0.5 
(ter Horst et al., 
2003) Plasma  
MDZ 
1´-OHMDZ LLE DAD 23.4 
(Yasui-Furukori et 
al., 2004) Plasma 
MDZ 
1´-OHMDZ 
LLE 
 UV (254 nm) 0.5 
DAD, Diode array detector 
UV, Ultra violet 
LOQ, Limit of quantification 
 
 
 
Table 7. Selection of  published GC(/MS) methods 
Reference Matrix Drugs  Extraction Detection method LOQ (ng/ml) 
(De Kroon et al., 
1989) Plasma 
MDZ 
1´-OHMDZ 
4-OHMDZ 
LLE GC ECD 2 
(Thummel et al., 
1994a) Plasma 
MDZ 
1´-OHMDZ LLE GC-MS 0.3 
(Backman et al., 
1996a) Plasma MDZ LLE GC NPD 0.1 
(Martens and 
Banditt, 1997) Serum 
MDZ 
1´-OHMDZ 
4-OHMDZ 
LLE GC-MS 0.2  
(Frison et al., 
2001) Plasma MDZ SPME GC-MS 1.5 
(Eap et al., 2004a) Plasma  
MDZ 
1´-OHMDZ 
4-OHMDZ 
LLE GC-MS 0.01 
(Gunnar et al., 
2006) Blood 
MDZ 
1´-OHMDZ LLE GC/NICI-MS 10 / 2 
ECD, Electron- capture detector 
NICI, negative-ion chemical ionisation 
NPD, Nitrogen-Phosphorus detector 
SPME, Solid phase micro extraction 
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GC(-MS) methods (Table 7), in general, appear to be more sensitive compared to HPLC 
methods for the quantification of MDZ and its metabolites in biological fluids, yielding LOQs 
in the lower pg/ml range. The sensitive GC-MS method published by Eap et al. have shown 
(Eap et al., 2004c) that MDZ and two of its metabolites can be determined in human plasma 
after oral administration of 75 μg MDZ. The use of such low doses of the probe drug would 
be advantageous in order to minimise MDZ related central nervous side effects particularly 
in patients, who are more sensitive to benzodiazepines (such as elderly persons). However, 
the disadvantage of using GC is that this chromatographic method often requires extensive 
sample pre-treatment such as clean-up and/or derivatisation for analysis. 
Coupling HPLC to mass spectrometry has shown to be a good alternative to GC-MS with 
regard to assay sensitivity. In addition, the usage of LC-MS(/MS) offers the opportunity to 
analyse also non-volatile, polar and thermal labile molecules. 
 
 
1.6.3 LC-MS and LC-MS/MS analysis 
In recent years, liquid chromatography coupled with single-stage (LC-MS) or tandem mass 
spectrometry (LC-MS/MS) is becoming increasingly important in routine analysis, especially 
for quantification of an analyte of interest. The advantages in using LC-MS(/MS) compared 
to HPLC and some of the GC(-MS) methods are better sensitivity, selectivity and specificity. 
Based on these characteristics, theoretically, sample clean-up can be reduced and 
chromatographic separation can be minimised, which would lead to higher throughput in 
routine analysis. However, LC-MS(/MS) is not completely without limitations which will be 
discussed in chapter 1.6.3.2.    
 
1.6.3.1 Theoretical background 
While GC can easily be coupled to MS, LC can only be coupled with MS via sophisticated 
interfaces to remove the mobile phase and ionise the analyte (Ardrey, 2003). Today, two 
relatively robust LC-MS interfaces have become the ‘golden standard’ of LC-MS: the 
atmospheric pressure ionisation (API) techniques, electrospray ionisation (ESI) and 
atmospheric pressure chemical ionisation (APCI). Although both interfaces perform so-
called ‘soft-ionisation’ and generate ions at atmospheric pressure, each is characterised by 
a specific ionisation mechanism which both are described by Bruins and Kerbarle (Bruins, 
1994; Kerbarle and Tang, 1993). ESI as well as APCI can be used in positive or negative 
polarity mode, dependent on the structure of the analyte of interest. Other interfaces such 
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as moving belt, fast atom bombardment (FAB) or particle beam (PB) are nowadays of minor 
relevance. 
Mass analysis of ionised substances is performed using one or two mass analysers 
(MS/MS), which consist predominantly of ion traps and quadrupoles, sometimes of sector 
field and time-of-flight instruments (TOF). MS/MS can be performed either in space, by 
placing one mass spectrometer after another (e.g. triple quadrupole MS) or by carrying out 
successive mass-selective operations in time in a quadrupole ion trap. A detailed 
introduction to the latter is given by March (March, 1997).  
MS/MS is used to produce structural information about a compound by fragmenting specific 
sample ions inside the mass spectrometer and identifying the resultant fragment ions. Using 
tandem mass spectrometry, it is also possible to detect a specific compound in a complex 
mixture on account of its specific and characteristic fragmentation patterns. In this way, 
selectivity and sensitivity can be gained.  
Tandem mass spectrometry (MS/MS) is the practice of carrying out one mass-selective 
operation after another. The objective of the first step is to isolate an ion species designated 
as parent ion, while that of the second operation is to determine the mass to charge ratio 
(m/z) of the fragment or daughter ion, formed by collision induced dissociation (CID) of the 
parent ions (March, 1997).  
The analysers can operate either in the full scan mode or in the more sensitive selected-ion 
monitoring mode (SIM) detecting positive or negative ions. For MS/MS analysis four 
different operating combinations are possible: Parent-ion scanning (scan mode in the first, 
SIM in the second analyser), daughter-ion scanning (DIS; SIM in the first, scan mode in the 
second analyser), constant neutral-loss scanning (CNLS; scan mode in both analysers) or 
selected-reaction monitoring (SRM; SIM in both analysers) (Careri et al., 1996; Hoja et al., 
1997). DIS is preferable for the identification of drugs and or their metabolites in complex 
matrices. Separation is performed on the LC and in the first mass analyser, while structural 
information is obtained by fragmentation in the second analyser. SRM (also named multiple-
reaction monitoring MRM) is the most powerful technique for quantification of small 
amounts of analyte in complex matrices. 
 
1.6.3.2 Matrix effect / Ion suppression 
One limitation associated with LC-MS analysis is its susceptibility to matrix effect. Matrix 
effect is defined as the effect of co-eluting residual matrix components on the ionisation of 
the target analyte, which can lead either to an enhancement or suppression of the ion 
intensity (Benijts et al., 2004; Dams et al., 2003). For LC-MS(/MS) method development, it 
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is therefore very important to take this effect into consideration because interfering matrix 
components are often accompanied with diminished precision, sensitivity and accuracy of a 
quantitative analytical procedure (Annesley, 2003).  
Of the two most currently used API sources, ESI is more likely to suffer from ion 
suppression than APCI (Dams et al., 2003). Non-volatile compounds, such as salts or ion 
pair agents (e.g. trifluoro acetic acid, TFA) but also endogenous compounds or drugs, can 
change the efficiency of droplet formation or droplet evaporation, which affects the amount 
of charged ions that reaches the detector. Molecules with higher masses can suppress the 
signal of smaller molecules and polar analytes are more susceptible to ion suppression 
(Annesley, 2003). 
Sample clean-up has been shown to be a very important factor that may influence the 
amount of ionisation of a compound. Bonfiglio et al. demonstrated that ion suppression is 
considered to be more likely a problem when using a simple protein precipitation step for 
sample preparation as compared to the more exhaustive LLE or SPE methods (Bonfiglio et 
al., 1999). 
There are several methods to overcome ion suppression. One solution would be, to use 
cleaner sample preparation whenever possible. Furthermore, the chromatographic 
conditions could be modified so that the compounds of interest elute in a region where ion 
suppression is not observed. In general, this involves an increase in chromatographic 
separation. Another possibility is the use of a suitable internal standard (IS), e.g. a stably 
labeled isotope of the analyte, which ideally co-elutes with the analyte of interest. In this 
way, the IS and the analyte should be affected by the matrix components to the same 
extent and peak area ratios should be therefore still reliable. For ion pairing, weaker acids, 
such as acetic or formic acid, can be used instead of TFA (Annesley, 2003; Bonfiglio et al., 
1999; Schuhmacher et al., 2003; van Hout et al., 2003). 
For reliable quantitative determinations it is preferable that the retention times of the test 
compounds are in the region of little or no ion suppression. The chromatographic profile and 
the extent of change in the analyte ESI response in the presence of interferences under 
assay conditions can be investigated by post column infusion (Bonfiglio et al., 1999). The 
analyte of interest is infused through a PEEK tee union into a chromatographic run of an 
extract or a blank matrix. This signal is then compared to the signal obtained with the post-
column infusion of the same model analyte in a chromatographic run with mobile phase 
only. Another method to assess the matrix effect is described by Matuszewski et al. 
(Matuszewski et al., 2003). Three sets of samples are necessary. Set A consists of 
standard solutions in mobile phase. For Set B, blank matrix (after extraction) is 
supplemented with the same amount of standard as used for set A. Set C consists of blank 
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matrix extract supplemented with the same amount of standard added before extraction. 
For each of the following calculations, the resulting peak areas are needed: Matrix effect 
(%) = B/A x 100, recovery (%) = C/B x 100 and process efficiency (%) can be calculated by 
C/A x 100. 
Because matrix effects may possibly have a great impact on assay sensitivity, accuracy and 
precision in quantitative LC-MS(/MS), it is very important to perform ion suppression studies 
during method development, especially when ESI is used. 
 
1.6.3.3 Analysis of MDZ and metabolites by LC-MS(/MS) 
Several LC-MS and LC-MS/MS methods for the quantititative determination of MDZ and 
metabolites have been published in recent years. A selection of the most important ones is 
presented in Table 8. It has been shown that in most cases, LC-MS is not as sensitive as 
GC-MS. However, LC coupled to tandem mass spectrometry yielded comparable LOQs. 
 
Table 8. Selection of the recently published LC-MS and LC-MS/MS methods 
Reference Matrix Drugs  Extraction Detection method LOQ (ng/ml) 
(Marquet et al., 
1999) Serum 
MDZ 
1´-OHMDZ LLE LC-MS 0.2/0.5 
(Shiran et al., 
2003) Plasma 
MDZ 
1´-OHMDZ LLE LC-MS 6.5 
(Lepper et al., 
2004) Plasma MDZ LLE LC-MS 1 
(Smink et al., 
2004) Blood MDZ LLE LC-MS 3.5 
(Quintela et al., 
2004) 
Plasma  
Saliva 
MDZ 
1´-OHMDZ LLE LC-MS 
1     (plasma) 
0.2  (saliva) 
(Muchohi et al., 
2005) Plasma 
MDZ 
1´-OHMDZ LLE LC-MS 5 
(Kashuba et al., 
1998) Plasma 
MDZ 
1´-OHMDZ 
4-OHMDZ 
 LC-MS/MS 0.25 
(Yin et al., 2004) Plasma MDZ 1´-OHMDZ SPE LC-MS/MS 1 
(Harris et al., 
2004) 
Plasma 
(dog) MDZ SPE LC-MS/MS 0.1 
(Jabor et al., 
2005) Plasma 
MDZ 
1´-OHMDZ LLE LC-MS/MS 0.1 
(Li et al., 2007) Plasma MDZ 1´-OHMDZ LLE LC-MS/MS 0.1 
 
 
Introduction 
42 
In summary, for CYP3A phenotyping using MDZ as probe drug, the availability of very 
sensitive analytical methods is of great importance due to the following reasons:  
• By improving the sensitivity of the analytical method, it should be possible to conduct 
phenotyping of CYP3A with a lower dose of the probe drug which would be less 
objectionable to patients 
• Simple, non-invasive CYP3A phenotyping methods would be highly welcome, both for 
routine use and development, using e.g. saliva as biological matrix. Since MDZ is 
extensively bound to plasma proteins (96%), the concentrations of free drug are 
expected to be very low in this matrix and therefore poses a challenge for to the 
analytical method development. 
 
As mentioned before, the use of LC-MS/MS compared to GC-MS has several advantages. 
Although numerous tandem mass spectrometry assays have been described in the 
literature, no LC-MS/MS method has been published so far, which is able to quantify MDZ 
and both metabolites, 1´-OHMDZ and 4-OHMDZ, in human plasma after the administration 
of a low oral MDZ dose. Furthermore, to our knowledge, no one has described an LC-
MS/MS method for the simultaneous quantitative determination of MDZ and its 
hydroxymetabolites in oral fluid, which shows enough sensitivity to analyse in-vivo samples 
after MDZ administration to humans and to determine the pharmacokinetic profiles of the 
mentioned substances. To date, the impact of analysing oral fluid samples for non-invasive 
CYP3A phenotyping is therefore not yet known. 
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2 Aims of the thesis 
The major goal of this thesis was to develop less/non-invasive CYP3A phenotyping 
procedures using midazolam as a probe drug.  
Among several phenotyping probes, MDZ plasma clearance appears to be the most reliable 
method to determine the “real-time” CYP3A activity. However, due to the limited sensitivity 
of most standard analytical methods, the use of therapeutic MDZ doses is often required, 
which may cause adverse reactions such as sedation or amnesia. To overcome this 
problem, the aim of the first project (Chapter 3) was, to develop and validate a very 
sensitive LC-MS/MS method, which allows the determination of midazolam and two of its 
metabolites at pg/ml levels in human plasma and, as a consequence, to minimize drug 
exposure. The method was applied to a pharmacokinetic study, where the administration of 
a sub-therapeutic oral MDZ dose has been studied in order to investigate the possibility of 
conducting low-dose CYP3A phenotyping.  
Another disadvantage of CYP3A phenotyping using MDZ plasma clearance is that the 
procedure requires multiple blood samples over a time frame of several hours, which limits 
its application as screening method. Since non-invasive methods would be very 
advantageous for this purpose, the second project (Chapter 4) concentrates on the LC-
MS/MS method development and validation in saliva. In a single subject study, the following 
questions were assessed: 
• Since the MDZ concentration is expected to be very low in saliva, is it possible at all to 
detect and quantify MDZ and its principal metabolites in saliva? If yes, 
• could the pharmacokinetics of MDZ in this matrix be determined and is a correlation of 
plasma and saliva MDZ concentrations existing? 
Based on the results of before mentioned studies, an open-label, randomized, two way 
cross-over trial in eight healthy subjects was conducted to study the kinetics of MDZ after 
intravenous and oral administration of the drug both under basal conditions and after 
CYP3A induction with rifampicin (Chapter 5). Our main interest was to find out whether: 
• the kinetics of MDZ can be assessed reliably in saliva and 
• saliva can be used as a matrix to determine CYP3A activity with MDZ as a probe drug. 
 
A further focus of the thesis was to investigate the pharmacokinetics of midazolam and 
metabolites in a patient with refractory status epilepticus treated with extraordinary doses of 
midazolam (Chapter 6) and the value of plasma level monitoring. 
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3.1 Abstract 
Midazolam (MDZ), a short-acting benzodiazepine, is a widely accepted probe drug for 
CYP3A phenotyping. So far published methods were using either therapeutic doses of 
MDZ, which may cause adverse reactions, or, if employing lower doses, were not able 
quantify the two hydroxy-metabolites. Avoidance of these problems necessitates sensitive 
analytical methods in order to minimise drug exposure. In the present study, a sensitive and 
specific liquid chromatography-electrospray ionisation tandem mass spectrometry method 
was developed and validated for the quantitative determination of MDZ and two of its 
metabolites, 1´-hydroxymidazolam (1´-OHMDZ) and 4-hydroxymidazolam (4-OHMDZ), in 
human plasma. After liquid-liquid extraction with hexane:dichlormethane (73:27, v/v), the 
analytes were separated on a Luna C18(2) (100 x 2.1 mm) analytical column using gradient 
elution. Detection was achieved using an ion-trap mass spectrometer operating in the 
tandem-mass spectrometry mode (MS/MS). Midazolam-d6 was used as internal standard 
for quantification. Calibration curves were linear (R2>0.998) between 0.05 and 20 ng/ml for 
MDZ and both metabolites. Using a 1 ml plasma sample, the limit of detection was 0.025 
ng/ml and the limit of quantification 0.05 ng/ml for all analytes. Intra- and inter-day 
accuracies, determined at three different concentrations, were between 92.1 and 102.3% 
and the corresponding coefficients of variation were <7.3%. The average recoveries were 
90.6%, 86.7% and 79.0% for MDZ, 1´-OHMDZ and 4-OHMDZ, respectively. The method 
was successfully applied to a pharmacokinetic study, showing that MDZ and both hydroxy-
metabolites can be determined precisely in samples obtained in vivo following a single oral 
dose of 2 mg MDZ. The method appears therefore to be useful for CYP3A phenotyping in 
plasma using sub-therapeutic MDZ doses, but larger studies are needed to proof this 
assumption. 
 
 
3.2 Introduction 
Midazolam (MDZ) is a short-acting benzodiazepine, which is used in humans as a hypnotic, 
for the induction of anaesthesia, and for the treatment of patients with status epilepticus or 
generalised seizures (Nordt and Clark, 1997). MDZ is extensively metabolised by 
cytochrome P450 3A (CYP3A), mainly to its pharmacologically active metabolite 1´-
hydroxymidazolam (1´-OHMDZ) and, to a smaller extent, to 4-hydroxymidazolam (4-
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OHMDZ) and 1,4-dihydroxymidazolam. The metabolites are excreted as 
glucuronoconjugates in urine (Heizmann and Ziegler, 1981; Kronbach et al., 1989).  
CYP3A, which usually includes CYP3A4 and CYP3A5 in adults, is the most important 
subfamily of drug metabolising enzymes in humans. More than 50% of clinical drugs and a 
variety of other xenobiotics and endogenous substances are metabolised by these enzymes 
(Maurel, 1996; Paine et al., 1996). They are expressed as the most abundant constituent in 
the liver CYP enzyme system and are also present in the intestinal epithelial cells. It is well 
known that CYP3A exhibits a marked interindividual variability in enzyme activity, rendering 
the dosing and therapeutic use of many CYP3A substrates difficult, especially of those with 
a narrow therapeutic range (Lin and Lu, 2001; Thummel et al., 1994a; Wilkinson, 1996). 
Therefore, the possibility to prospectively determine the CYP3A activity with phenotyping 
probes is potentially useful to identify individuals at risk for potential drug-drug interactions 
(resulting from inhibition or induction of the catalytic activity) and also to predict insufficient 
drug response or toxic effects from CYP3A substrates.  
Several methods for CYP3A phenotyping have been proposed, including 14C-labeled 
erythromycin, alfentanil, midazolam, nifedipine or endogenous cortisol (Kharasch et al., 
2004; Streetman et al., 2000; Thummel et al., 1994b; Watkins, 1994). However, the MDZ 
plasma clearance appears to be the most reliable of the available methods and is therefore 
widely used to assess the activity of CYP3A (Streetman et al., 2000). MDZ can be 
administered by both, intravenous and oral routes, and therefore offers the opportunity to 
assess the hepatic as well as the combined intestinal and hepatic CYP3A activity (Gorski et 
al., 1998; Thummel et al., 1996; Tsunoda et al., 1999). In addition, MDZ is not a substrate of 
p-glycoprotein (Kim et al., 1999). 
Numerous chromatographic methods have been reported for the determination of MDZ and 
its metabolites in human biosamples including high performance liquid chromatography 
(HPLC) with UV detection (Carrillo et al., 1998; Drummer, 1998; Eeckhoudt et al., 1998; Ha 
et al., 1993; Lehmann and Boulieu, 1995; Mastey et al., 1994; ter Horst et al., 2003), gas 
chromatography (GC) equipped with different detecting systems (Backman et al., 1996a; De 
Kroon et al., 1989; Frison et al., 2001; Martens and Banditt, 1997) and HPLC coupled to 
mass spectrometry (LC-MS) (Marquet et al., 1999; Muchohi et al., 2005; Quintela et al., 
2004; Shiran et al., 2003) or tandem mass spectrometry (LC-MS/MS) (Jabor et al., 2005; 
Yin et al., 2004). For all of these methods, the limit of quantification for MDZ was either in 
the ng/ml range or in the high pg/ml range. 
For CYP3A phenotyping, the administration of therapeutic MDZ doses (oral administration 
of 5 to 7.5 mg) is often required due to the limited sensitivity of most standard analytical 
methods used for this purpose. This may lead to adverse drug reactions such as sedation 
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or amnesia. To overcome these problems, more sensitive methods are needed to assess 
the CYP3A activity with safe and sub-therapeutic MDZ doses. Recently, Eap et al. 
published a very sensitive GC-MS method which allows the measurement of MDZ and two 
of its metabolites in human plasma after oral administration of 75 μg MDZ without 
production of any central nervous side effects (Eap et al., 2004). However, the 
pharmacokinetic profile of the 4-hydroxy-metabolite could not be assessed with such a low 
dose (Eap et al., 2004b) and, in addition, GC requires extensive sample pretreatment such 
as clean up and derivatisation for analysis. 
To our knowledge, no LC-MS/MS method has been published so far that is able to quantify 
both, MDZ and its hydroxy-metabolites in human plasma after the administration of a low 
oral dose of MDZ. Since we plan to use CYP3A phenotyping in the future in special patient 
populations, such as elderly patient or patients with HIV infection, the purpose of this work 
was to develop and validate a very sensitive and selective LC-MS/MS method which allows 
the simultaneous quantification of MDZ, 1´-OHMDZ and 4-OHMDZ (Figure 1) in human 
plasma. 
 
Figure 1. Chemical structures of (A) midazolam and two of its metabolites (B) 1´-hydroxymidazolam 
and (C) 4-hydroxymidazolam. 
 
 
3.3 Materials and Methods 
3.3.1 Chemicals 
Midazolam hydrochloride (MDZ, purity 99.6%), 1´-hydroxymidazolam (1´-OHMDZ, purity 
99.7%) and 4-hydroxymidazolam (4-OHMDZ, purity 99.1%) were purchased from Lipomed 
AG (Arlesheim, Switzerland). The internal standard (IS) midazolam-d6 was kindly provided 
from F. Hoffmann-La Roche (Basel, Switzerland). Acetic acid (Suprapur®) as well as 
LiChrosolv® grade water, acetonitrile, hexane and dichlormethane were from Merck 
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(Darmstadt, Germany). Glycine was of ultra pure grade and purchased from Fluka (Buchs, 
Switzerland). All other chemicals and solvents were of analytical grade or better.  
 
3.3.2 Preparation of stock solutions, standards and quality control samples 
The primary standard stock solutions of MDZ, 1´-OHMDZ, 4-OHMDZ were prepared at 0.6 
mg/ml in methanol and stored in the dark at -70°C for up to 6 months. Working solutions of 
each analyte were made by diluting the stock solutions with methanol. A mixed working 
solution containing both midazolam and metabolites was prepared from the individual 
working solutions. After subsequent dilution with methanol, a series of mixed standard 
spiking solutions, ranging from 2-800 ng/ml, were obtained, which were further used to 
prepare calibration and quality control (QC) standards. An IS stock solution was prepared at 
12 μg/ml in methanol. A working solution containing 1.2 μg/ml midazolam-d6 was obtained 
by diluting the IS stock solution with methanol. All standard solutions were stored at -70°C. 
QC samples were made by spiking pooled blank plasma with the mixed standard QC 
spiking solution to give final concentrations of 0.6 (QC low), 3.7 (QC medium) and 15 ng/ml 
(QC high). 
 
3.3.3 Plasma sample collection 
Heparinised human blank plasma samples were obtained from the blood collection centre of 
the University Hospital of Basel (Basel, Switzerland) and stored frozen at -20°C. For the 
development and validation of the method, drug-free plasma from six different sources were 
pooled and used to prepare plasma calibrators and plasma quality control samples. 
 
3.3.4 Preparation of samples and calibration standards 
To 1 ml plasma, 10 μl IS working solution (1.2 μg/ml in methanol) and 1 ml 0.75 M glycine 
buffer (pH 9.2) were added. The extraction was carried out with 7 ml n-
hexane:dichlormethane (73:27, v/v) by mixing on a flat-bed shaker (Infors AG, Basel, 
Switzerland) for 15 min. After centrifugation at 2500 x g for 5 min, the aqueous layer was 
frozen in a dry ice/acetone bath and the organic phase was transferred into a silanised 
glass tube. The organic solvent was evaporated to dryness at 40°C under a gentle stream 
of nitrogen using a TurboVap® evaporator (Zymark, Hopkinton, MA, USA). The residue was 
reconstituted in 150 μl acetonitrile:water (23:77, v/v) and 20 μl were injected onto the 
column for LC-MS/MS analysis. 
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Calibration standards were prepared freshly each day by spiking 1 ml blank plasma with 25 
μl of the appropriate mixed standard spiking solution at concentrations of 0.05, 0.1, 0.2, 0.5, 
1, 2, 5, 10 and 20 ng/ml and were extracted according to the above described procedure. 
To blank samples and samples containing only IS, the same volume of methanol was 
added as for standard solutions. 
 
3.3.5 Instrumentation and chromatographic conditions 
The analytes were separated on a HP 1100 system (Agilent Technologies, Palo Alto, CA, 
USA) which consisted of a degaser, a quaternary pump and an autosampler. Gradient 
elution was performed on a Luna C18(2) analytical column (100 x 2.1 mm i.d., particle size 
3 μm) equipped with a corresponding guard column C18 ODS, 4 x 2.1 mm i.d. 
(Phenomenex, Torrance, CA, USA). The column oven temperature was set at 40°C and the 
autosampler was maintained at 15°C. Mobile phases consisted of 0.1% acetic acid in 
water:acetonitrile (90:10, v/v) (eluent A) and 0.1% acetic acid in acetonitrile (eluent B). 
Starting at 5% B, the gradient settings were as follows: 0-0.5 min linear increase to 17% B, 
0.5-2 min 17% B, 2-3.5 min linear increase to 80% B. After 2.5 min at these conditions, the 
column was re-equilibrated with 5% B for 4.5 min. The flow rate was 0.24 ml/min. 
The analytes were detected using a LCQDECA ® ion trap mass spectrometer (Thermo Fischer 
Scientific, Inc., Waltham, MA, USA) equipped with an electrospray ionization source (ESI) 
operating in the positive ion mode (4kV). The other main parameters were as follows: 
heated capillary temperature 255 °C, sheath gas (N2) pressure 80 arbitrary units, auxiliary 
gas (N2) pressure 6 arbitrary units and capillary voltage 3 kV. Helium was used as collision 
gas. Data acquisition and quantitative analysis were performed using Xcalibur 1.2 software 
(Thermo Fischer Scientific, Inc.). For the quantification of MDZ and its metabolites, the 
MS/MS product ion scan mode was chosen. A mass filter for the two most abundant 
product ions (Table 1) was used in the quantification software afterwards. Each compound 
was associated with a specific retention time segment, within which one precursor ion, 
[M+H]+, was stored and further fragmented with a collision energy that allowed a sufficient 
fragmentation of the selected ion. As the IS is a stable isotope labeled version of MDZ, it 
elutes in the same segment. Detailed fragmentation parameters are shown in Table 1. 
Automatic gain control was employed using one microscan and a maximum injection time of 
200 ms.  
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Table 1. LC-MS/MS parameters for the quantitative determination of midazolam and its metabolites 
in human plasma 
 
 
Compound 
 
Segment 
(min) 
 
Scan range 
(m/z) 
Precursor 
ion 
(m/z) 
Product ions 
(m/z) used for 
quantification 
 
CE 
(eV) 
 
Isolation 
width (m/z)
4-hydroxymidazolam 1  (5.50-6.75) 120-400 342.2 325.2, 234.2 35 1.4 
Midazolam-d6 (IS) 2  (6.75-7.40) 180-405 332.3 297.4, 247.2 40 1.5 
Midazolam 2  (6.75-7.40) 100-390 326.2 291.3, 244.2 40 1.5 
1´-hydroxymidazolam 3  (7.40-8.10) 190-445 342.2 324.2, 203.2 35 1.4 
CE, collision energy; IS, internal standard 
The most abundant product ion is underlined 
 
 
3.3.6 Method validation 
Spiked plasma calibration standards at 9 concentrations ranging from 0.05 to 20 ng/ml for 
each analyte were prepared freshly and analysed in six independent analytical runs. 
Calibration curves were constructed using the analyte to IS peak area ratio versus the 
analyte concentration of the nominal standard, and were fitted by linear regression analysis 
with a weighting factor of 1/x. To assess linearity, deviations of the mean calculated 
concentrations over six runs had to be ≤15% of the nominal concentration, except for the 
limit of quantification (LOQ), where a deviation of 20% was permitted. 
Intra-day precision and accuracy were determined at three concentrations (0.6, 3.7 and 15 
ng/), by analysing on the same day six replicates of each QC level. Inter-day precision and 
accuracy were assessed by the analysis of QC samples at three concentrations each day 
for six days. Precision should not exceed 15% of the coefficient of variation (CV) at each 
concentration level, except for the LOQ for which 20% was acceptable. Accuracy was 
calculated by comparing the mean experimental concentration of assayed samples with 
their nominal values, and the percentage bias was used as the index. The acceptable bias 
was set at ≤ 15% of the theoretical values at each concentration level except for the LOQ, 
for which 20% was acceptable.  
The validation of the analysis of samples with concentrations above the upper limit of 
quantification (ULOQ), was carried out by diluting additional QCs (100 ng/ml and 50 ng/ml) 
with human blank plasma by a factor of 10 or 5, respectively. Four replicates of each control 
sample were analyzed together with a calibration curve, after appropriate dilution of the 
samples. Accuracy and precision of the calculated QC concentrations, when multiplied with 
their respective dilution factors, had to be in the range of ±15% (Dadgar et al., 1995). 
The specificity of the method was evaluated by analysing plasma samples from six different 
sources to investigate the potential interferences at the LC peak region for each analyte and 
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IS. In addition, drugs which could be used in combination with MDZ (alprazolam, diazepam, 
flunitrazepam, oxazepam, lorazepam, carbamazepine, rifampicin and ketokonazole,) were 
dissolved in methanol (500 ng), dried, reconstituted with 150 μl acetonitrile:water (23:77, 
v/v) and were then injected under assay conditions. 
Recoveries at three concentrations (0.6, 3.7 and 15 ng/ml) were determined by comparing 
the peak areas of extracted samples (n=6) with those of pure QC standards prepared in 
mobile phase, which had not been extracted and were directly measured, containing the 
corresponding concentration of analytes. 
Possible matrix effects on the ESI response were investigated via post column continuous 
infusion (Annesley, 2003; Bonfiglio et al., 1999; Muller et al., 2002). Mobile phase was 
delivered into the electrospray interface at a flow rate of 0.24 ml/min while analyte (1μg/ml) 
was being infused, post column, through a PEEK tee union using a syringe pump (5 μl/min). 
Twenty μl of mobile phase or reconstituted blank plasma samples, extracted as previously 
described, were then injected onto the analytical column. Effluent from the column, 
combined with the infused analytes, entered the ESI interface and were analysed.  
The stability of MDZ and its metabolites in spiked human plasma was investigated under 
various storage conditions. In particular, QC samples (n=3) at two concentrations (0.6 and 
3.7 ng/ml) were stored for 24h at ambient temperature, 48h at 4°C and at –70°C over a time 
period of 8 months. To asses the stability of processed samples, QC samples were 
extracted and placed in the autosampler at 15°C for 24h and 48h, and then injected for 
analysis. Freeze-thaw stability was also evaluated by three complete cycles of freezing (-
70°C) and thawing (ambient temperature). Stability samples were analysed together with 
freshly prepared calibration samples. The percent deviation in concentration was used as 
indicator of stability. The analytes were considered to be stable, when the percent deviation 
was within ±15% of the expected concentration.  
 
3.3.7 Method application 
The developed method was used to investigate the plasma kinetic profiles of MDZ and its 
two metabolites 1´-OHMDZ and 4-OHMDZ. This study had been approved by the local 
ethics committee. After having given written informed consent, a healthy volunteer was 
treated with a single dose of 2 mg midazolam after an overnight fast. Blood samples were 
collected into heparinised tubes at 0, 30, 40, 60, 90, 120, 180, 240, 360 and 600 min after 
MDZ administration. Plasma samples were stored frozen at -70°C until analysis. 
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3.4 Results and Discussion 
3.4.1 Liquid chromatography and mass spectrometry 
Midazolam and its metabolites are basic compounds possessing a tertiary amine in their 
structure. Therefore, the positive ion mode was chosen for their determination. The 
electrospray ionisation process showed a predominant protonated molecule of [M+H]+ for all 
analysed compounds (data not shown). The formation of these ions may also be supported 
by the presence of acetic acid in the mobile phase. These [M+H]+ ions were selected as 
precursor ions to undergo collision-induced dissociation in the ion trap to produce the 
product ion spectra. Quantification was then carried out in the MS/MS product ion scan 
mode, from the [M+H]+ ion as precursor ion by using the two most abundant product ions 
(Table 1). 
In Figure 2A, a chromatogram (product ion scan) obtained from the analysis of a 
representative blank plasma sample is shown. No interfering peaks were observed in the 
extract. A chromatogram of a blank plasma sample spiked with 0.05 ng/ml MDZ and 
hydroxy-metabolites and 12 ng of IS is shown in Figure 2B. All compounds were well 
separated from each other, except the deuterated IS, which, as excpected, eluted at the 
same time as the unlabeled MDZ. The retention times for 4-OHMDZ, MDZ-d6 (IS), MDZ and 
1´-OHMDZ were 6.55, 6.99, 7.05 and 7.61 min. The total run time was 10.5 min.  
Stably labeled isotopes of the analytes of interest are desirable as internal standard when 
the analysis is performed by mass spectrometry. They are essentially identical regarding 
their chemical and chromatographic properties to the respective unlabeled compound, while 
being easily distinguishable by mass spectrometry because of their mass difference. In this 
case, as shown in Figure 2B, MDZ-d6 was used as IS. 
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Figure 2. Chromatograms (product ion scan) of (A) an extract of a blank plasma sample and (B) an 
extract of blank plasma spiked with 0.05 ng/ml midazolam (MDZ) 1´-hydroxymidazolam (1´-OHMDZ), 
4-hydroxymidazolam (4-OHMDZ) and 12 ng of MDZ-d6 (IS). The product ions used for quantification 
are as follows: MDZ m/z 326.2 Æ 291.3, 244.2; 1´-OHMDZ m/z 342.2 Æ 324.2, 203.2 ; 4-OHMDZ 
m/z 342.2 Æ 325.2, 234.2 and MDZ-d6 m/z 332.3 Æ 297.4, 247.2. 
 
 
 
To maximise the response of the respective precursor ion [M+H]+, the MS settings of the 
analyte were optimised while infusing solutions (1 μg/ml) of each compound at 8 μl/min into 
a flow of 240 μl/min of 45% mobile phase B. Various MS conditions (sheath and auxiliary 
gas flow, ESI probe temperature and capillary voltage) were investigated. The ESI probe 
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temperature was set at a minimum acceptable value (255°C) considering the flow rate of 
the mobile phase so as to avoid thermal degradation of the compounds. 
In order to detect midazolam and its metabolites at very low concentrations, a sufficient 
number of data points for each peak are required. Because an alternate switching from the 
MS (full MS) to the MS/MS (product ion scan) mode would reduce the sensitivity, due to the 
resulting reduction in the number of scans per peak, the full-scan (MS) mode was not used 
in this method. Additionally, by dividing the chromatographic run into segments and due to 
baseline separation of all substances analysed, the sensitivity of the method has been 
optimised.  
 
3.4.2 Validation data 
Validation of the assay was conducted according to FDA guidelines (Administration, 2001). 
Quantification was carried out in the MS/MS product ion scan mode using the two most 
abundant product ions (Table 1). The calibration curves were constructed by plotting the 
analyte/IS peak area ratio against the nominal concentrations of MDZ or its two metabolites, 
respectively. Good linear relationships were observed between 0.05-20 ng/ml. The 
recalculated calibrator concentrations (recalculation performed with 1/x weighted linear 
regressions, n=6) were used to validate the linearity. The results for MDZ showed 
accuracies of 100.0±4.2% and CV of better than 6.8%. The metabolites 1´-OHMDZ and 4-
OHMDZ had accuracies of 100.2±3.4% and 99.8±3.4% and CV between 3.2-9.3% and 2.7-
10.4%, respectively. The coefficients of determination (R2), obtained from six independent 
experiments, were better than 0.998. The validation data concerning linearity, LOD, LOQ 
and recovery are shown in detail in Table 2. 
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Table 2. Calibration and recovery data for midazolam (MDZ), 1´-hydroxymidazolam (1´-OHMDZ) and 
4-hydroxymidazolam (4-OHMDZ) in human plasma 
    Limits (ng/ml) Recovery (n=6)   
 
Compound 
Linear range 
(ng/ml) 
Slope 
(CV%) 
 
Mean R2  
 
LOD  
 
LOQ 
Nominal  
conc. (ng/ml) 
Mean ± 
SD (%) 
CV 
(%) 
MDZ 0.05-20 0.199  0.9991  0.025 0.05   0.6 87.7 ± 6.2 7.1 
  (2.2)      3.7 87.6 ± 5.9 6.7 
      15.0 96.4 ± 4.9 5.1 
    
1´-OHMDZ 0.05-20 0.207  0.9978  0.025 0.05   0.6 82.3 ± 2.2 2.7 
  (3.0)      3.7 89.9 ± 1.3 1.4 
      14.7 88.0 ± 2.6 2.9 
    
4-OHMDZ 0.05-20 0.112  0.9986  0.025 0.05   0.6 74.6 ± 3.2 4.3 
  (3.4)      3.7 82.3 ± 5.3 6.5 
      14.9 80.2 ± 1.9 2.3 
SD, standard deviation; CV, coefficient of variation; R2, coefficient of determination; LOD, limit of 
detection ; LOQ, limit of quantification 
 
 
The liquid-liquid extraction used in the assay yielded average recoveries of 90.6%, 86.7% 
and 79.0% for MDZ, 1´-OHMDZ and 4-OHMDZ, respectively. The limit of detection (LOD), 
defined as the lowest tested concentration yielding a signal-to-noise ratio higher than three, 
was 0.025 ng/ml in plasma, when a 1 ml sample volume was used. The LOQ was 
determined based on the criteria that (1) the signal-to noise ratio at the LOQ is at least 5 
(shown in Figure 2B) and (2) that the analyte response at LOQ can be determined with a 
CV of ≤20% and an accuracy of 80-120% (n=6) (Administration, 2001). Using the present 
method, the LOQ were found to be 0.05 ng/ml for all three substances investigated, 
showing accuracies between 102.1 and 106.4% and CV between 5.8 and 10.4%. A recently 
published GC-MS method has yielded a lower LOD and LOQ than the present technique 
(Eap et al., 2004). However GC methods require in general time-consuming sample 
preparation and derivatisation procedures for analysis. Compared to previously published 
LC-MS and LC-MS/MS assays, our method was found to be 2-70 times more sensitive for 
the quantification of MDZ and 1´-OHMDZ in human plasma (Jabor et al., 2005; Muchohi et 
al., 2005; Quintela et al., 2004; Smink et al., 2004). Furthermore, the present method offers 
the opportunity to detect and quantify the 4-hydroxy metabolite of MDZ as well. 
Intra- and inter-day precision and accuracy data were obtained at three different 
concentrations, covering the concentration range of the calibration standards used, and are 
summarised in Table 3. The CV ranged from 1.2 to 7.3% for MDZ, from 1.9 to 6.3% for 1´-
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OHMDZ and from 3.2 to 6.2% for 4-OHMDZ. The accuracy, presented as the percentage 
bias against the nominal concentration, was between 92.1 and 102.3%. 
 
Table 3. Intra-day and inter-day precision and accuracy for midazolam and metabolites in human 
plasma (n=6 determinations) 
 Intra-day    Inter-day   
 Low Medium  High  Low Medium  High 
Midazolam        
Nominal concentration (ng/ml)     0.6   3.7 15.0      0.6    3.7 15.0 
Mean found concentration (ng/ml)     0.6   3.6 14.3      0.6    3.7 14.5 
CV (%)     3.1   3.4   1.2      6.0    4.2   7.3 
Accuarcy (%) 100.4 96.2 95.6  102.3  99.5 96.6 
  
1´-hydroxymidazolam        
Nominal concentration (ng/ml)     0.6   3.7 14.7      0.6   3.7 14.7 
Mean found concentration (ng/ml)     0.6   3.5 14.0      0.6   3.5 14.0 
CV (%)     6.0   6.3   4.8      3.9   3.0   1.9 
Accuarcy (%)   98.8 95.5 95.3    98.5 94.3 95.5 
  
4-hydroxymidazolam        
Nominal concentration (ng/ml)     0.6   3.7 14.9      0.6   3.7 14.9 
Mean found concentration (ng/ml)     0.6   3.6 13.7      0.6   3.6 14.2 
CV (%)     4.4   6.1   4.6      6.2   3.5   3.2 
ccuarcy (%)   96.9 97.2 92.1    95.6 95.9 95.1 
CV, coefficient of variation 
 
Extrapolation of the calibration curve for the measurement of concentrations above the 
ULOQ, is not acceptable (Dadgar et al., 1995). Therefore, the effect of dilution of 
concentrated samples with human blank plasma was tested. The validation of this 
procedure showed the following results: For all substances, the 1/10 and 1/5 dilution yielded 
accuracies of 97.0-104.4% and 95.8-99.9%, respectively, with CV <6.5%. All of these 
values fall within the defined precision and accuracy criteria (Administration, 2001; Dadgar 
et al., 1995). 
Ion suppression, caused by co-eluting matrix components which can reduce the ionization 
efficiency of the analytes of interest, is often accompanied by diminished sensitivity, 
accuracy and precision of an analytical method. Due to the susceptibility of ESI to ion 
suppression, this matrix effect in plasma was evaluated by postcolumn continuous infusion, 
in order to observe the chromatographic profile and the analyte response in the presence of 
possible interferences (Annesley, 2003; Bonfiglio et al., 1999; Muller et al., 2002). No 
suppressive effects could be detected in the regions of interest under assay conditions. 
Determination of midazolam and its metabolites in plasma 
 67 
The specificity of the assay was also evaluated. No interfering peaks were observed 
following the extraction of plasma samples from six different human controls who were not 
receiving any medication. The extracted ion chromatogram of a representative blank 
plasma sample is shown in Figure 2A. Interferences with common drugs, which may be 
ingested in combination with the analyte, were also tested and found not to interfere with 
the analytes on the basis of different retention times and mass spectra (data not shown). 
All analytes were found to be stable in plasma when stored at -70°C for up to 8 months and 
at 4°C for 48h or after three freeze-thaw cycles. The mean deviations in the concentration of 
the analytes were -8.2 to 7.1%. The analytes were also stable for 24h at room temperature, 
except for 4-OHMDZ, where deviations in the concentration were up to -18.5%. However, if 
samples are analysed immediately after thawing, this limitation should be of minor 
importance. When dissolved in acetic solutions, the 4-hydroxy metabolite was not stable 
(data not shown), which has also been reported by other authors (Ha et al., 1993; Kuhn et 
al., 2003). A later eluting degradation product was present in the chromatogram under these 
conditions with a specific precursor ion (m/z 343,2) and product ion (m/z 315,2). To prevent 
4-OHMDZ from degradation, we were using acetonitrile:water (23:77, v/v) without 
supplementation of acetic acid for the dissolution of plasma extract residues. No significant 
loss was observed when extracts were kept in the autosampler at 15°C for up to 48h. The 
deviations in concentration were -6.8 to 4.8% for MDZ and 1´-OHMDZ and up to -11.0% for 
4-OHMDZ. Nearly no degradation product was observed under these conditions.  
 
3.4.3 Method application 
We have successfully used the described method for the quantitative measurement of MDZ 
and the two hydroxy-metabolites in plasma samples. Figure 3 shows an example of a 
chromatogram (product ion scan) obtained from a plasma sample drawn 90 min after the 
intake of a single oral dose of 2 mg midazolam by a healthy volunteer. The measured 
concentrations of MDZ, 1´-OHMDZ and 4-OHMDZ were 8.1, 2.2 and 0.3 ng/ml, 
respectively. The semi-logarithmic concentration-versus-time curves of MDZ and 
metabolites in this subject are shown in Figure 4. MDZ and 1´-OHMDZ could be quantified 
precisely in plasma until 10 h after the administration of a low oral MDZ dose. Since the 4-
hydroxy-metabolite is produced to a much smaller extent compared to 1´-OHMDZ, the 
pharmacokinetic profile of 4-OHMDZ in plasma has shown to be not assessable in many of 
the reported in-vivo studies due to the limited assay sensitivities (Carrillo et al., 1998; Eap et 
al., 2004). The presented LC-MS/MS method however showed a sufficient sensitivity, which 
allows the reliable quantification also of this minor metabolite until 6 h after drug 
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administration. The method therefore appears to be useful for the assessment of the 
CYP3A activity in humans following sub-therapeutic MDZ doses, allowing to minimise MDZ 
related adverse reactions. 
 
 
Figure 3. Chromatogram (product ion scan) of a plasma sample obtained after 90 min following the 
administration of a 2 mg single oral dose to a healthy volunteer. The measured concentrations were 
8.1, 2.2 and 0.3 ng/ml for midazolam (MDZ), 1´-hydroxymidazolam (1´-OHMDZ) and 4-
hydroxymidazolam (4-OHMDZ), respectively. The product ions used for quantification are the same 
as those shown in Figure 2. 
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Figure 4. Semi-logarithmic plasma concentration-versus-time profiles of midazolam (MDZ), 1´-
hydroxymidazolam (1´-OHMDZ) and 4-hydroxymidazolam (4-OHMDZ) following a single oral dose (2 
mg) of midazolam in a healthy volunteer. 
 
 
 
3.5 Conclusions 
We have developed a very sensitive, selective and reliable LC-MS/MS method for the 
quantitative determination of MDZ and two of its hydroxy-metabolites in human plasma. The 
method has been completely validated, including dilution and ion suppression effects, 
showing excellent results for all the parameters studied. The present method has been 
successfully applied to a human pharmacokinetic study, showing sufficient sensitivity to 
determine plasma concentrations of MDZ, 1´-OHMDZ and 4-OHMDZ following the 
administration of a sub-therapeutic oral MDZ dose (2 mg). Further studies are necessary to 
proof that the method is useful for low-dose CYP3A phenotyping in special populations such 
as elderly patient or patients with HIV infection. 
 
 
Acknowledgements 
We would like to thank F. Hoffmann-La Roche for providing the internal standard 
midazolam-d6. The study was supported by Swiss National Science Foundation Grant SNF 
310000-112483/1 (to S.K.). 
Determination of midazolam and its metabolites in plasma 
70 
3.6 References 
Administration UDoHaHSFaD (ed) (2001) Guidance for Industry: Bioanalytical Method Validation. US 
Department of Health and Human Sevices Beltsville, MD. 
Annesley TM (2003) Ion suppression in mass spectrometry. Clin Chem 49(7):1041-1044. 
Backman JT, Olkkola KT and Neuvonen PJ (1996) Rifampin drastically reduces plasma 
concentrations and effects of oral midazolam. Clin Pharmacol Ther 59(1):7-13. 
Bonfiglio R, King RC, Olah TV and Merkle K (1999) The effects of sample preparation methods on 
the variability of the electrospray ionization response for model drug compounds. Rapid 
Commun Mass Spectrom 13(12):1175-1185. 
Carrillo JA, Ramos SI, Agundez JA, Martinez C and Benitez J (1998) Analysis of midazolam and 
metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Ther 
Drug Monit 20(3):319-324. 
Dadgar D, Burnett PE, Choc MG, Gallicano K and Hooper JW (1995) Application issues in 
bioanalytical method validation, sample analysis and data reporting. J Pharm Biomed Anal 
13(2):89-97. 
De Kroon IF, Langendijk PN and De Goede PN (1989) Simultaneous determination of midazolam 
and its three hydroxy metabolites in human plasma by electron-capture gas chromatography 
without derivatization. J Chromatogr 491(1):107-116. 
Drummer OH (1998) Methods for the measurement of benzodiazepines in biological samples. J 
Chromatogr B Biomed Sci Appl 713(1):201-225. 
Eap CB, Bouchoux G, Powell Golay K and Baumann P (2004a) Determination of picogram levels of 
midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-
negative chemical ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life 
Sci 802(2):339-345. 
Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, 
Telenti A and Kerb R (2004b) Oral administration of a low dose of midazolam (75 microg) as 
an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 60(4):237-246. 
Eeckhoudt SL, Desager JP, Horsmans Y, De Winne AJ and Verbeeck RK (1998) Sensitive assay for 
midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-
performance liquid chromatography. J Chromatogr B Biomed Sci Appl 710(1-2):165-171. 
Frison G, Tedeschi L, Maietti S and Ferrara SD (2001) Determination of midazolam in human plasma 
by solid-phase microextraction and gas chromatography/mass spectrometry. Rapid Commun 
Mass Spectrom 15(24):2497-2501. 
Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Jr. and Hall SD (1998) The 
contribution of intestinal and hepatic CYP3A to the interaction between midazolam and 
clarithromycin. Clin Pharmacol Ther 64(2):133-143. 
Ha HR, Rentsch KM, Kneer J and Vonderschmitt DJ (1993) Determination of midazolam and its 
alpha-hydroxy metabolite in human plasma and urine by high-performance liquid 
chromatography. Ther Drug Monit 15(4):338-343. 
Heizmann P and Ziegler WH (1981) Excretion and metabolism of 14C-midazolam in humans 
following oral dosing. Arzneimittelforschung 31(12a):2220-2223. 
Jabor VA, Coelho EB, Dos Santos NA, Bonato PS and Lanchote VL (2005) A highly sensitive LC-
MS-MS assay for analysis of midazolam and its major metabolite in human plasma: 
applications to drug metabolism. J Chromatogr B Analyt Technol Biomed Life Sci 822(1-2):27-
32. 
Kharasch ED, Walker A, Hoffer C and Sheffels P (2004) Intravenous and oral alfentanil as in vivo 
probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use 
of pupillary miosis. Clin Pharmacol Ther 76(5):452-466. 
Determination of midazolam and its metabolites in plasma 
 71 
Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, 
Chaudhary AK, Roden DM, Wood AJ and Wilkinson GR (1999) Interrelationship between 
substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16(3):408-414. 
Kronbach T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA (1989) Oxidation of midazolam and 
triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36(1):89-96. 
Kuhn F, Oehme M and Schleimer M (2003) Performance and reliability of splitless microliter gradient 
pumps in a metabolic stability study using cytochrome P450/3A4 and capillary liquid 
chromatography-mass spectrometry. J Chromatogr A 1018(2):203-212. 
Lehmann B and Boulieu R (1995) Determination of midazolam and its unconjugated 1-hydroxy 
metabolite in human plasma by high-performance liquid chromatography. J Chromatogr B 
Biomed Appl 674(1):138-142. 
Lin JH and Lu AY (2001) Interindividual variability in inhibition and induction of cytochrome P450 
enzymes. Annu Rev Pharmacol Toxicol 41:535-567. 
Marquet P, Baudin O, Gaulier JM, Lacassie E, Dupuy JL, Francois B and Lachatre G (1999) 
Sensitive and specific determination of midazolam and 1-hydroxymidazolam in human serum 
by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 
734(1):137-144. 
Martens J and Banditt P (1997) Simultaneous determination of midazolam and its metabolites 1-
hydroxymidazolam and 4-hydroxymidazolam in human serum using gas chromatography-
mass spectrometry. J Chromatogr B Biomed Sci Appl 692(1):95-100. 
Mastey V, Panneton AC, Donati F and Varin F (1994) Determination of midazolam and two of its 
metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B 
Biomed Appl 655(2):305-310. 
Maurel P (1996) The CYP3 family, in Cytochromes P450: metabolic and toxicological aspects (C 
Ioannidis ed) p 241, CRC Press, Boca Raton. 
Muchohi SN, Ward SA, Preston L, Newton CR, Edwards G and Kokwaro GO (2005) Determination of 
midazolam and its major metabolite 1'-hydroxymidazolam by high-performance liquid 
chromatography-electrospray mass spectrometry in plasma from children. J Chromatogr B 
Analyt Technol Biomed Life Sci 821(1):1-7. 
Muller C, Schafer P, Stortzel M, Vogt S and Weinmann W (2002) Ion suppression effects in liquid 
chromatography-electrospray-ionisation transport-region collision induced dissociation mass 
spectrometry with different serum extraction methods for systematic toxicological analysis with 
mass spectra libraries. J Chromatogr B Analyt Technol Biomed Life Sci 773(1):47-52. 
Nordt SP and Clark RF (1997) Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 
15(3):357-365. 
Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS and 
Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin 
Pharmacol Ther 60(1):14-24. 
Quintela O, Cruz A, Concheiro M, de Castro A and Lopez-Rivadulla M (2004) A sensitive, rapid and 
specific determination of midazolam in human plasma and saliva by liquid 
chromatography/electrospray mass spectrometry. Rapid Commun Mass Spectrom 
18(24):2976-2982. 
Shiran MR, Gregory A, Rostami-Hodjegan A, Tucker GT and Lennard MS (2003) Determination of 
midazolam and 1'-hydroxymidazolam by liquid chromatography-mass spectrometry in plasma 
of patients undergoing methadone maintenance treatment. J Chromatogr B Analyt Technol 
Biomed Life Sci 783(1):303-307. 
Smink BE, Brandsma JE, Dijkhuizen A, Lusthof KJ, de Gier JJ, Egberts AC and Uges DR (2004) 
Quantitative analysis of 33 benzodiazepines, metabolites and benzodiazepine-like substances 
in whole blood by liquid chromatography-(tandem) mass spectrometry. J Chromatogr B Analyt 
Technol Biomed Life Sci 811(1):13-20. 
Determination of midazolam and its metabolites in plasma 
72 
Streetman DS, Bertino JS, Jr. and Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in 
adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 
10(3):187-216. 
ter Horst PG, Foudraine NA, Cuypers G, van Dijk EA and Oldenhof NJ (2003) Simultaneous 
determination of levomepromazine, midazolam and their major metabolites in human plasma 
by reversed-phase liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 
791(1-2):389-398. 
Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral 
first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated 
metabolism. Clin Pharmacol Ther 59(5):491-502. 
Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr 
DM, Perkins JD and et al. (1994a) Use of midazolam as a human cytochrome P450 3A probe: 
II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver 
transplantation. J Pharmacol Exp Ther 271(1):557-566. 
Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, 
McVicar JP, Barr DM and et al. (1994b) Use of midazolam as a human cytochrome P450 3A 
probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 
271(1):549-556. 
Tsunoda SM, Velez RL, von Moltke LL and Greenblatt DJ (1999) Differentiation of intestinal and 
hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of 
ketoconazole. Clin Pharmacol Ther 66(5):461-471. 
Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4(4):171-184. 
Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in 
humans. J Pharmacokinet Biopharm 24(5):475-490. 
Yin OQ, Lam SS, Lo CM and Chow MS (2004) Rapid determination of five probe drugs and their 
metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: 
application to cytochrome P450 phenotyping studies. Rapid Commun Mass Spectrom 
18(23):2921-2933. 
 
Determination of midazolam and its metabolites in saliva 
 73 
 
4 Highly sensitive method for the simultaneous 
quantification of midazolam and two of its 
metabolites in oral fluid using liquid 
chromatography-electrospray ionisation ion trap 
tandem mass spectrometry 
Bettina Link, Markus Wenk, Manuel Haschke and Stephan Krähenbühl  
 
Division of Clinical Pharmacology & Toxicology and Department of Research, 
 University Hospital Basel, Switzerland 
 
 
 
 
 
 
 
 
 
 
 
Determination of midazolam and its metabolites in saliva 
74 
4.1 Abstract 
Midazolam (MDZ), a short-acting benzodiazepine, is widely used as a probe drug for 
CYP3A phenotyping. So far, MDZ and two of its metabolites, 1´-hydroxy and 4-
hydroxymidazolam have been determined in human plasma for assessing the CYP3A 
activity. Since it may be of advantage to use oral fluid as a non-invasive matrix for this 
purpose, we developed and validated a sensitive liquid chromatography-electrospray 
ionisation tandem mass spectrometry (LC-MS/MS) method for the simultaneous detection 
and quantification of MDZ and its metabolites in oral fluid. The procedure includes liquid-
liquid extraction with hexane:dichlormethane (73:27, v/v), which is followed by the 
separation on a Luna C18(2) (100 x 2.1 mm I.D.) column using gradient elution. The 
detector was an ion trap mass spectrometer and quantification was carried out in the 
MS/MS product ion scan mode using midazolam-d6 as internal standard. Calibration curves 
were linear (R2>0.999) between 0.05 and 20 ng/ml and the limit of quantification was 0.05 
ng/ml for all analytes using a 1 ml oral fluid sample. Accuracies were between 96.6 and 
108% and the coefficients of variation were <7.6%. The method was successfully applied to 
a pharmacokinetic study, showing that the assay is suitable for analysing oral fluid samples 
obtained in vivo. Furthermore, it could be shown that the kinetics of MDZ and its 1´-
hydroxymetabolite in plasma and oral fluid are comparable with each other, resulting in a 
satisfactory correlation for MDZ (R2=0.972). Therefore, the method appears to be useful for 
CYP3A phenotyping in oral fluid. But larger studies are needed for definitive proof of this 
assumption.  
 
 
4.2 Introduction 
Midazolam (MDZ) is a short-acting benzodiazepine with hypnotic, anticonvulsant, muscle-
relaxant and anxiolytict properties. In clinical practise, it is used for the induction of 
anaesthesia, sedation and the treatment of generalized seizures or status epilepticus (Nordt 
and Clark, 1997). Furthermore, MDZ is a widely accepted probe drug for CYP3A 
phenotyping (Streetman et al., 2000). MDZ is rapidly metabolised by cytochrome P450 3A 
(CYP3A) to its primary, pharmacologically active metabolite 1´-hydroxymidazolam (1´-
OHMDZ) and to a smaller extent, to 4-hydroxymidazolam (4-OHMDZ) and 1,4-
dihydroxymidazolam. These metabolites are conjugated and then excreted as glucuronides 
in the urine (Bauer et al., 1995; Heizmann and Ziegler, 1981; Kronbach et al., 1989). 
Determination of midazolam and its metabolites in saliva 
 75 
Oral fluid has been increasingly used as an alternative biological matrix for therapeutic drug 
monitoring, pharmacokinetic studies, and detection of illicit drugs (Aps and Martens, 2005; 
Choo and Huestis, 2004; Drummer, 2005; Kidwell et al., 1998; Kintz and Samyn, 2002; 
Maurer, 2005). As compared to more conventional biological matrices used for these 
purposes, such as urine or blood, specimen collection for oral fluid is non-invasive and 
therefore less objectionable to patients, and is easy to perform without medical supervision, 
possibly representing therefore a cost-effective approach for screening large populations. 
The disadvantages of oral fluid usage include insufficient production, rendering quantitative 
analysis impossible, and a shorter time span for the possible detection of substances than 
in plasma (Choo and Huestis, 2004; Langman, 2007). 
The most common way of drug molecules to pass from blood to oral fluid is passive 
diffusion through lipid membranes, which is restricted to molecules that are lipophilic, 
uncharged, and not bound to plasma proteins (Aps and Martens, 2005; Choo and Huestis, 
2004). Since the salivary drug concentration correlates with the free, pharmacologically 
active concentration of drugs in plasma, for certain drugs the concentration in oral fluid may 
reflect drug effects better than the total plasma concentration (Horning et al., 1977). Active 
transportation and ultrafiltration through pores in cell membranes are additional 
mechanisms for drugs and metabolites to reach oral fluid (Chiappin et al., 2007; Langman, 
2007). Due to the extensive binding of benzodiazepines (MDZ 96%) to plasma proteins 
(Nordt and Clark, 1997), their concentrations in oral fluid are generally very low compared to 
that in plasma. For this reason, highly sensitive analytical methods must be used for their 
detection and quantification.  
Numerous methods have been developed for the determination of MDZ (and its 
metabolites) in biological matrices, including gas chromatography (GC) with different 
detecting systems (De Kroon et al., 1989; Eap et al., 2004; Frison et al., 2001; Martens and 
Banditt, 1997), high performance liquid chromatography (HPLC) with UV detection (Carrillo 
et al., 1998; Eeckhoudt et al., 1998; Ha et al., 1993; Lehmann and Boulieu, 1995; Yasui-
Furukori et al., 2004) and HPLC coupled to mass spectrometry (LC-MS) (Kratzsch et al., 
2004; Marquet et al., 1999; Quintela et al., 2004) or tandem mass spectrometry (LC-
MS/MS) (Jabor et al., 2005; Kapron et al., 2003; Yin et al., 2004).  
However, there are only few reports about the determination of MDZ in oral fluid. Quintela et 
al. have developed a sensitive LC-MS method for the quantification of MDZ in oral fluid 
(Quintela et al., 2005; Quintela et al., 2004) and Kintz et al. described a screening method 
for benzodiazepines and hypnotics in oral fluid by LC-MS/MS after the extraction of 0.5 ml 
matrix (Kintz et al., 2005). Gunnar et al. have described a GC-MS method for the 
simultaneous determination of various drugs of abuse in oral fluid, including MDZ. However, 
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none of the three methods used in these studies determined the metabolites of MDZ 
(Gunnar et al., 2005). Very recently, a method has been reported for screening urine and 
oral fluid for benzodiazepines and benzodiazepine-like substances by LC-MS(/MS) and an 
immunoassay (Smink et al., 2006). For all of these methods, the limit of quantification for 
MDZ was either in the ng/ml range or in the high pg/ml range. 
To our knowledge, no analytical method for the separation and quantification of MDZ and its 
1´- and 4-hydroxymetabolites in oral fluid has been described so far. For this reason, the 
aim of our study was to develop and validate a very sensitive LC-MS/MS method, which 
allows the simultaneous detection and quantification of MDZ, 1´-OHMDZ and 4-OHMDZ in 
the pg/ml range in oral fluid. The validated method was applied to a pharmacokinetic study 
to determine the oral fluid concentrations of MDZ and its metabolites after the administration 
of a single intravenous dose of 2 mg MDZ to a healthy volunteer. 
 
 
4.3 Experimental 
4.3.1 Chemicals 
Midazolam hydrochloride (MDZ, purity 99.6%), 1´-hydroxymidazolam (1´-OHMDZ, purity 
99.7%) and 4-hydroxymidazolam (4-OHMDZ, purity 99.1%) were purchased from Lipomed 
AG (Arlesheim, Switzerland). The internal standard (IS) midazolam-d6 was a kind gift from 
F. Hoffmann-La Roche (Basel, Switzerland). Acetic acid (Suprapur®) as well as LiChrosolv® 
grade water, acetonitrile, hexane and dichlormethane were from Merck (Darmstadt, 
Germany). Glycine was of ultra pure grade and purchased from Fluka (Buchs, Switzerland). 
All other chemicals and solvents were of analytical grade or better and were purchased 
either from Fluka, Sigma-Aldrich (Buchs, Switzerland) or from Merck. 
 
4.3.2 Preparation of stock and standard solutions 
Standard stock solutions of MDZ, 1´-OHMDZ, 4-OHMDZ were prepared in methanol at 0.6 
mg/ml and stored light protected at -70°C for up to 6 months. From these stock solutions, 
methanolic working solutions of each compound at 60 µg/ml were made. A mixed working 
solution containing MDZ, 1´-OHMDZ and 4-OHMDZ was prepared from the individual 
working solutions and was used to prepare a series of mixed standard spiking solutions 
after subsequent dilution with methanol to give concentrations in the range 2-800 ng/ml. 
Three mixed standard QC spiking solutions of 600, 148 and 12 ng/ml were obtained by the 
dilution of an independently prepared mixed working solution with methanol. 
Determination of midazolam and its metabolites in saliva 
 77 
An IS stock solution of 12 μg/ml midazolam-d6 was prepared in methanol. A working 
solution containing 1.2 μg/ml IS was obtained by diluting the IS stock solution with 
methanol. All standard solutions were stored at -70°C. 
 
4.3.3 Oral fluid collection 
Human blank oral fluid samples were obtained from healthy volunteers by spitting into a 
polypropylene tube without any stimulation of the saliva production. The oral fluid donors 
were instructed not to eat or to drink 30 min before sampling and to rinse their mouth with 
fresh water before spitting. After centrifugation at 2500 x g for 10 min to remove potential 
food debris, the supernatant was stored frozen at -20°C. All blank samples were screened 
prior to use to ensure that they were free from endogenous interferences at the retention 
time of the analytes. For the development and validation of the method, drug-free oral fluid 
from seven different sources were pooled and used to prepare oral fluid calibrators and 
quality control (QC) samples.  
 
4.3.4 Spiked oral fluid calibration standards and quality control samples 
Oral fluid calibration standards as well as QC samples were prepared freshly each day with 
concentrations of 0.05, 0.1, 0.2, 0.5, 1, 2, 5, 10 and 20 ng/ml or of 0.3 (QC low), 3.7 (QC 
medium) and 15 ng/ml (QC high), respectively, by spiking blank oral fluid with the 
appropriately mixed (QC) standard spiking solution.  
 
4.3.5 Sample preparation  
To 1 ml oral fluid, 1 ml 0.75 M glycine buffer (pH 9.2), 10 μl IS working solution (1.2 μg/ml in 
methanol) and 25 μl of the appropriate mixed spiking solution (in case of the calibrators or 
QC samples) or methanol (for unspiked oral fluid samples) were added. Extraction was 
performed by adding 7 ml n-hexane:dichlormethane (73:27, v/v) to each tube and mixing on 
a flat-bed shaker (Infors AG, Basel, Switzerland) for 15 min. After centrifugation at 2500 x g 
for 5 min, the two phases were separated by freezing out of the water phase in a dry 
ice/acetone bath. The organic layer was then transferred into a silanised glass tube and 
evaporated to dryness under nitrogen at 40°C using a TurboVap® evaporator (Zymark, 
Hopkinton, MA, USA). The residue was reconstituted in 150 μl acetonitrile:water (23:77, v/v) 
and 20 μl were injected onto the column for LC-MS/MS analysis. 
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4.3.6 Instrumentation and chromatographic conditions 
Separation of the analytes was performed on a HP 1100 system (Agilent Technologies, 
Palo Alto, CA, USA), which consisted of a degaser, a quaternary pump and an autosampler. 
Aliquots (20 µl) were injected onto a Luna C18(2) analytical column (100 x 2.1 mm I.D., 
particle size 3 μm) equipped with a corresponding pre-column C18 ODS, 4 x 2.1 mm I.D. 
(Phenomenex, Torrance, CA, USA) maintained at 40°C. The mobile phases consisted of 
0.1% acetic acid in water:acetonitrile (90:10, v/v) (eluent A) or in acetonitrile (eluent B). 
Starting at 5% B, the gradient increased linear to 17% B in 0.5 min, was kept at 17% B for 
1.5 min and was increased linear to 80% B within 1.5 min, which was followed by a plateau 
at 80% B for 3 min. The column was then re-equilibrated with 5% B for 4.5 min. The flow 
rate was 0.24 ml/min and the autosampler temperature was set at 15°C. 
Detection was performed using a LCQDECA ® ion trap mass spectrometer (Thermo Fischer 
Scientific, Inc., MA, USA). Ionisation was achieved using electrospray in the positive 
ionisation mode (ESI+, 4kV). In order to maximise the response of the respective precursor 
ion [M+H]+, acquisition parameters were determined by the direct infusion of standard 
solutions (1 μg/ml) at 8 μl/min into a flow of 240 μl/min of 45% mobile phase B. Various MS 
conditions such as sheath and auxiliary gas flow, ESI probe temperature and capillary 
voltage were investigated. During the experiment, a mass range from m/z 100-500 was 
monitored and the acquisition was carried out in the selected ion monitoring (SIM) mode. 
The final operating conditions were chosen as follows: sheath gas (N2) pressure was set at 
80 arbitrary units, auxiliary gas (N2) pressure was set at 6 arbitrary units and capillary 
voltage at 3 kV. The heated capillary temperature was kept at 255 °C so as to avoid thermal 
degradation of the compounds. Helium was used as collision gas. 
Data acquisition and quantitative analysis were performed using Xcalibur 1.2 software 
(Thermo Fischer Scientific, Inc.). For quantification of MDZ and its hydroxymetabolites, the 
MS/MS product ion scan mode was chosen. Each compound was associated with a specific 
retention time segment. During this time window, one precursor ion [M+H]+ was stored and 
further fragmented with a collision energy that allowed a sufficient fragmentation of the 
selected ion. MDZ-d6 is a stable isotope of MDZ and therefore elutes in the same segment 
as its respective analyte. Detailed fragmentation parameters are given in Table 1. Automatic 
gain control was employed using one microscan and a maximum injection time of 200 ms.  
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Table 1. LC-MS/MS parameters for the quantitative determination of midazolam and two of its 
metabolites in oral fluid 
CE, collision energy; Rt, retention time; IS, internal standard 
The most abundant product ion is underlined 
 
 
 
4.3.7 Method validation 
Validation was performed based on Guidance for Industry, Bioanalytical method validation 
issued by the Food and Drug Administration (FDA) in May 2001 (Administration, 2001). 
Linearity of the developed LC-MS/MS method was investigated for MDZ and two of its 
metabolites in oral fluid in six independent analytical runs. To construct calibration curves, 
the peak area ratios of the appropriate standard to those of the IS were plotted against the 
analyte concentration of the standard. Linear regressions were calculated with a weighting 
factor of 1/x. Calibrations (nine points) were prepared in concentration ranges of 0.05 to 20 
ng/ml. Oral fluid employed for the validation was screened prior to use to determine the 
absence of interfering peaks.  
In order to evaluate the precision and accuracy of the method, QC samples were processed 
in six replicates at each of the three different concentrations covering the calibration range, 
on the same (intra-day variability) and on different days (inter-day variability). Precision 
should not exceed 15% of the coefficient of variation (CV) at each concentration level, 
except for the lower limit of quantification (LLOQ) for which 20% was acceptable. Accuracy 
was calculated by comparing the mean experimental concentration of assayed samples 
with their nominal values, and the percentage bias was used as the index. The acceptable 
bias was set at ≤15% of the theoretical values at each concentration level except for the 
LLOQ, for which 20% was acceptable.  
The limit of detection (LOD) was calculated at a signal-to-noise ratio of higher than three. 
The LLOQ was determined based on the criteria that (1) the signal-to noise ratio at the 
LLOQ is at least 5 and (2) that the analyte response at LLOQ can be determined with CV of 
≤20% and accuracy of 80-120% (n=6). 
The efficiency of the extraction procedure was assessed by analysing six replicates of 
spiked oral fluid samples at each of the three different concentrations (0.3, 3.7 and 15 
 
 
Compound 
 
Rt (min) 
 
Segment 
(min) 
 
Scan range
(m/z) 
 
Precursor 
ion (m/z) 
Product ions 
(m/z) used for 
quantification 
 
CE 
(eV) 
 
Isolation 
Width (m/z) 
4-hydroxymidazolam 6.55 1  (5.50-6.75) 120-400 342.2 325.2, 234.2 35 1.4 
Midazolam-d6 (IS) 6.99 2  (6.75-7.40) 180-405 332.3 297.4, 247.2 40 1.5 
Midazolam 7.05 2  (6.75-7.40) 100-390 326.2 291.3, 244.2 40 1.5 
1´-hydroxymidazolam 7.61 3  (7.40-8.10) 190-445 342.2 324.2, 203.2 35 1.4 
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ng/ml). Recoveries were determined by comparing the peak areas of the extracted spiked 
samples with those of extracted blank sample spiked with the same amount of analyte after 
extraction. 
Possible matrix effects on the ESI response were investigated via post column continuous 
infusion (Annesley, 2003; Bonfiglio et al., 1999; Muller et al., 2002). Mobile phase was 
delivered into the electrospray interface at a flow rate of 0.24 ml/min while analyte (1μg/ml) 
was being infused, post column, through a PEEK tee union using a syringe pump (5 μl/min). 
20 μl of mobile phase or reconstituted blank plasma samples, extracted as previously 
described, were then injected onto the analytical column. Effluent from the column 
combined with the infused analytes entered the ESI interface and was analyzed.  
Specificity of the method was also evaluated. Drugs which are often used in combination 
with MDZ (alprazolam, diazepam, flunitrazepam, oxazepam, lorazepam, carbamazepine, 
rifampicin and ketokonazole) were diluted in either methanol or ethanol, dried under 
nitrogen, reconstituted with 150 µl acetonitrile:water (23:77 v/v) and injected onto the 
column.  
The stability of MDZ and its metabolites was investigated under various storage conditions 
using spiked oral fluid (n=3) prepared at two QC concentrations (0.3 and 3.7 ng/ml). 
Samples were stored for 24h at ambient temperature, 48h in the refrigerator and at –70°C 
over a time period of 10 months. For the evaluation of freeze-thaw stability, QC samples 
were analysed after three complete cycles of freezing (-70°C) and thawing (ambient 
temperature). To asses the stability of processed samples, QC samples were extracted and 
placed in the autosampler at 15°C for 24h and 48h, and then injected for analysis. Stability 
samples were analysed together with freshly prepared samples. The percent deviation in 
concentration was used as an indicator of stability. The analytes were considered to be 
stable, when the percent deviation was within ±20% of the expected concentration.  
 
4.3.8 Method application 
The developed LC-MS/MS method was used to investigate oral fluid kinetic profiles of MDZ 
and two of its metabolites 1´-OHMDZ and 4-OHMDZ in a pharmacokinetic study that was 
approved by the local ethics committee. After having given written informed consent, a 
healthy male volunteer (46 years, 74 kg) was treated with a single intravenous dose of 2 mg 
midazolam after an overnight fast. Oral fluid samples were collected at 0, 10, 20, 30, 40, 60, 
80, 100, 120, 150, 180, 240, 360 and 480 min after MDZ administration. Blood samples 
were drawn into heparinised tubes at the following time points: 0, 10, 20, 30, 40, 60, 90, 
120, 240, 360, 480, 600, 1440 min after drug administration. After centrifugation of both 
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matrices at 2500 x g for 10 min, plasma and oral fluid samples were separated and stored 
frozen at -70°C until analysis. The analysis of plasma was carried out by a validated LC-
MS/MS method as described in Chapter 3.  
 
 
4.4 Results and Discussion 
4.4.1 Liquid chromatography and mass spectrometry 
MDZ and its metabolites could be well separated in less than 8 min by reversed phase 
liquid chromatography using gradient elution. The retention times for 4-OHMDZ, MDZ-d6 
(IS), MDZ and 1´-OHMDZ were 6.55, 6.99, 7.05 and 7.61 min, respectively. The total run 
time was 11 min. Figure 1B shows a representative chromatogram (product ion scan) of a 
blank oral fluid sample spiked with 0.05 ng/ml MDZ and metabolites (LLOQ) and 12 ng of IS 
under the developed conditions. For mass spectrometry analysis, stably labeled isotopes of 
the analytes of interest are desirable as internal standard. They are essentially identical 
regarding their chemical and chromatographic properties to the respective unlabeled 
compound, while being easily distinguishable by mass spectrometry because of their mass 
difference. In the present study, MDZ-d6 was used, which, as expected, elutes in the same 
time segment as unlabeled MDZ. As shown in Figure 1A, no interfering peaks were 
observed following the extraction of representative pooled oral fluid samples from seven 
different human controls who were not receiving any medication.   
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Figure 1. LC-MS/MS chromatograms (product ion scan) of (A) an extract of a blank oral fluid sample 
and (B) an extract of blank oral fluid spiked with 0.05 ng/ml midazolam (MDZ), 1´-hydroxymidazolam 
(1´-OHMDZ), 4-hydroxymidazolam (4-OHMDZ) and 12 ng of MDZ-d6 (IS). The product ions used for 
quantification are as follows: MDZ m/z 326.2 Æ 291.3, 244.2; 1´-OHMDZ m/z 342.2 Æ 324.2, 203.2; 
4-OHMDZ m/z 342.2 Æ 325.2, 234.2; IS m/z 332.3 Æ 297.4, 247.2. 
 
 
As MDZ and its metabolites are basic compounds, possessing a tertiary amine in their 
structures, the positive ion mode was chosen for their determination. For all analysed 
compounds, the electrospray ionisation process showed a predominant protonated 
molecule [M+H]+ (data not shown). These [M+H]+ ions were selected as precursor ions to 
undergo collision-induced dissociation in the ion trap. The resultant MS/MS product ion 
scan spectra and structures are presented in Figure 2. The precursor and product ions 
selected for each analyte are given in Table 1, together with the optimal collision energy 
and isolation width.  
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Formation of the positively charged ions may also be supported using acidic condition in the 
mobile phase. Among the acids tested, acetic acid provided high production efficiency of 
[M+H]+ combined with low baseline noise. 
 
 
Figure 2. Chemical structures and/or product ion spectra of (A) midazolam, its two metabolites (B) 
1´-hydoxymidazolam and (C) 4-hydroxymidazolam, and (D) midazolam-d6, which was used as 
internal standard. 
 
 
For the determination of MDZ and its two metabolites in the pg/ml range in oral fluid, a very 
sensitive analytical method was required. Therefore, the MS/MS settings were adjusted to 
maximise the response of each precursor-product ion combination. In addition, the 
chromatographic run was divided into segments in which only one or two precursor ions 
were stored for further fragmentation. In this way, the number of cycles of measurement 
increased and more data points per peak could be gained.  
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4.4.2 Validation data 
The linearity of the method was evaluated for MDZ, 1´-OHMDZ and 4-OHMDZ in oral fluid. 
Calibration curves were linear from 0.05 to 20 ng/ml for all analytes. Using 1/x weightened 
linear regressions, coefficients of determination (R2) of better than 0.999 were obtained in 
six independent analytical runs (Table 2). Quantification was carried out in the MS/MS 
product ion scan mode using the two most abundant product ions (see Table 1, Figure 2) 
and calibration curves were constructed by plotting the analyte/IS peak area ratio against 
the nominal concentrations of the respective analyte. The recalculated calibrator 
concentrations (n=6) were used to validate linearity. Deviations of the mean calculated 
concentrations should not exceed ±15% of the nominal concentration, except for the lower 
limit of quantification (LLOQ) where a deviation of 20% was permitted. With accuracies of 
100.1 ± 4.1% and CV of better than 5.4%, the results for MDZ fulfil the defined validation 
criteria. Similar data were obtained for the metabolites with accuracies between 95.0 and 
105.4% and CV of better than 7%. 
 
Table 2. Calibration and recovery data for midazolam (MDZ), 1´-hydroxymidazolam (1´-OHMDZ) and 
4-hydroxymidazolam (4-OHMDZ) in human oral fluid 
SD, standard deviation; CV, coefficient of variation; R2, coefficient of determination; LOD, limit of 
detection; LOQ, limit of quantification  
 
 
Limits of quantification were determined as the lowest concentration with a relative deviation 
of replicate runs of less than 20%. Using 1 ml oral fluid sample, the LLOQ were found to be 
0.05 ng/ml for all three compounds (Table 2) with accuracies between 102.6 and 105.4% 
and CV between 5.4 and 7.4%. The limit of detection was 0.025 ng/ml. This represents a 2-
45-fold increase in sensitivity as compared to previously published analytical methods for 
    Limits (ng/ml) Recovery (n=6)  
 
Compound 
Linear range 
(ng/ml) 
 
Mean R2 
Slope 
(CV %) 
 
LOD 
 
LOQ 
Nominal 
conc. (ng/ml) 
Mean ± 
SD (%) 
CV 
(%) 
MDZ 0.05-20 0.9992 0.181 0.025 0.05 0.3 94.8 ± 4.4 4.6 
   (2.2)   3.7 95.5 ± 3.2 3.4 
      14.9 95.6 ± 4.7 4.7 
     
1´-OHMDZ 0.05-20 0.9994 0.197 0.025 0.05 0.3 97.9 ± 1.3 1.4 
   (4.2)   3.7 96.7 ± 2.5 2.6 
      14.8 95.1 ± 4.7 4.9 
     
4-OHMDZ 0.05-20 0.9991 0.111 0.025 0.05 0.3 87.2 ± 2.7 3.1 
   (3.9)   3.7 85.9 ± 3.5 4.1 
      14.7 87.4 ± 4.9 5.6 
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the quantitative determination of MDZ and 1´-OHMDZ in oral fluid (Gunnar et al., 2005; 
Kintz et al., 2005; Quintela et al., 2005; Quintela et al., 2004; Smink et al., 2006).  
Using a mixture of hexane:dichlormethane (73:27 v/v), MDZ and two of its metabolites can 
be simultaneously extracted from oral fluid yielding extraction recoveries between 86 and 
98% with CV < 5.6% (see Table 2). As shown in Table 3, intra-day precision and accuracy 
were determined at three concentrations, covering the concentration range of the calibration 
standards used, by analysing on the same day six replicates of each QC level. CV ranged 
from 1.3 to 4.0% and accuracies were between 96.6 and 108.0%. Inter-day variabilities 
were assessed by the analysis of QC samples at three concentrations each day for six 
days. The accuracy values ranged from 96.8 to 104.3% and CV were between 1.3 and 
7.6%.  
An important problem when using ESI is the possible reduction of ionisation. The so-called 
ion suppression results from the presence of co-eluting compounds (salts, drugs, 
endogenous compounds, ion-pair agents) that can change the efficiency of droplet 
formation or droplet evaporation, which affects the amount of charged ions that reaches the 
detector (Annesley, 2003; Dams et al., 2003; Liang et al., 2003; Muller et al., 2002). Ion 
suppression could possibly influence assay sensitivity, accuracy and precision of an LC-
MS(/MS) method. Due to the susceptibility of ESI to ion suppression, this matrix effect in 
oral fluid was evaluated by postcolumn continuous infusion, in order to observe the 
chromatographic profile and the analyte response in the presence of the possible interfering 
species (Annesley, 2003; Bonfiglio et al., 1999; Muller et al., 2002). Large differences in 
matrix effect were observed between various sample preparation techniques (data not 
shown). Liquid-liquid extraction with hexane:dichlormethane (27:73 v/v) yields very clean 
oral fluid extracts. No suppressive effects could be detected in the regions of interest under 
assay conditions.  
To evaluate the specificity of the method, 500 ng of the following drugs, which are often co-
administered with MDZ, were injected under assay conditions: alprazolam, diazepam, 
flunitrazepam, oxazepam, lorazepam, carbamazepine, rifampicin and ketokonazole. 
Interferences could be excluded for all the compounds on the basis of different retention 
times and mass spectra (data not shown). 
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Table 3. Intra-day and inter-day precision and accuracy for midazolam and metabolites in human 
oral fluid (n=6 determinations) 
  Intra-day     Inter-day   
  Low Medium  High  Low Medium  High 
Midazolam       
Nominal concentration (ng/ml)       0.3     3.7   14.9       0.3      3.7   14.9 
Mean found concentration (ng/ml)       0.3     3.9   14.7       0.3      3.8   14.6 
CV (%)       4.0     2.5     2.7       2.9      2.2     1.3 
Accuarcy (%)     98.0 103.2   98.3     98.3  101.9   97.8 
   
1´-hydroxymidazolam       
Nominal concentration (ng/ml)       0.3     3.7   14.8       0.3     3.7   14.8 
Mean found concentration (ng/ml)       0.3     3.7   14.3       0.3     3.8   14.4 
CV (%)       1.3     3.4     2.8       1.5     7.4     3.2 
Accuarcy (%)     99.6   99.4   96.6   102.1 101.5   96.8 
   
4-hydroxymidazolam       
Nominal concentration (ng/ml)       0.3     3.7   14.7       0.3     3.7   14.7 
Mean found concentration (ng/ml)       0.3     4.0   15.7       0.3     3.8   15.1 
CV (%)       3.4     2.8     2.6       5.0     7.6    3.6 
Accuarcy (%)   108.0 107.8 106.6    104.3 102.6 103.0 
CV, coefficient of variation 
 
All analytes were found to be stable in oral fluid when stored at -70°C for up to 10 months, 
kept in the autosampler at 15°C for up to 48h or after three freeze-thaw cycles. The mean 
deviations in the concentration of the analytes were between -17.7 and 7.4%. No significant 
loss for MDZ and 1´-OHMDZ was observed when samples were stored at ambient 
temperature for 24h or in the refrigerator for 48h. However, the 4-hydroxy metabolite seems 
to be less stable in oral fluid at these conditions with deviations in concentrations up to -
24.5%. A later eluting degradation product was present in the chromatogram with a base 
ion m/z 343.2 and a product ion m/z 315.2. Therefore, to overcome this problem, the oral 
fluid samples were immediately extracted and analysed after thawing. 
 
4.4.3 Method application 
We have successfully applied the described LC-MS/MS method for the determination and 
quantitative measurement of midazolam and metabolites in oral fluid samples originated 
from a small pharmacokinetic study. Figure 3 shows an example of a chromatogram 
(product ion scan) obtained from the analyses of an oral fluid sample drawn 30 min after the 
administration of a single intravenous dose of 2 mg midazolam to a healthy volunteer. The 
measured concentration of MDZ and 1´-OHMDZ were 0.9 and 0.2 ng/ml, respectively. 
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Despite the very low concentrations of parent drug found in oral fluid, the analytical method 
showed a sufficient sensitivity to detect also the minor metabolite 4-OHMDZ, which has not 
been described in the literature so far. However, quantification of this metabolite was not 
possible in this volunteer (concentrations were <0.05 ng/ml).  
 
Figure 3. LC-MS/MS chromatograms (product ion scan) obtained from the analysis of an oral fluid 
sample drawn 30 min after the intravenous administration of a 2 mg single dose of midazolam to a 
healthy volunteer. The measured concentrations were 0.9 ng/ml for midazolam (MDZ) and 0.2 ng/ml 
1´-hydroxymidazolam (1´-OHMDZ). The concentration of 4-OHMDZ was too low for quantification. 
The product ions used for quantification are the same ones as those shown in Figure 1. 
 
 
In the present study, concentrations of MDZ, 1´-OHMDZ and 4-OHMDZ have also been 
determined in plasma, in order to evaluate a possible correlation between the oral fluid and 
plasma drug concentration. The semi-logarithmic concentration-versus-time curves of MDZ 
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and its major metabolite in oral fluid and plasma are shown in Figure 4. To our knowledge, 
this is the first method that has shown a sufficient sensitivity permitting the determination of 
the pharmacokinetic profiles of MDZ and its major metabolite in oral fluid. Quantification of 
MDZ was at least possible for 8 h after intravenous administration of a single intravenous 
dose of 2 mg MDZ. As compared to plasma, the oral fluid MDZ concentrations were roughly 
two orders of magnitude lower, which was assigned to the extensive binding of MDZ to 
plasma proteins of about 96%. However, Figure 4 shows that the patterns of MDZ and 1´-
OHMDZ pharmacokinetic profiles in oral fluid and plasma agreed well with each other. The 
comparison of oral fluid and plasma concentrations from 30 to 480 min after administration 
showed a linear relationship (R2=0.9717), suggesting the existence of a good correlation 
(Figure 5). Further studies are necessary to definitely confirm these results and to proof the 
suitability of oral fluid for CYP3A phenotyping. 
 
Figure 4. Semi-logarithmic concentration-versus-time profiles of midazolam (MDZ) and 1´-
hydroxymidazolam (1´-OHMDZ) in oral fluid and plasma following a single intravenous dose (2 mg) 
of midazolam in a healthy volunteer.   
 
One of the major disadvantages of using oral fluid as a diagnostic specimen is that subjects 
may produce insufficient sample volume for analysis. In the study of Quintela et al., an 
adequate oral fluid volume could be obtained in <50% of cases using a Salivette® device 
(Quintela et al., 2004) . Stimulation of the oral fluid flow by various methods might increase 
the sample volume and therefore permit the collection of larger samples in a shorter time, 
but this method may impact the analytical results, e.g. by altering the oral fluid pH (Choo 
and Huestis, 2004). In our study, collection of oral fluid by spitting into a polypropylene tube 
Time (min)
0 200 400 600 800 1000 1200 1400
P
la
sm
a 
an
d 
or
al
 fl
ui
d 
co
nc
en
tra
tio
n 
(n
g/
m
l)
0.01
0.1
1
10
100
1000
MDZ in plasma
 MDZ in oral fluid
1´-OHMDZ in plasma 
1´-OHMDZ in oral fluid
Determination of midazolam and its metabolites in saliva 
 89 
produced enough oral fluid volume (> 1 ml) without necessitating stimulation of saliva 
production for the quantitative analysis.  
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Figure 5. Correlation between MDZ plasma and saliva concentrations at 30-480 min after the 
administration of a 2 mg single intravenous dose of MDZ. The relationship is characterised by the 
following equation y=0,0295x + 0,0132 (R2=0,9717). 
 
 
4.5 Conclusions 
In this paper, we presented the development of a sensitive, selective and reliable LC-
MS/MS method which allows for the first time the simultaneous determination of MDZ and 
two of its metabolites in human oral fluid. It has been completely validated, showing good 
results for all the parameters studied. Since the method can be used to determine the 
pharmacokinetics of MDZ and 1´-OHMDZ in oral fluid and since a correlation between 
plasma and oral fluid MDZ concentrations seems to be very probable, the described method 
should be suitable for assessing the CYP3A activity in oral fluid. This may offer several 
advantages as compared to other matrices such as plasma or urine. The possibility of 
conducting simple and non-invasive CYP3A phenotyping with our method has to be 
investigated in a larger population under various conditions of CYP3A activity. 
 
 
Acknowledgements 
We would like to thank F. Hoffmann-La Roche for providing the internal standard 
midazolam-d6 
Determination of midazolam and its metabolites in saliva 
90 
4.6 References  
Administration UDoHaHSFaD (ed) (2001) Guidance for Industry: Bioanalytical Method Validation. US 
Department of Health and Human Sevices Beltsville, MD. 
Annesley TM (2003) Ion suppression in mass spectrometry. Clin Chem 49(7):1041-1044. 
Aps JK and Martens LC (2005) Review: The physiology of saliva and transfer of drugs into saliva. 
Forensic Sci Int 150(2-3):119-131. 
Bonfiglio R, King RC, Olah TV and Merkle K (1999) The effects of sample preparation methods on 
the variability of the electrospray ionization response for model drug compounds. Rapid 
Commun Mass Spectrom 13(12):1175-1185. 
Chiappin S, Antonelli G, Gatti R and De Palo EF (2007) Saliva specimen: a new laboratory tool for 
diagnostic and basic investigation. Clin Chim Acta 383(1-2):30-40. 
Choo RE and Huestis MA (2004) Oral fluid as a diagnostic tool. Clin Chem Lab Med 42(11):1273-
1287. 
Dams R, Huestis MA, Lambert WE and Murphy CM (2003) Matrix effect in bio-analysis of illicit drugs 
with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J Am Soc Mass 
Spectrom 14(11):1290-1294. 
Drummer OH (2005) Review: Pharmacokinetics of illicit drugs in oral fluid. Forensic Sci Int 150(2-
3):133-142. 
Gunnar T, Ariniemi K and Lillsunde P (2005) Validated toxicological determination of 30 drugs of 
abuse as optimized derivatives in oral fluid by long column fast gas chromatography/electron 
impact mass spectrometry. J Mass Spectrom 40(6):739-753. 
Horning MG, Brown L, Nowlin J, Lertratanangkoon K, Kellaway P and Zion TE (1977) Use of saliva in 
therapeutic drug monitoring. Clin Chem 23(2 PT. 1):157-164. 
Kidwell DA, Holland JC and Athanaselis S (1998) Testing for drugs of abuse in saliva and sweat. J 
Chromatogr B Biomed Sci Appl 713(1):111-135. 
Kintz P and Samyn N (2002) Use of alternative specimens: drugs of abuse in saliva and doping 
agents in hair. Ther Drug Monit 24(2):239-246. 
Kintz P, Villain M, Concheiro M and Cirimele V (2005) Screening and confirmatory method for 
benzodiazepines and hypnotics in oral fluid by LC-MS/MS. Forensic Sci Int 150(2-3):213-220. 
Langman LJ (2007) The use of oral fluid for therapeutic drug management: clinical and forensic 
toxicology. Ann N Y Acad Sci 1098:145-166. 
Liang HR, Foltz RL, Meng M and Bennett P (2003) Ionization enhancement in atmospheric pressure 
chemical ionization and suppression in electrospray ionization between target drugs and 
stable-isotope-labeled internal standards in quantitative liquid chromatography/tandem mass 
spectrometry. Rapid Commun Mass Spectrom 17(24):2815-2821. 
Maurer HH (2005) Advances in analytical toxicology: the current role of liquid chromatography-mass 
spectrometry in drug quantification in blood and oral fluid. Anal Bioanal Chem 381(1):110-118. 
Muller C, Schafer P, Stortzel M, Vogt S and Weinmann W (2002) Ion suppression effects in liquid 
chromatography-electrospray-ionisation transport-region collision induced dissociation mass 
spectrometry with different serum extraction methods for systematic toxicological analysis with 
mass spectra libraries. J Chromatogr B Analyt Technol Biomed Life Sci 773(1):47-52. 
Nordt SP and Clark RF (1997) Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 
15(3):357-365. 
Quintela O, Cruz A, Castro A, Concheiro M and Lopez-Rivadulla M (2005) Liquid chromatography-
electrospray ionisation mass spectrometry for the determination of nine selected 
benzodiazepines in human plasma and oral fluid. J Chromatogr B Analyt Technol Biomed Life 
Sci 825(1):63-71. 
Determination of midazolam and its metabolites in saliva 
 91 
Quintela O, Cruz A, Concheiro M, de Castro A and Lopez-Rivadulla M (2004) A sensitive, rapid and 
specific determination of midazolam in human plasma and saliva by liquid 
chromatography/electrospray mass spectrometry. Rapid Commun Mass Spectrom 
18(24):2976-2982. 
Smink BE, Mathijssen MP, Lusthof KJ, de Gier JJ, Egberts AC and Uges DR (2006) Comparison of 
Urine and Oral Fluid as Matrices for Screening of Thirty-Three Benzodiazepines and 
Benzodiazepine-like Substances using Immunoassay and LC-MS(-MS). J Anal Toxicol 
30(7):478-485. 
Streetman DS, Bertino JS, Jr. and Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in 
adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 
10(3):187-216. 
 
 
CYP3A phenotyping with midazolam in saliva 
92 
 
5 Pharmacokinetics of intravenous and oral midazolam 
in plasma and saliva in humans: usefulness of saliva 
as matrix for CYP3A phenotyping 
 
 
   Bettina Link1, Manuel Haschke1, Nathalie Grignaschi, Michael Bodmer,       
Yvonne Zysset Aschmann, Markus Wenk and Stephan Krähenbühl 
 
1contributed equally to this work 
Division of Clinical Pharmacology & Toxicology and Department of Research, 
University Hospital Basel, Switzerland 
Br J Clin Pharmacol 2008; 66(4):473-84 
 
 
 
CYP3A phenotyping with midazolam in saliva 
 93 
5.1 Summary 
Aims 
To compare midazolam kinetics between plasma and saliva and to find out whether saliva is 
suitable for CYP3A phenotyping. 
Methods 
This was a two way cross-over study in eight subjects treated with 2 mg midazolam iv or 7.5 
mg orally under basal conditions and after CYP3A induction with rifampicin. 
Results 
Under basal conditions and iv administration, midazolam and 1′-hydroxymidazolam 
(plasma, saliva), 4-hydroxymidazolam and 1′-hydroxymidazolam-glucuronide (plasma) were 
detectable. After rifampicin, the AUC of midazolam [mean differences plasma 53.7 (95% CI 
4.6, 102.9) and saliva 0.83 (95% CI 0.52, 1.14) ng ml-1 h] and 1′-hydroxymidazolam [mean 
difference plasma 11.8 (95% CI 7.9, 15.7) ng ml-1 h] had decreased significantly. There was 
a significant correlation between the midazolam concentrations in plasma and saliva (basal 
conditions: r = 0.864, P < 0.0001; after rifampicin: r = 0.842, P < 0.0001). After oral 
administration and basal conditions, midazolam, 1′-hydroxymidazolam and 4-
hydroxymidazolam were detectable in plasma and saliva. After treatment with rifampicin, 
the AUC of midazolam [mean difference plasma 104.5 (95% CI 74.1, 134.9) ng ml-1 h] and 
1′-hydroxymidazolam [mean differences plasma 51.9 (95% CI 34.8, 69.1) and saliva 2.3 
(95% CI 1.9, 2.7) ng ml-1 h] had decreased significantly. The parameters separating best 
between basal conditions and post-rifampicin were: (1′-hydroxymidazolam + 1′-
hydroxymidazolam-glucuronide)/midazolam at 20–30 min (plasma) and the AUC of 
midazolam (saliva) after iv, and the AUC of midazolam (plasma) and of 1′-
hydroxymidazolam (plasma and saliva) after oral administration. 
Conclusions 
Saliva appears to be a suitable matrix for non-invasive CYP3A phenotyping using 
midazolam as a probe drug, but sensitive analytical methods are required. 
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5.2 Introduction 
Midazolam (MDZ) is a short-acting benzodiazepine with hypnotic, anticonvulsant, muscle-
relaxant and anxiolytic properties. In clinical practice, it is used for the induction of 
anesthesia, sedation and the treatment of generalized seizures or status epilepticus (Nordt 
and Clark, 1997). Furthermore, MDZ is a widely accepted probe drug for CYP3A 
phenotyping (Streetman et al., 2000). MDZ is rapidly metabolized by cytochrome P450 3A 
(CYP3A) to its primary, pharmacologically active metabolite 1´-hydroxymidazolam (1´-
OHMDZ) and, to a smaller extent, to 4-hydroxymidazolam (4-OHMDZ) and 1,4-
dihydroxymidazolam. These metabolites are conjugated and then excreted as glucuronides 
in the urine (Bauer et al., 1995; Heizmann and Ziegler, 1981; Kronbach et al., 1989). 
Oral fluid, consisting of saliva from the salivary glands and the gingival cervical sulci, 
mucosal cells, bacteria and food debris, has been increasingly used as an alternative 
biological matrix for therapeutic drug monitoring, pharmacokinetic studies, and detection of 
illicit drugs (Aps and Martens, 2005; Choo and Huestis, 2004; Drummer, 2005; Kidwell et 
al., 1998; Kintz and Samyn, 2002; Maurer, 2005). Oral fluid testing has several advantages 
over more conventional biological matrices used for these purposes, such as blood or urine. 
Specimen collection is noninvasive and therefore less objectionable to patients, easy to 
perform without medical supervision and may represent a cost-effective approach for 
screening of large populations. Disadvantages include that people are sometimes unable to 
produce sufficient amounts of oral fluid for quantitative analysis and that substances tend to 
be detectable for shorter periods in oral fluid than in plasma (Choo and Huestis, 2004). 
The most common way of drug molecules to pass from blood to oral fluid is passive 
diffusion through lipid membranes, which is restricted to molecules that are lipophilic, 
uncharged, and not bound to plasma proteins (Aps and Martens, 2005; Choo and Huestis, 
2004). Therefore, the salivary drug concentration reflects only the free concentration of 
drugs in plasma. Active transport and ultrafiltration through pores in cell membranes are 
additional mechanisms for drugs and metabolites to reach oral fluid. Due to the extensive 
binding of benzodiazepines (MDZ 96%) to plasma proteins (Nordt and Clark, 1997), their 
concentrations in oral fluid are generally very low compared with plasma. For this reason, 
highly sensitive analytical methods must be used for their detection and quantification (Link 
et al., 2007).  
CYP3A phenotyping with MDZ is based on the determination of MDZ clearance, 
necessitating serial blood sampling (Lee et al., 2002; Lee et al., 2006; Li et al., 2006). 
Although the more recently proposed single point methods in plasma are less invasive 
(Chaobal and Kharasch, 2005; Lin et al., 2001; Rogers et al., 2002; Zhu et al., 2001), 
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noninvasive methods would be welcome, both for research and for routine use. If the 
kinetics of MDZ and its principal metabolites could be assessed in saliva, it might be 
possible to use saliva as a matrix for CYP3A phenotyping after oral or intravenous 
administration of MDZ. As shown recently in a single subject, using a sensitive liquid 
chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) method, it appears to 
be possible to determine the kinetics of MDZ in saliva (Link et al., 2007). Based on these 
results, we decided to study the kinetics of MDZ in human subjects after intravenous (iv) or 
oral (po) administration of the drug both under basal conditions and after CYP3A induction 
with rifampicin. 
 
 
5.3 Methods 
The clinical protocol was approved by the Ethics Committee of both Cantons of Basel. All 
subjects gave written informed consent before undergoing any study-related procedures. 
 
5.3.1 Subjects 
Ten healthy male volunteers (all non-smokers) were included in the study. The use of any 
drug, including over the counter medication, as well as vitamins and dietary or herbal 
supplements known to affect CYP3A activity was prohibited at least 14 days before study 
start and for the entire duration of the study. Subjects had to abstain from grapefruit-
containing foods or juices at least 1 week prior to the study, as well as during and between 
the study sessions. Subjects with clinically significant abnormalities on pre-study 
examination, known or suspected history of alcohol or drug abuse or known hypersensitivity 
to benzodiazepines or to rifampicin were excluded. Caffeine containing food and beverages, 
and alcohol (24 h before and during study visits) were not permitted. 
 
5.3.2 Study design 
This study used an open-label, randomized, two way cross-over design. In phase I, subjects 
were randomly assigned to receive either an oral dose of 7.5 mg midazolam (Dormicum® F. 
Hoffmann-LaRoche Ltd., Basel, Switzerland, sequence A, n = 4) with 200 ml of water in the 
morning or an iv infusion of 2 mg midazolam (sequence B, n = 4) to assess the 
pharmacokinetics of midazolam and two of its metabolites under baseline conditions 
(control). After the 24 h blood sample, subjects started to take 600 mg rifampicin 
(Rimactan®, 600 mg coated tablet, Medika AG, Aesch, Switzerland) once daily in the 
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morning for 6 days to induce hepatic as well as intestinal CYP3A activity. One day after the 
last rifampicin dose, subjects received a second dose of 7.5 mg midazolam orally 
(sequence A) or 2 mg midazolam iv (sequence B) to assess the kinetics of MDZ and its 
metabolites after CYP3A induction. Phase I was followed by a wash out phase of at least 5 
weeks. During this washout phase, subjects were probed weekly with oral MDZ (7.5 mg, n = 
4 subjects) or with iv MDZ (2 mg, n = 4 subjects) to assess CYP3A induction. On day 43 
phase II started: subjects assigned to sequence A received 2 mg midazolam iv and subjects 
assigned to sequence B received 7.5 mg midazolam orally and again the pharmacokinetics 
of midazolam and its metabolites were assessed before and 1 day after induction with 
rifampicin 600 mg orally once daily for 6 days. Rifampicin was provided in blister packages 
that were returned by the subjects for the assessment of compliance. 
All subjects were asked to stay in supine position until the sedative effects of MDZ had 
resolved. Additionally, subjects were monitored with a pulse oximeter for 2 h after MDZ 
administration. Standardized meals were served 4 h and 8 h following drug administration. 
Subjects were permitted to drink water as desired.  
 
5.3.3 Sampling 
On each test day, after an overnight fast, an iv catheter was inserted into a forearm vein 
and blood samples were collected into heparinized tubes. For iv administration of MDZ, a 
second iv catheter was placed on the opposite forearm. 
Blood samples (5.5 ml each) were taken before and at 10, 20, 30, 40, 60, 90, 120, 180, 240, 
360, 480, 600 and 1440 min after MDZ administration. After iv midazolam administration, an 
additional blood sample was drawn at 5 min and the 180 min sample was skipped. For the 
assessment of CYP3A induction during the washout phase, blood samples were obtained 
before drug administration and after 30, 60, 90, 120 and 240 min. Oral fluid samples were 
collected by spitting into a polypropylene tube without pharmacological stimulation before 
and at 10, 30, 40, 60, 80, 100, 120, 150, 180, 240, 360 and 480 min after drug intake. An 
additional sample was drawn 20 min after iv midazolam administration. All blood and oral 
fluid samples were placed on ice and centrifuged within 30 min at 2500 g for 10 min at 5°C 
after collection. Plasma and saliva (after centrifugation of oral fluid, the supernatant was 
considered to be saliva) were then separated and stored at -70°C until analysis. 
In order to test for MDZ contamination in the oral cavity, subjects were instructed to rinse 
their mouth carefully with 200 ml of water after having ingested oral MDZ and 200 ml of 
water. After having rinsed the mouth, a saliva sample was obtained as described above. 
These saliva samples were randomly analyzed for MDZ. MDZ was not detectable in any of 
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these saliva samples, indicating that there was no carry over of orally administered MDZ 
into saliva. 
 
5.3.4 Drug analysis 
The concentrations of unconjugated MDZ, 1´-OHMDZ and 4-OHMDZ were determined in 
plasma and saliva by LC-MS/MS analysis as described previously (Link et al., 2007). In 
brief, 1 ml plasma or saliva were spiked with 10 µl internal standard (1.2 µg ml-1 solution of 
MDZ-d6, IS) and 1 ml 0.75 M glycine buffer (pH 9.2). Standards containing known amounts 
of MDZ and its metabolites were prepared similarly using the respective blank matrix. 
Liquid-liquid extraction was carried out by using n-hexane : dichlormethane (73 : 27, v : v). 
After centrifugation, the aqueous layer was frozen in a dry ice/acetone bath and the organic 
phase was transferred into a silanized glass tube. The organic fraction was evaporated to 
dryness under nitrogen and the remaining residue was reconstituted in 150 µl acetonitrile : 
water (23 : 77, v : v). 20 µl of the sample was injected into the LC-MS/MS system. 
Separation was performed at 40°C using a reversed-phase Luna C18 analytical column, 
100 x 2.1 mm i.d., 3 µm (Phenomenex, Torrance, CA, USA) and gradient elution at a flow 
rate of 0.24 ml min-1. Detection was carried out using an LCQDeca ion trap mass 
spectrometer (Thermo Fischer Scientific, Inc., Waltham, MA, USA) equipped with an 
electrospray ionization (ESI) source operating in the positive ion mode (4 kV). For the 
quantification of MDZ and its metabolites the MS/MS product ion scan mode was chosen 
using a mass filter for the two must abundant product ions: MDZ, m/z 326.2Æ291.3, 244.2; 
1´-OHMDZ, m/z 342.2Æ324.2, 203.2; 4-OHMDZ, 342.2Æ325.2, 234.2 and MDZ-d6, 
332.3Æ297.4, 247.2. Intra- and interday coefficients of variation (CV) were determined at 
three different concentrations by analyzing six replicates of each quality control 
concentration (0.6, 3.7 and 15 ng ml-1 for plasma and 0.3, 3.7 and 15 ng ml-1 for saliva). The 
corresponding CV ranged from 1.2 to 7.3% for MDZ, from 1.3 to 7.4% for 1′-OHMDZ and 
from 2.6 to 7.6% for 4-OHMDZ, respectively, in plasma and saliva. The limit of quantification 
(LOQ) was determined based on the criteria that 1) the signal to noise ratio at the LOQ is at 
least 5 and that 2) the analyte response at LOQ can be determined with a CV of ≤ 20% and 
an accuracy of 80–120% (n = 6). For MDZ and both metabolites the LOQs were 0.05 ng ml-
1 in both biological matrices with accuracies between 102.1 and 106.4% and CV between 
5.4 and 10.4%. The accuracy for all compounds was between 92.1 and 102.3% in plasma 
and between 96.6 and 108.0% in saliva. Linear calibration curves were obtained between 
0.05 to 20 ng ml-1 for midazolam and the hydroxy-metabolites in plasma and saliva (r2 > 
0.998). Plasma samples with high concentrations of MDZ and metabolites were diluted up 
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to 10-fold with drug free human plasma in order to reach the calibration range. No 
interference from rifampicin was noted during the analysis. 
For the determination of total 1´-OHMDZ in plasma (conjugated and unconjugated) the 
same analytical method was used after treatment of the sample with β-glucuronidase. To 1 
ml of plasma, 1 ml 0.2 M ammonium acetate buffer (pH 4.7) and 40 µl of a solution 
containing 20 000 U ml-1 of β-glucuronidase from Helix pomatia (G7770, Sigma, Buchs, 
Switzerland) were added and the mixture was incubated at 37°C. After 20 h, the reaction 
was stopped by adding 50 µl of aqueous ammonia (8%). IS (10 µl) and 1 ml 0.75 M glycine 
buffer (pH 9.2) were added and the sample was then further processed in the same manner 
as described above. Calibration curves, ranging from 0.05–20 ng ml-1 for all three analytes, 
were constructed in drug-free plasma under the same conditions. 1´-OHMDZ glucuronide 
concentration was determined by subtracting unconjugated 1´-OHMDZ concentrations from 
those obtained after treatment with β-glucuronidase. 4-OHMDZ was found to be unstable 
under hydrolytic conditions, with a later eluting degradation product of this metabolite 
(specific precursor ion m/z 343.2 and product ion m/z 315.5) being apparent in the 
chromatograms (Link et al., 2007; Paine et al., 1996). Therefore, 4-OHMDZ glucuronide 
concentrations were not determined. 
Plasma and saliva samples were prepared and measured once. Each subject’s samples for 
assessing the concentration of MDZ and its metabolites at baseline and after induction of 
CYP3A4 were analyzed on the same day for the intravenous as well as for the oral MDZ 
administration. 
 
5.3.5 Pharmacokinetic analysis 
Plasma and saliva MDZ, 1´-OHMDZ and 4-OHMDZ data were analyzed using either non-
compartmental or compartmental methods (WinNonlin, version 5.01, Pharsight Corp., 
Mountain View, CA, USA), depending on the model fitting the concentration vs. time data 
the best. The area under the drug concentration–time curves (AUCinf) were calculated using 
the trapezoidal rule with extrapolation to infinity. The elimination rate constant (ke) was 
calculated by log-linear regression analysis after semilogarithmic transformation of the data. 
The elimination half-life (t1/2) was calculated as follows: 
e
1/2 k
ln2t =   (1)  
Systemic clearances (CLiv) after iv MDZ administration were calculated as follows: 
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iv
iv
iv AUC
dose
CL =    (2) 
The apparent oral clearances (CL/F) were calculated as the ratio of dose administered over 
AUCpo. Bioavailability (Foral) was calculated as follows: 
poiv
ivpo
oral doseAUC
doseAUC
F ×
×=   (3) 
The maximum drug concentration in plasma or saliva (Cmax) and time to reach these peak 
concentrations (tmax) were obtained directly from the concentration–time data. The volume 
of distribution (Vd) was calculated as follows: 
e
d k*AUC
doseV =    (4) 
 
5.3.6 Statistics 
Results are expressed as median and range. Statistical analysis was performed using the 
SPSS software package for Windows, version 15.0 (SPSS, Chicago, IL, USA). The 
nonparametric Wilcoxon signed rank test for paired data was used to analyse changes in 
the pharmacokinetic parameters before (baseline conditions, control) and after rifampicin 
administration (CYP3A induction) in both biological matrices. For relevant endpoints mean 
difference and corresponding 95% confidence intervals (CI) of the difference were 
calculated. A two-tailed P value less than 0.05 was considered to be statistically significant. 
Linear regression analysis was performed using least squares fitting to assess the relation 
between the concentrations of MDZ or 1´-OHMDZ in plasma and saliva. 
 
 
5.4 Results 
Ten male subjects were enrolled in the study. Eight subjects completed the study, one 
subject withdrew during the second induction phase (phase II) because of adverse 
reactions to rifampicin (headache, flu-like symptoms, abdominal pain and diarrhoea) and 
one subject discontinued the treatment for personal reasons unrelated to the study 
medication. The data of the excluded subjects were not used for analysis. Mean ± standard 
deviation (SD) age was 27.7 ± 9.6 years (range: 21–46 years) and a mean weight 70 ± 6 kg 
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(range: 60–78 kg). As expected, most subjects experienced light sedation after the 
administration of midazolam. No other adverse events were detected. 
After iv administration of 2 mg MDZ, MDZ, 1´-OHMDZ and 4-OHMDZ could be detected in 
plasma and the kinetics of MDZ and its metabolites could be assessed. MDZ was rapidly 
hydroxylated, maximal concentrations of 1´-OHMDZ and 4-OHMDZ were reached after 22 
and 42 min, respectively (Figure 1 and Table 1). The half-lives of the two hydroxy-
metabolites were similar to MDZ, indicating rapid glucuronidation of the metabolites. MDZ 
and 1´-OHMDZ could also be detected in saliva, whereas the concentration of 4-OHMDZ 
was too low for reliable quantification. There was a significant linear correlation between the 
MDZ concentrations obtained in plasma and in saliva, both under basal conditions (r = 
0.864, P < 0.0001) and after induction with rifampicin (r = 0.842, P < 0.0001, Figure 2). As 
expected from the extensive protein-binding of MDZ (Bodmer et al., 2008), the 
concentrations of MDZ were much lower in saliva than in plasma (Figure 1). For the same 
reason, Vd and clearance of MDZ in saliva were much higher compared with the values 
obtained in plasma, whereas the elimination half-life was lower (Table 1). The kinetics of 1′-
OHMDZ could also be assessed in saliva (Figure 1). Compared with plasma, the maximal 
concentrations in saliva appeared clearly later (22 vs. 52 min). While the concentrations of 
1′-OHMDZ were also lower in saliva than in plasma, the difference was not as large as for 
MDZ, compatible with lower binding to serum proteins (Bodmer et al., 2008). 
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Figure 1. Kinetics of MDZ and 1´-OHMDZ in plasma (left panel) and saliva (right panel) 
after iv administration of 2 mg MDZ in eight healthy volunteers. CYP3A induction by 
rifampicin is associated with a decrease in the concentrations MDZ (plasma and saliva) and 
1´-OHMDZ (plasma). The data are presented as mean ± SD. The results of the kinetic 
calculations are presented in Table 1. 
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Table 1. Pharmacokinetic parameters of midazolam and its metabolites after intravenous administration of 2 mg midazolam before (control) and after 
treatment with rifampicin in eight healthy subjects 
 Plasma      Saliva 
 Control Rifampicin Control Rifampicin 
Midazolam         
  Vd (l) 3.53 (0.35-26.97) 2.6  (1.2-16.8) 1918 (943-2963) 1793 (836-2146) 
Vd/kg (l kg-1) 0.05 (0.01-0.39) 0.04 (0.02-0.23) 28.2 (15.7-43.6) 26.2 (13.9-29.0) 
AUCinf (ng ml-1 h) 125.8 (83.7-268.7) 82.4 (58.5-101.9)** 1.7 (1.4-2.4) 0.96 (0.77-1.37)** 
t1/2 (h) 2.9  (1.8-3.4) 1.4 (1.1-1.8)** 1.3 (0.7-1.6) 0.58 (0.40-0.73)** 
CL (l h-1) 15.9 (7.4-23.9) 24.4 (19.6-34.2)* 1185 (841-1448) 2081 (1457-2590)** 
Cmax (ng ml-1) 151 (89-388) 167 (83-253) 1.05 (0.67-2.12) 1.12 (0.93-2.39) 
1´-hydroxymidazolam     
AUCinf (ng ml-1 h) 14.7 (8.9-21.6) 2.0 (1.4-6.4)** 0.68 (0.45-1.12) na1  
t1/2 (h) 2.2 (1.8-4.2) 1.4 (1.2-2.7)* 2.1 (1.7-3.5) na  
Cmax (ng ml-1) 3.5 (1.7-6.5) 1.3 (0.59-3.54)** 0.18 (0.11-0.31) na  
tmax (min)  22.0 (20.0-47.0) 10.5 (10.0-61.0) 52.0 (35.0-80.0) na  
4-hydroxymidazolam    
AUCinf (ng ml-1 h) 1.9 (1.5-2.5) na  na  na  
t1/2 (h) 2.9 (2.7-3.6) na  na  na  
Cmax (ng ml-1) 0.39 (0.26-0.52) na  na  na  
tmax (min)  44.4 (28.05-61.30) na  na  na  
Data are presented as median and range. Vd, volume of distribution; AUCinf, area under the concentration-time curve extrapolated to infinity; t1/2, 
elimination half-life; CL, clearance; Cmax, maximum plasma or saliva concentration; tmax, time to maximum plasma or saliva concentration. * P<0.05 
rifampicin versus control in the same matrix. ** P=0.012 rifampicin versus control in the same matrix. na1: not assessable. 
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After induction of CYP3A by rifampicin, the AUC and the half-life of MDZ in plasma dropped 
significantly [mean difference for AUC 53.7 ng ml-1 h (95% CI 4.6, 102.9), P = 0.012, mean 
difference for half-life 1.2 h (95% CI 0.7, 1.7)], whereas the clearance increased [mean 
difference 8.9 l h-1 (95% CI 4.2, 13.7), P < 0.05, Figure 1, Table 1]. Unexpectedly, AUC and 
half-life dropped also for 1′-OHMDZ, whereas 4-OHMDZ could not be quantified reliably. In 
saliva, only MDZ could be quantified, but not 1′-OHMDZ or 4-OHMDZ. Similar to plasma, 
AUC and half-life of MDZ dropped significantly [mean difference AUC 0.83 ng ml-1 h (95% 
CI 0.52, 1.14), mean difference half-life 0.62 h (95% CI 0.38, 0.85), P = 0.012], whereas the 
clearance of MDZ increased. 
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Figure 2. Correlation between MDZ concentrations in plasma and saliva. Single values and the 95% 
confidence interval are shown. After iv administration of 2 mg MDZ, there is a linear correlation 
between the MDZ concentrations determined in plasma and saliva both under basal conditions (left 
panel, r = 0.864) and after treatment with rifampicin (right panel, r = 0.842). 
 
 
In order to find the reason for the unexpected drop of the 1′-OHMDZ concentrations in 
plasma and in saliva after induction with rifampicin, 1′-OHMDZ-glucuronide was analyzed in 
both matrices. As shown in an individual subject, the reason for the fall of the plasma 
concentration of 1′-OHMDZ was the rapid conversion into the corresponding glucuronide 
(Figure 3). Accordingly, 20 and 30 min after iv administration of MDZ, the 1′-OHMDZ 
glucuronide plasma concentrations were approximately doubled in subjects treated with 
rifampicin compared with basal conditions (Table 2). In contrast to plasma, 1′-OHMDZ-
glucuronide could not be detected in saliva (data not shown). 
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Figure 3. Plasma concentrations of 1´-OHMDZ and 1´-OHMDZ-glucuronide under basal conditions 
and after treatment with rifampicin in one subject. Surprisingly, CYP3A induction by rifampicin is 
associated with a decrease in the plasma concentrations of 1´-OHMDZ. The explanation for this 
finding is an increase in the plasma concentrations of 1’-OHMDZ-glucuronide. The 1´-OHMDZ 
concentrations at 20 and 30 min are presented in Table 2. 1´-OHMDZ baseline (●); 1´-OHMDZ-
glucuronide baseline (?);1´-OHMDZ induced (○); 1´-OHMDZ-glucuronide induced (?).  
 
 
 
 
Table 2. Plasma concentrations of midazolam (MDZ), 1´-hydroxymidazolam (1´-OHMDZ), 1´-
hydroxymidazolam-glucuronide (1´-OHMDZ-gluc) and 1´-OHMDZ + 1´-OHMDZ-gluc (1´-OHMDZtotal) 
after intravenous administration of 2 mg midazolam before (control) and after pre-treatment with 
rifampicin in eight healthy subjects  
 20 minutes 30 minutes
 Control Rifampicin Control Rifampicin 
MDZ (ng ml-1) 32.4  (22.2-43.1) 24.8 (19.8-31.1) 29.2 (20.2-34.1) 19.2  (13.2-23.9)* 
1´-OHMDZ (ng ml-1) 3.52  (2.06-6.46) 0.99 (0.59-1.81)* 3.10 (1.47-5.54) 0.73  (0.53-1.58)* 
1´-OHMDZ-gluc (ng ml-1) 18.0  (11.9-25.2) 40.9 (29.3-61.6)* 22.7 (16.4-38.1) 40.5  (31.0-55.7)* 
1´-OHMDZtotal (ng ml-1) 20.9  (15.2-30.5) 41.8 (30.0-62.6)* 21.5 (16.4-38.1) 39.6  (31.0-55.7)* 
1´-OHMDZ/MDZ 0.136  (0.074-0.150) 0.040 (0.024-0.073)* 0.104 (0.069-0.169) 0.040  (0.031-0.093)* 
1´-OHMDZ-gluc/MDZ 0.497  (0.305-0.920) 1.56 (0.94-2.55)* 0.733 (0.446-1.16) 2.39  (1.27-2.87)* 
1´-OHMDZtotal/MDZ 0.627  (0.391-1.07) 1.52 (0.968-2.59)* 0.840 (0.551-1.33) 2.34  (1.30-2.91)* 
*P<0.008 rifampicin versus control at the same time point. 
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Good markers of induction with rifampicin (no overlap of the basal values with the values 
obtained after treatment with rifampicin) after iv administration of MDZ were in plasma the 
drop in the AUC of 1′-OHMDZ, the drop in the 1′-OHMDZ concentration (20 min), the 
increase in the 1′-OHMDZ-glucuronide concentration (20 min), the drop in the ratio 1′-
OHMDZ : MDZ (20 min) and the increases in the ratios 1′-OHMDZ-glucuronide : MDZ and 
1′-OHMDZtotal : MDZ (20 and 30 min) (Tables 1 and 2). Interestingly, while the AUC of MDZ 
in plasma showed some overlap between basal conditions and after treatment with 
rifampicin, there was no overlap of this ratio in saliva (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Markers of CYP3A induction after iv administration of MDZ. A) The AUC of MDZ under 
basal conditions and after treatment with rifampicin partially overlap in plasma, but not in saliva. B) 
The AUC of 1´-OHMDZ separates well between basal conditions and CYP3A induction in plasma, 
but could not be determined in saliva after treatment with rifampicin. C) A good separation between 
basal conditions and CYP3A induction in plasma was also obtained by the concentration of 1´-
OHMDZ-glucuronide or the ratio (1´-OHMDZ + 1´-OHMDZ-glucuronide) : MDZ 20 or 30 minutes after 
administration of MDZ. (1´-OHMDZ + 1´-OHMDZ-glucuronide) = 1´-OHMDZtot 
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During the washout phase, the decrease in CYP3A induction was assessed to ascertain 
that the probands had reached basal conditions before starting phase II of the study. After 
stopping the treatment with rifampicin, it lasted 3 weeks until the AUC(0,4 h) (oral and iv 
administration of MDZ) had reached the values before ingestion of rifampicin in every 
subject (data not shown). 
After oral ingestion of 7.5 mg MDZ, MDZ and its hydroxy-metabolites could be detected in 
plasma and in saliva (Figure 5) and the respective kinetics could be assessed (Table 3). 
Similar to iv administration, there was a significant linear correlation between MDZ plasma 
and saliva concentrations (r = 0.913, P < 0.0001; data not shown). Under basal conditions, 
the bioavailability calculated from the plasma data was in the range of 20%, whereas the 
half-life was 3.2 h, a value close to that obtained after iv administration. The ratios between 
the AUC of 1′-OHMDZ or 4-OHMDZ to MDZ were much higher after oral compared with iv 
administration of MDZ, most probably reflecting intestinal metabolism of MDZ. Accordingly, 
the concentrations of 1′-OHMDZ and 4-OHMDZ were higher in saliva after oral compared 
with iv administration, whereas the MDZ concentrations in saliva were comparable with the 
values after iv administration. After administration of rifampicin, the AUC of MDZ in plasma 
decreased dramatically compared with basal conditions [mean difference 104.5 ng ml-1 h 
(95% CI 74.1, 134.9), P = 0.012, Figure 5]. Similar to iv administration of MDZ, the 
concentrations of 1′-OHMDZ and 4-OHMDZ in plasma were lower after rifampicin compared 
with basal conditions. Accordingly, in saliva, MDZ and 4-OHMDZ could not be detected 
after treatment with rifampicin, whereas the concentration of 1′-OHMDZ was lower 
compared with basal conditions. 
Good markers of induction with rifampicin (no overlap of the basal values with the values 
obtained after treatment with rifampicin) after oral administration of MDZ were the drop in 
AUC and Cmax of MDZ and the drop in the AUC of 1′-OHMDZ in plasma as well as the drop 
in AUC and Cmax of 1′-OHMDZ in saliva (Figure 6). 
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Figure 5. Kinetics of MDZ and 1´-OHMDZ in plasma (left panel) and saliva (right panel) after oral 
administration of 7.5 mg MDZ in eight healthy volunteers. Similar to iv administration, CYP3A 
induction is associated with a decrease in the plasma concentrations of MDZ (plasma) and 1´-
OHMDZ (plasma and saliva). In saliva, MDZ can only be detected under basal conditions, but not 
after CYP3A induction. The data are presented as mean ± SD. The results of the kinetic calculations 
are presented in Table 3. 
 
 
5.5 Discussion 
With our study, we primarily wanted to answer the following questions: i) Can the kinetics of 
MDZ be assessed reliably in saliva? and ii) Can saliva be used as a matrix to determine 
CYP3A activity with MDZ as a probe drug? If yes, is the ability of the values obtained in 
saliva to separate CYP3A-induced from non-induced individuals comparable to plasma 
values? 
Regarding the good correlation between the MDZ concentrations in plasma and saliva 
(Figure 2), it is evident that the kinetics of MDZ can be reliably assessed also in saliva both 
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Table 3. Pharmacokinetic parameters of midazolam and its metabolites after oral administration of 7.5 mg midazolam before (control) and after pre-
treatment with oral rifampicin to eight healthy subjects 
 Plasma Saliva 
 Control Rifampicin Control Rifampicin 
Midazolam    
AUCinf (ng ml-1 h) 102.9 (64.0-163.7) 1.6 (1.0-7.2)** 2.5 (1.1-3.3)* na1  
t1/2 (h) 3.2 (2.1-4.8) 1.8 (0.98-8.21) 6.9 (1.3-13.4) na  
Cmax (ng ml-1) 63.1 (25.9-80.2) 2.2 (0.64-10.4)** 0.94 (0.61-1.58) na  
tmax (min) 20.6 (12.9-72.4) 29.9 (13.2-39.6) 39.2 (12.7-86.8) na  
F 0.19 (0.15-0.33) 0.005 (0.004-0.02) na na  
1´-hydroxymidazolam  
AUCinf (ng ml-1 h) 56.6 (30.7-91.9) 5.4 (3.9-13.1)** 2.8 (1.9-3.2) 0.44 (0.31-0.62)** 
t1/2 (h) 5.8 (1.8-21.8) 3.2 (1.8-6.3) 1.6 (1.2-2.0) 0.91 (0.55-1.26)* 
Cmax (ng ml-1) 36.9 (15.0-52.6) 4.4 (2.0-11.7)** 1.3 (0.75-1.65) 0.21 (0.14-0.58)** 
tmax (min)  24.5 (13.7-70.1) 31.2 (18.2-39.4) 43.5 (30.0-80.0) 43.5 (32.0-80.0) 
4-hydroxymidazolam   
AUCinf (ng ml-1 h) 6.3 (5.4-9.8) na  0.37 (0.29-0.70) na  
t1/2 (h) 1.8 (1.4-2.0) na  2.3 (1.5-3.3) na  
Cmax (ng ml-1) 3.1 (1.5-3.9) na  0.10 (0.09-0.12) na  
tmax (min)  31.5 (20.0-93.0) na  61.0 (42.0-100.0) na  
Data are presented as median and range. Vd, volume of distribution; AUCinf, area under the concentration-time curve extrapolated to infinity; t1/2, 
elimination half-life; CL, clearance; Cmax, maximum plasma or saliva concentration; tmax, time to maximum plasma or saliva concentration. * P<0.05 
rifampicin versus control in the same matrix. ** P=0.012 rifampicin versus control in the same matrix. na1: not assessable. 
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Figure 6. Markers of CYP3A induction after oral administration of MDZ. In plasma, the drop in the 
AUC of MDZ (A) and in the AUC of 1´-OHMDZ (B) separate well between basal conditions and 
CYP3A induction. In saliva, the drop in the AUC of 1´-OHMDZ (C) shows an excellent separation 
between basal conditions and CYP3A induction. 
 
 
after iv and oral administration of MDZ. However, several points have to be taken into 
account. Because MDZ is highly plasma protein-bound and only free MDZ distributes into 
saliva, the MDZ concentration is much lower in saliva than in plasma. In contrast to plasma, 
where we determined the kinetics of total MDZ, the kinetics of free MDZ was therefore 
assessed in saliva. Accordingly, the AUC of MDZ was much lower and the clearance much 
higher in saliva compared with plasma. Similar to MDZ, 1´-OHMDZ kinetics could be 
calculated in plasma as well as in saliva. Interestingly, 1´-OHMDZ reached its maximum 
concentration in saliva much later than in plasma, indicating a slow transport into saliva. 
The exact mechanism of how 1´-OHMDZ gains access to saliva is not known but may be by 
diffusion, depending on protein binding and lipophilicity of the compound (Loscher and Frey, 
1984). Most probably due to the lower binding to plasma proteins compared with MDZ 
(Bodmer et al., 2008), the ratio of 1´-OHMDZ to MDZ was higher in saliva than in plasma. 
1´-OHMDZ-glucuronide could not be detected in saliva, most probably reflecting low or even 
lacking transport into this compartment due to its hydrophilic properties. Similar findings 
have been reported for the glucuronides of morphine (Friedrich et al., 1992). 
After induction with rifampicin, the clearance of MDZ was increased compared with basal 
values, and, accordingly, the AUC decreased both after iv and oral administration of MDZ. 
However, the effects of rifampicin differed in their extent between iv and oral administration, 
most probably reflecting both hepatic and intestinal induction of the first pass metabolism of 
oral MDZ. While the AUC of MDZ in plasma dropped only by 34.5% after iv administration, 
this drop was 98.5% after oral ingestion of MDZ. These effects of rifampicin are consistent 
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with other reports in the literature (Backman et al., 1996a; Gorski et al., 2003). After oral 
administration, MDZ could therefore not be detected in saliva, precluding its use as a 
marker of CYP3A induction with the quantification limits of current analytical methods.  
Interestingly, the plasma concentrations and AUCs of the hydroxy-metabolites of MDZ did 
not show the expected increase, but a decrease, after treatment with rifampicin. As 
evidenced by the current study for 1´-OHMDZ, the hydroxy-metabolites of MDZ undergo 
extensive glucuronidation, explaining our findings. Although it is well known that intestinal 
and hepatic metabolism of MDZ is altered significantly by induction (Gorski et al., 2003) or 
inhibition (Kupferschmidt et al., 1995) of CYP3A activity, it was less clear that induction of 
UDP-glucuronyltransferases exhibits such dramatic effects on the kinetics of the hydroxy-
MDZ metabolites. Different authors have reported an up to three-fold increase in 
glucuronidation activity in humans (Ebert et al., 2000), human hepatocytes (Soars et al., 
2004) or rats (Oesch et al., 1996) after treatment with rifampicin (Ebert et al., 2000; Oesch 
et al., 1996; Soars et al., 2004). In contrast, Reinach et al. did not find a significant effect of 
rifampicin on AZT glucuronidation in human hepatocytes (Reinach et al., 1999). Until very 
recently, glucuronidation of 1´-OHMDZ was not well characterized. Recently, Zhu et al. (Zhu 
et al., 2008) demonstrated in vitro that glucuronidation of 1´-OHMDZ was catalyzed by 
UGT2B4 and UGT2B7. Nakajima et al. (Nakajima et al., 1999) studied the effects of 
glucocorticoids (moderate inducers of CYP3A activity) on MDZ kinetics in humans. Although 
not statistically significant, a trend towards a lower AUC of MDZ and 1´-OHMDZ in plasma, 
and a higher cumulative excretion of 1´-OHMDZ-glucuronide in the urine compared with 
baseline could be observed. In addition, Eap et al. (Eap et al., 2004) studied single dose 
MDZ kinetics before and after induction with rifampicin in human subjects. After 4 days of 
treatment with 450 mg rifampicin per day, they could demonstrate a significant decrease of 
MDZ and 1´-OHMDZ plasma concentrations. Interestingly, in their study, the ratio 1´-
OHMDZtot : MDZ (1´-OHMDZtot represents the concentration of 1´-OHMDZ plus 1´-OHMDZ-
glucuronide) obtained after 30 min discriminated well (P < 0.0001) between constitutive and 
induced CYP3A activity. Unfortunately, they did not report specifically the pharmacokinetics 
of the glucuronide metabolites. In our work, the ratio 1´-OHMDZtot : MDZ showed also a 
significant increase after administration of rifampicin (P < 0.05) but there was a slight 
overlap of values obtained at baseline and after treatment with rifampicin both after 20 and 
30 min (Table 2). 
MDZ is a well established probe drug to assess in vivo CYP3A activity (Streetman et al., 
2000). Various authors demonstrated that the AUC of MDZ, in most cases obtained by 
limited sampling models (Chainuvati et al., 2003; Lee et al., 2006), or even single point 
sampling strategies in plasma (Chaobal and Kharasch, 2005; Lin et al., 2001) are able to 
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discriminate between constitutive, induced, and inhibited CYP3A activity. Various authors 
investigated the ratio of 1´-OHMDZ : MDZ in plasma as an index for CYP3A activity, but 
with inconsistent results (Eap et al., 2004; Lee et al., 2006; Rogers et al., 2002; Zhu et al., 
2001). As nicely demonstrated in our work, glucuronidation plays a major role in the kinetics 
of the hydroxy-MDZ metabolites, especially after induction with rifampicin. Therefore, the 
ratio (1´-OHMDZ + 1´-OHMDZ-glucuronide) : MDZ rather than 1´-OHMDZ : MDZ may be 
used to assess induction of CYP3A activity in plasma. 
Whereas various limited sampling strategies to assess CYP3A activity using MDZ are 
simpler, less invasive and cost saving compared with the determination of the entire AUC, 
all techniques so far reported require invasive blood sampling. In our work, we were able to 
show that MDZ kinetics in saliva, an easily assessable body fluid, may be a useful tool to 
differentiate between constitutive and induced CYP3A activity. After iv administration of 
MDZ, there was no overlap in the AUCs of MDZ under basal conditions and after treatment 
with rifampicin in saliva, showing a better separation between these two conditions 
compared with the AUC in plasma. Similarly, after oral ingestion of MDZ, there was no 
overlap in the AUC for 1´-OHMDZ in saliva, a finding obtained also for the corresponding 
AUC in plasma. Saliva may therefore be suited at least as well as plasma for the 
determination of the CYP3A phenotype using MDZ as a probe drug. However, more work is 
needed regarding the use of saliva as a matrix for this purpose, for example for evaluating 
the most suitable sampling strategy. Furthermore, it has to be shown that inhibition of 
CYP3A can be assessed in saliva as well. 
In conclusion, we provide evidence that MDZ and 1´-OHMDZ can be determined reliably in 
saliva and that the concentrations in saliva correlate well with those in plasma. Saliva may 
be a suitable matrix for the non-invasive determination of the CYP3A phenotype using MDZ 
as a probe drug. 
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6.1 Abstract 
The authors present a patient with refractory epilepsy who was treated with very high doses 
(up to 4 mg/min) of intravenous midazolam, phenytoin, carbamazepine, and other 
antiepileptics. Because it was known from the literature that the half-life of midazolam can 
increase at high dosage, the kinetics of midazolam (MDZ), 1´-hydroxymidazolam, and 4-
hydroxymidazolam were assessed at steady state (dosage 1 mg/min) and after stopping 
treatment. Total body clearance of MDZ (33 l/kg) and intrinsic hepatic clearance (19 
ml/min/kg) at steady state were both 5 to 10 times higher than after normal therapeutic 
doses, demonstrating hepatic cytochrome (CYP) 3A induction. Despite the high body 
clearance, the half-life of MDZ was in the range of 24 hours, approximately 10 times higher 
than after normal therapeutic doses. The volume of distribution at steady state was 33 l/kg, 
approximately 50 times higher than after normal therapeutic doses. The free fraction of 
MDZ was 58% at steady state, much higher than the 3-6% at normal therapeutic doses. 
The kinetics of intravenous MDZ is strongly dependent on its dose and on hepatic CYP3A 
activity. Even in patients with hepatic CYP3A induction, the half-life of MDZ increases with 
high doses as a result of a rise in its volume of distribution, which is a consequence of an 
increase in the free fraction of MDZ. 
  
 
6.2 Introduction 
Midazolam is often used for long-term sedation and treatment of status epilepticus in 
patients in intensive care units. The short elimination half-life (1.8-3.5 h) in healthy persons 
after intravenous administration (Gorski et al., 2003; Klotz and Ziegler, 1982; Tsunoda et al., 
1999) is an advantage compared with longer-acting benzodiazepines. Midazolam is highly 
protein-bound (94-97%), primarily to albumin (Fragen, 1997). It is metabolized by 
cytochrome P450 (CYP) 3A to 1´-hydroxymidazolam and 4-hydroxymidazolam, which are 
subsequently glucuronidated and eliminated mainly in urine. Midazolam is an intermediate-
to-high clearance drug with a hepatic extraction ratio (Ehep) in the range of 0.27-0.44 
(Masica et al., 2004; Thummel et al., 1996) rising to 0.6 after CYP3A induction (Gorski et 
al., 2003). 
In patients in intensive care units, the half-life (t½) of midazolam shows greater variation and 
tends to be longer compared with healthy individuals (Fragen, 1997; Malacrida et al., 1992; 
Vree et al., 1989). Total body clearance of midazolam, in healthy subjects in the range of 
240 to 620 ml/min (Gorski et al., 2003; Klotz and Ziegler, 1982; Lee et al., 2002; Tsunoda et 
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al., 1999), is similar in patients in intensive care units but with a higher variation (Dirksen et 
al., 1987; Oldenhof et al., 1988). The volume of distribution of midazolam ranges between 
1.0 and 3.3 l/kg in healthy subjects treated with common therapeutic doses (Gorski et al., 
2003; Kupferschmidt et al., 1995; Tsunoda et al., 1999) and increases with decreasing 
albumin plasma concentrations (Vree et al., 1989). 
In this report, we describe the pharmacokinetics of midazolam administered at 
extraordinarily high doses in a patient with prolonged nonconvulsive status epilepticus 
(NCSE) who was treated concomitantly with phenytoin and carbamazepine. The report 
illustrates the value of plasma level monitoring for understanding the kinetics of midazolam 
in patients treated with very high doses of this drug. 
 
 
6.3 Methods 
Midazolam and its metabolites were analyzed by liquid chromatography-mass 
spectrometry/mass spectrometry (LC-MS/MS) as described previously (Link et al., 2007). 
The metabolite 1´-hydroxymidazolam glucuronide was measured as 1´-hydroxymidazolam 
after deglucuronidation using the same LC-MS/MS method. Free concentrations of 
midazolam and 1´-hydroxymidazolam were determined after ultrafiltration of the plasma 
samples. 
The steady-state plasma concentration (Css) of midazolam was determined during a period 
of continuous infusion of midazolam (1 mg/min), which had been administered at this 
dosage for more than 4 days. CLss was then calculated as follows (IR = infusion rate of 
midazolam = 1 mg/min):  
      
ss
ss C
IRCL =     (1) 
The elimination rate constant (ke) was calculated by least square regression of the log 
concentration-time curve assuming first order terminal elimination kinetics. The terminal 
half-life (t½) was then calculated using equation (2): 
     
e
1/2 k
ln2t =     (2) 
The volume of distribution (Vss) of midazolam was calculated according to equation (3) 
      
e
ss
ss k
CL
V =     (3) 
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According to the venous equilibrium model (Shand et al., 1975), hepatic clearance (CLhep) of 
midazolam is given by equation (4). The blood flow across the liver (Q) was assumed to be 
25.5 ml/min/kg (Wynne et al., 1989). Because the renal clearance of midazolam is 
negligible (Dirksen et al., 1987; Gorski et al., 2003), CLhep equals CLss: 
    ss
intu
intu
hep CL)CL(fQ
)CL(fQ
CL ≈⋅+
⋅⋅=   (4) 
CLint represents the intrinsic hepatic clearance and fu the unbound fraction of midazolam. 
From equation (4), the intrinsic hepatic clearance (CLint) can be derived as follows: 
     
)CL(Qf
CLQ
CL
ssu
ss
int −
⋅=    (5) 
Finally, taking into account that CLhep = CLss, the hepatic extraction ratio (Ehep) of midazolam 
can be calculated according to equation (6): 
     
Q
CL
E sshep =     (6) 
The formation clearances of 1´-hydroxymidazolam and 1´-hydroxymidazolam glucuronide 
(CLm) were calculated according to equation (7): 
     ssmm CLfCL ⋅=     (7) 
fm represents the fraction of midazolam which is converted to 1´-hydroxymidazolam or 1´-
hydroxymidazolam glucuronide, respectively. 
 
 
6.4 Case report 
A 52-year-old woman (body weight 60 kg, calculated creatinine clearance 77 
ml/min/1.72m2) with a history of temporal lobe epilepsy, chronic schizophrenia and 
benzodiazepine abuse for decades was admitted to the hospital with an acute confusional 
state. A few weeks previously, she had deliberately stopped her antiepileptic treatment 
consisting of carbamazepine and lamotrigine. A focal NCSE was diagnosed and 
antiepileptic treatment with lorazepam and valproic acid was started. Because of refractory 
NCSE, lorazepam was stopped and oral topiramate and levetiracetam as well as 
intravenous midazolam and propofol were started on day 3. However, focal epileptic activity 
persisted, midazolam and propofol were replaced by pentobarbital and oxcarbazepine on 
day 9, and phenytoin was added on day 13. This treatment led to a complete suppression of 
convulsive activity on the electroencephalogram. As a result of toxicity associated with this 
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treatment, on day 27, valproate, oxcarbazepine, pentobarbital, levetiracetam and topiramate 
were stopped and intravenous midazolam was added to phenytoin, which was continued. 
Epileptic activity reappeared, however, and pulse therapy with methylprednisolone was 
initiated from day 35 to day 40. On day 41, oral carbamazepine was added to midazolam 
and phenytoin. Intravenous midazolam was tapered from day 54 to 57 and replaced by oral 
lorazepam. The patient was discharged on day 61 without electroencephalographic 
evidence of epileptic activity. Her treatment at that time consisted of oral lorazepam, 
phenytoin and carbamazepine. 
It is noteworthy that the patient experienced variable degrees of sedation, but she could 
always be aroused during this treatment, even when the highest midazolam doses (4 
mg/min) were infused. Bonati et al. already described the same patient in a report focussing 
on the EEG findings (Bonati et al., 2006). 
 
 
6.5 Results 
Continuous infusion of midazolam at a rate of 1 mg/min led to high steady-state plasma 
concentrations of 860 ng/ml for midazolam, 433 ng/ml for 1´-hydroxymidazolam and 3608 
ng/ml for 1´-hydroxymidazolam glucuronide (Figure 1). In addition, minor amounts of 4-
hydroxymidazolam could be detected. After dose reduction, plasma concentrations of 
midazolam and metabolites decreased accordingly. 
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Figure 1. Plasma concentrations of midazolam, its hydroxymetabolites and 1´-hydroxymidazolam 
glucuronide. The determinations were performed using liquid chromatography-mass 
spectrometry/mass spectometry. 
 
 
After stopping the continuous infusion on day 57, the half-life (t½) of midazolam was found 
to be in the range of 24 h (Figure 1; Table 1), which is much longer than the t½ of 1.8 to 3.5 
h after common therapeutic doses of midazolam (Gorski et al., 2003; Klotz and Ziegler, 
1982; Tsunoda et al., 1999). In accordance with, and as a possible explanation of the long 
t½, the volume of distribution (Vss) of midazolam was found to be 33 l/kg, a value up to 30 
times higher than after common therapeutic doses (Table 1) (Gorski et al., 2003; 
Kupferschmidt et al., 1995; Tsunoda et al., 1999; Vree et al., 1989). As a possible 
explanation for this increase in Vss, the unbound fraction (fu) of midazolam was very high 
(58% versus 3-6% at a therapeutic dosage), compatible with saturation of the protein-
binding sites. This statement is further substantiated by the drop in the free fraction of 
midazolam with decreasing midazolam dose rate (Figure 2). For 1´-hydroxymidazolam, the 
protein-binding was generally lower than for midazolam, a finding most probably explained 
by its lower lipophilicity, and showed no saturation at high concentrations (Figure 2). 4-
Hydroxymidazolam showed protein-binding properties similar to 1´-hydroxymidazolam (data 
not shown).  
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Table 1. Pharmacokinetic parameters of Midazolam* 
Parameter Patient Comparative values 
Css (ng ml-1)  860  116-2817 (Dirksen et al., 1987; Vree et al., 1989) 
fu (%)    58  3-6 (Fragen, 1997) 
CLss (ml min-1) 1160  240-620 (Gorski et al., 2003; Klotz and Ziegler, 1982; Lee et al., 2002; Tsunoda et al., 1999) 
CLint (ml min-1 kg-1) 138  13.3 (Tsunoda et al., 1999) 
Vss (l kg-1) 33  1.0-3.3 (Gorski et al., 2003; Kupferschmidt et al., 1995; Tsunoda et al., 1999) 
Ehep       0.76 0.25-0.44 (Lee et al., 2002; Masica et al., 2004; Thummel et al., 1996) 
ke (h-1)       0.03 
0.09-0.19 (Vree et al., 1989);  
0.34 (Kupferschmidt et al., 1995) 
t½ (h) 24  
1.8-3.5 (Gorski et al., 2003; Klotz and Ziegler, 1982; 
Tsunoda et al., 1999);  
3.7-9.4 (Vree et al., 1989) 
CLm (1´-hydroxymidazolam)  
(ml min-1 kg-1) 
   2.9  na 
CLm (1´-hydroxymidazolam 
glucuronide) (ml min-1 kg-1) 
16.4  na 
* Steady-state values were determined at a midazolam dose rate of 1000 µg/min on November 9, 2006.  
Css, steady state plasma concentration; fu, free fraction; CLss, total blood clearance in steady-state; CLint, intrinsic 
hepatic clearance; Vss, volume of distribution in steady-state; Ehep, hepatic extraction ratio; ke, terminal 
elimination constant; t½, terminal elimination half-life; CLm, formation clearance. Comparative values are values 
published from studies with healthy volunteers or with patients as indicated by the references; na, not available. 
 
 
Despite the prolonged half-life, total body clearance (CLss) of midazolam was 19 ml/min/kg, 
which is much higher than usual clearance values at therapeutic doses (Gorski et al., 2003; 
Klotz and Ziegler, 1982; Lee et al., 2002; Tsunoda et al., 1999) and which was approaching 
the blood flow across the liver (Table 1). The intrinsic hepatic clearance (CLint), calculated 
according to equation (5), reached a value of 138 ml/min/kg. This value is approximately 10 
times higher than after common therapeutic doses (Table 1), demonstrating hepatic CYP3A 
induction. The product of the free fraction of midazolam and the intrinsic hepatic clearance 
of midazolam (fu x CLint) was found to be substantially larger than the blood flow across the 
liver:  
min
ml25.5
min
ml80.0
kgmin
ml1380.58CLf intu >>=⋅×=×  
According to equation (6), the hepatic extraction ratio (Ehep) was calculated to be 0.76. This 
value is approximately 100% higher than the values observed after common therapeutic 
doses of midazolam in normal subjects (see Table 1) (Lee et al., 2002; Masica et al., 2004; 
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Thummel et al., 1996) again demonstrating hepatic CYP3A induction. The formation 
clearance of 1´-hydroxymidazolam was 2.9 ml/min/kg (fm =0.15) and for the main metabolite 
1´-hydroxymidazolam glucuronide 16.4 ml/min/kg (fm=0.85). 
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Figure 2. Plasma concentrations of total and free midazolam (A) and total and free 1´-
hydroxymidazolam (B). The respective free fractions are given as a percentage of the total 
concentration. The determinations were performed using liquid chromatography-mass 
spectrometry/mass spectometry after ultrafiltration of the plasma. 
 
 
 
6.6 Discussion 
We describe a patient with refractory focal NCSE for weeks, who was treated with multiple 
antiepileptic drugs. In addition to carbamazepine, phenytoin and methylprednisolone, all 
including CYP3A, and thereby increasing the clearance of midazolam (Backman et al., 
1996b; Nakajima et al., 1999), midazolam was administered at very large doses (up to 4 
mg/min) as a continuous infusion for approximately 30 days. To our knowledge, there are 
no other reports in the literature describing the administration of similarly high cumulative 
doses of midazolam in critically ill patients. Taking into account the possible development of 
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tolerance with long-term use of high doses of midazolam (Bateson, 2002), such high doses 
of midazolam may have been necessary to control seizure activity in this patient. 
As mentioned earlier, midazolam is highly bound to plasma protein (94-97%), primarily to 
albumin (Fragen, 1997). Before the continuous midazolam infusion of 1 mg/min 
(administered for the last 4.5 days before November 9, 2006) was tapered, an unbound 
midazolam fraction of 58% could be measured in our patient, which is much higher than the 
3 to 6% observed after therapeutic dosages. Possible explanations were displacement by 
other drugs or endogenous substances, a very low serum albumin concentration or 
saturation of the protein binding resulting from the high midazolam concentration. The 
slightly decreased serum albumin concentration (26 g/l) was considered to contribute, but 
not to offer a full explanation for this finding (Vree et al., 1989). Competition with another 
drug could also not be ruled out completely, because phenytoin is also highly bound to 
albumin. After stopping the administration of midazolam, however, the free fraction of 
midazolam (fu) significantly dropped (from 58% to approximately 9%), although the serum 
albumin concentration remained low and phenytoin continued to be administered, indicating 
that saturation of the protein binding of midazolam contributed most to this finding. 
As expected regarding the high free fraction of midazolam and hepatic CYP3A induction, 
the calculated total body clearance (CLss) of 1160 ml/min was much higher than reported 
after therapeutic doses in healthy volunteers (Table 1) and in most patients in intensive care 
units who were described in the literature. Gorski et al. administered intravenous midazolam 
to healthy subjects before and after pre-treatment with the CYP3A inducer rifampicin and 
could demonstrate an increase in total body clearance of midazolam from 470 ml/min at 
baseline to 920 ml/min in men and from 430 ml/min to 1120 ml/min in women (Gorski et al., 
2003). They calculated a hepatic extraction ratio (Ehep) of 0.6 and concluded that the hepatic 
clearance remained sensitive to increases in the intrinsic hepatic clearance and is not 
limited by hepatic blood flow. Our patient was treated concomitantly with carbamazepine 
and phenytoin, most probably leading to maximal CYP3A induction. Accordingly, the total 
body clearance in our patient had reached a value close to the estimated hepatic blood 
flow, and the product of the free fraction of midazolam and the intrinsic hepatic clearance 
CLint of midazolam (fu x CLint) of 80 ml/min/kg exceeded hepatic blood flow (estimated to be 
25.5 ml/min/kg (Wynne et al., 1989)) by far. The interpretation of this finding is that the 
hepatic clearance of midazolam can become limited by hepatic blood flow in patients 
treated with very high midazolam doses and induction of CYP3A. In accordance with this 
interpretation, a very high hepatic extraction ratio (Ehep) of 0.76 could be calculated (Delco 
et al., 2005). 
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The determined intrinsic hepatic clearance (CLint) of 138 ml/min/kg in our patient is much 
higher than reported in healthy volunteers receiving a single dose of midazolam. Tsunoda et 
al. reported a mean value for CLint of 13.3 ml/min/kg (Tsunoda et al., 1999) after a single 
intravenous midazolam dose in healthy volunteers. Therefore, we believe that the CYP3A 
isozymes of our patient were induced substantially. At this point, it has to be mentioned that 
we applied a conservative estimation of the hepatic blood flow; other authors (Thummel et 
al., 1996) suggested 21.6 ml/min/kg (1296 ml/min in our patient), which would result in a 
higher estimate of CLint. 
Despite of the high total body clearance of midazolam, we observed a markedly prolonged 
t1/2 of 24 h. This value can be explained by the large volume of distribution Vss of midazolam 
in our patient. An increase in the volume of distribution after high doses of midazolam has 
been described in other reports (Malacrida et al., 1992; Oldenhof et al., 1988; Vree et al., 
1989). Such an increase can be explained by the high free concentration of midazolam 
resulting from saturation of its protein binding, possibly leading to widespread distribution of 
midazolam in deep body compartments. Accordingly, prolonged terminal half-lifes, varying 
from 2 h to 53 h, have been reported in patients in intensive care units treated with 
intravenous midazolam (Fragen, 1997; Naritoku and Sinha, 2000; Oldenhof et al., 1988; 
Vree et al., 1989). However, to the best of our knowledge, such a large Vss as observed in 
our patient has so far not been reported. 
As could be demonstrated by our case report, dose-dependent pharmacokinetics and 
therefore prolongation of the half-life of midazolam can occur in patients in intensive care 
units even if they have normal renal and hepatic function. The dose-dependent prolongation 
of the half-life of midazolam may lead to extended sedation in individuals susceptible to the 
benzodiazepine effects (Spina and Ensom, 2007). Patients with low serum albumin levels 
may be at a particularly high risk because of their low binding capacity for midazolam. The 
determination of a pharmacokinetic profile of midazolam in an individual patient may 
therefore be helpful to rule out or to substantiate the suspicion of midazolam-associated 
prolonged sedation. On the other hand, single plasma concentrations appear not to be very 
helpful for guiding the midazolam administration in such patients as a result of the lack of 
appropriate reference values and a large interindividual variability towards the central 
effects of this drug. 
In conclusion, we presented a patient with refractory focal NCSE who was treated with 
carbamazepine, phenytoin, methylprednisolone, and very high doses of midazolam over 
weeks. We observed a substantially prolonged terminal half-life of midazolam, mainly due to 
an extraordinarily large volume of distribution caused by saturation of protein binding. The 
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hepatic clearance of midazolam appeared to be limited by liver blood flow and the high 
intrinsic hepatic clearance suggested a substantial induction of CYP3A. 
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7 Conclusions and Outlook 
The aim of an ideal drug therapy is to provide the patient with the most efficient and safest 
treatment possible. In this context, pharmacotherapy should also be as price effective as 
possible to avoid cost explosion in health care. The most efficient treatment considers 
mainly pharmacodynamic parameters, whereas the safest outlines mostly the 
pharmacokinetic aspects of an administered drug.  
Currently, most medications are dosed based upon the assumption that each individual 
metabolizes drugs at approximately the same rate. However, patients are often showing 
pronounced interindividual differences of both the intensity and duration of drug action and 
side effects, when receiving the same ("standard") dose of a drug. One mechanism leading 
to those inter-patient differences is the variability in drug metabolizing enzyme activity, 
and/or the alteration of these enzymes, which may lead to unwanted therapeutic outcomes 
such as lack of efficacy or harmful response due to sub-therapeutic or toxic drug levels. 
Both extremes may incur in relevant health care costs.  
Among the drug metabolizing enzymes, Cytochrome P450 enzymes - and especially 
CYP3A, which is the most important subfamily of these enzymes - play a pivotal role in the 
elimination process. Of the currently marketed drugs, more than 50% are metabolized by 
CYP3A. Furthermore, it is well known that the enzyme is prone to be involved in clinically 
significant interactions. Many different factors (such as genetic polymorphism, age, gender, 
disease status, concomitant drug therapy and dietary interactions) may influence the 
hepatic and intestinal CYP3A activity which makes the dosing and therapeutic use of many 
CYP3A substrates difficult, especially those with a narrow therapeutic range. Therefore, the 
direct assessment of the functional CYP3A activity ("Phenotyping") might be helpful to 
predict enzyme induction or inhibition, to improve the therapeutic outcome, by minimizing 
side effects and maximizing therapeutic efficiency, and might be also useful for guiding 
therapeutic dosing.  
 
Among several possible CYP3A phenotyping probes, midazolam clearance represents one 
of the most reliable of the available methods, however, necessitating serial intravenous 
blood samples and mainly the administration of therapeutic doses. This thesis wants to 
provide improved CYP3A phenotyping procedures, which are easy to perform, safe for the 
patient, less/non-invasive and suitable for the screening of a larger patient population. To 
develop such alternatives, very sensitive analytical methods are required to detect and 
quantify the analytes of interest in different biological matrices. The validated LC-MS/MS 
methods described in this work, enables to measure midazolam, and to our knowledge for 
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the first time both of its major metabolites, 1´-hydroxymidazolam and 4-hydroxymidazolam 
in plasma and oral fluid at pg/ml levels. This allows on one hand for low-dose phenotyping, 
which is less objectionable to the subjects as compared to using therapeutic doses and 
which might be of special importance when phenotyping special populations such as elderly 
patients. On the other hand this opens the possibility to investigate the usefulness of saliva 
as matrix for non-invasive CYP3A phenotyping. In recent years, saliva has gained more and 
more interest as an alternative biological matrix for therapeutic drug monitoring and 
detection of illicit drugs since in principle, salivary drug concentration correlates with the 
free, pharmacologically active concentration of drugs in plasma, which may reflect for 
certain drugs, the drug effect better than the total plasma concentration. 
Applying the herein described analytical methods to a randomized, two-way cross-over 
study, provided evidence that MDZ and 1´-OHMDZ can be determined reliably in saliva and 
that the concentrations in saliva correlate well with those in plasma both after intravenous 
and oral administration of MDZ. In this work we could show, that MDZ kinetics in saliva may 
be a useful tool to differentiate between constitutive and induced CYP3A activity. 
Consequently, saliva appears to be a suitable matrix for non-invasive CYP3A phenotyping 
using midazolam as a probe drug. Further studies in this field should be conducted to 
evaluate the most suitable sampling strategy and to investigate whether inhibition of the 
CYP3A activity could be assessed in saliva as well. 
 
In conclusion, this thesis offers improved CYP3A phenotyping procedures, thus opening 
new ways to further investigate CYP3A mediated drug interactions and to better predict 
individual drug responses. In the future, the procedures might also be helpful to guide 
individual therapeutic dosing. 
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Untersuchung einer vereinfachten, nichtinvasiven Methode zur in vivo 
Phänotypisierung von Cytochrom P450 3A4 in Speichel mittels Midazolam 
Bettina Link, Yvonne Zysset-Aschmann, Markus Wenk, Stephan Krähenbühl 
Klinik für Pharmakologie und Toxikologie, Universitätsspital Basel 
 
Synopsis 
Cytochrom P450 (CYP) 3A4 spielt eine entscheidende Rolle im oxidativen 
Fremdstoffmetabolsimus. Eine gleichzeitige Gabe mehrerer Arzneimittel, welche über 
CYP3A4 metabolisiert werden, kann zur Induktion oder Inhibition des Enzyms und damit zu 
potentiellen Interaktionen führen. Weiterhin charakteristisch ist die große interindividuelle 
Variabilität von CYP3A4. Da mehr als 50% aller therapeutisch eingesetzten Medikamente 
über CYP3A4 abgebaut werden, sind Kenntnisse über potentielle Interaktionen, und damit 
verbundenen unzureichenden Arzneimittelwirkungen oder Toxizität, von enormer klinischer 
Relevanz. 
Eine der bisher verlässlichsten CYP3A4 Phänotypisierungsmethoden stellt die Bestimmung 
der Midazolam Plasmaclearance dar. Leider ist diese Methode invasiv und zeitaufwändig, 
was den Einsatz als Screeningmethode limitiert. Könnte eine Korrelation zwischen der 
Midazolam Plasmaclearance und den Konzentrationen an Midazolam im Speichel 
festgestellt werden, könnte der Nachweis von Midazolam im Speichel eine einfache, 
nichtinvasive Alternative zur Bestimmung der CYP3A4 Aktivität in vivo darstellen. Hierzu 
wurden bisher noch keine Daten publiziert. 
Ziele der Studie 
Primäre Fragestellung 
Als Hauptziel der Studie soll geklärt werden, ob sich die Bestimmung der 
Midazolamkonzentration im Speichel zur nichtinvasiven Phänotypisierung von CYP3A4 in 
vivo eignet. 
 
 
Weitere Fragestellungen 
Von Interesse ist außerdem: 
• Wie die Kinetik von Midazolam im Speichel unter induzierten und nichtinduzierten 
Bedingungen, sowie nach p.o. und i.v. Applikation verläuft. 
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• Welche Metaboliten von Midazolam im Speichel identifiziert werden können und ob es 
einen Unterschied zwischen i.v. und p.o. Applikation gibt. 
• Ob es einen Zusammenhang zwischen dem Verhältnis von 6-β-Hydroxycortisol/Cortisol 
und der Midazolam Plasmaclearance bzw. der Clearance in Speichel unter induzierten 
und nichtinduzierten Bedingungen gibt. 
Studiendesign 
In einer randomisierten cross-over Studie mit 8 gesunden männlichen freiwilligen 
Probanden soll geklärt werden, ob sich die Messung von Midazolam im Speichel zur 
nichtinvasiven Phänotypisierung von CYP3A4 in vivo eignet. Hierzu erhalten die Probanden 
6 Tage lang einmal täglich 600 mg Rifampicin (hepatische und intestinale CYP3A 
Induktion). Vor und nach Induktion mit Rifampicin wird die Aktivität von CYP3A4 mittels 
eines Midazolamtests in Plasma und Speichel untersucht. Ausserdem soll zwischen 
intestinalem (p.o. Midazolam Applikation) und hepatischem Metabolismus (i.v. Midazolam 
Applikation) unterschieden werden. Zum Vergleich verschiedener 
Phänotypisierungsmethoden wird die Aktivität des Enzyms zudem über die renale 
Elimination von 6-β-Hydroxycortisol bestimmt.  
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Einleitung 
Die Cytochrom P450 (CYP) 3A Subfamilie spielt eine zentrale Rolle im oxidativen 
Fremdstoffmetabolismus. Etwa 30% aller P450 Enzyme in der Leber und 70% im 
menschlichen Dünndarm entfallen auf CYP3A (Thummel and Wilkinson, 1998). Sie 
besitzen eine breite Substratspezifität und metabolisieren mehr als 50% aller therapeutisch 
verabreichten Medikamente (Guengerich, 1999; Thummel and Wilkinson, 1998). Das 
wichtigste Isoenzym dieser Familie stellt CYP3A4 dar. Charakteristisch für CYP3A4 ist die 
stark ausgeprägte interindividuelle Enzymaktivität, die in der Leber bis zu 100-fach, im 
Darm bis zu 30-fach schwanken kann (Lee et al., 2002). Weiterhin hat sich gezeigt, dass 
eine gleichzeitige Gabe mehrerer Arzneimittel, welche über CYP3A4 abgebaut werden, 
häufig zur Induktion oder Inhibition des Enzyms und damit zu Arzneimittelinteraktionen 
führen kann (Dresser et al., 2000; Gorski et al., 2003). Daher ist es von großer klinischer 
Relevanz, die Aktivität des Enzyms zu bestimmen, um potentielle Drug-Drug Interaktionen 
und damit verbundene unzureichende Arzneimittelwirkung oder Toxizität verhindern zu 
können. 
Neben verschiedenen anderen Phänotypisierungsmethoden (z.B. Erythromycin, Cortisol 
oder Nifedipin als CYP3A4 Substrat) stellt die Midazolam (MDZ) Plasmaclearance bzw. das 
Verhältnis Midazolam/1’-Hydroxymidazolam eine der verlässlichsten Methoden zur 
quantitativen Bestimmung der in vivo Enzymaktivität dar (Streetman et al., 2000; Thummel 
et al., 1994a; Thummel et al., 1994b). Jedoch erfordert diese Methode eine Vielzahl an 
Blutproben über den Zeitraum der Studie, was den Einsatz als Screeningmethode limitiert.  
Es konnte gezeigt werden, dass das Verhältnis von Paraxanthin/Coffein im Speichel eine 
hohe Korrelation zum Verhältnis Paraxanthin/Coffein im Plasma und zur totalen Coffein 
Clearance aufweist und sich daher gut für die Bestimmung der in vivo CYP1A2 Aktivität 
eignet (Carrillo et al., 2000; Fuhr and Rost, 1994). Bisherige Untersuchungen in unserem 
Labor haben gezeigt, dass Midazolam, sowie dessen Hauptmetabolite 1’-
Hydroxymidazolam und 4-Hydroxymidazolam mittels LC-MS/MS auch im Speichel 
nachgewiesen werden können. Eine erste, kürzlich veröffentlichte Publikation hat dies 
bestätigt, jedoch konnte dort aufgrund zu weniger Probeentnahmen, sowie ungeeigneter 
Speichel-kollektionsgefässen, keine Korrelation zwischen der Konzentration an MDZ im 
Speichel und der MDZ Plasmaclearance festgestellt werden (Quintela et al., 2004). 
Ergebnisse aus einer bereits von uns durchgeführten Pilotstudie deuten darauf hin, dass 
eine Korrelation der Pharmakokinetik in beiden Matrices bestehen könnte. Falls sich diese 
Vermutung bestätigen würde, könnte der Nachweis von MDZ bzw. dessen Metaboliten im 
Speichel eine einfache, nichtinvasive und kostensparende Screeningmethode zur in vivo 
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Phänotypisierung von CYP3A4 darstellen, welche einfach auf eine große Anzahl an 
Probanden angewendet werden könnte. 
 
 
Ziele der Studie 
Primäre Fragestellung 
Als Hauptziel der Studie soll geklärt werden, ob sich die Bestimmung der 
Midazolamkonzentration im Speichel zur nichtinvasiven Phänotypisierung von CYP3A4 in 
vivo eignet. 
 
Weitere Fragestellungen 
Von Interesse ist außerdem: 
• Wie die Kinetik von Midazolam im Speichel unter induzierten und nichtinduzierten 
Bedingungen, sowie nach p.o. und i.v. Applikation verläuft. 
• Welche Metaboliten von Midazolam im Speichel identifiziert werden können und ob es 
einen Unterschied zwischen i.v. und p.o. Applikation gibt. 
• Ob es einen Zusammenhang zwischen dem Verhältnis von 6-β-Hydroxycortisol/Cortisol 
und der Midazolam Plasmaclearance bzw. der Clearance in Speichel unter induzierten 
und nichtinduzierten Bedingungen gibt. 
 
 
Studiendesign 
Geplant sind folgende 5 Studienphasen mit 8 gesunden männlichen Freiwilligen:  
Session 1:  Baselinemessung (Midazolam p.o.) 
 Induktionsphase, Messung nach Induktion (Midazolam p.o.) 
Wash out: Prüfen auf Andauer der CYP3A4 Induktion 
Session 2:   Baselinemessung (Midazolam i.v.) 
 Induktionsphase, Messung nach Induktion (Midazolam i.v.) 
Am Besprechungstag wird dem Probanden die Studie erklärt, die Ein- und 
Ausschlusskriterien geprüft und die Einwilligungserklärung eingeholt. Danach werden die 
Testsubstanzen, die Probenbehälter und Protokollblätter verteilt. 
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Die Studie beginnt mit einer Basislinienmessung, bei der die Aktivität von CYP3A4 ohne 
Modulation gemessen wird, gefolgt von einer Messung der Enzymaktivität nach Induktion 
mit Rifampicin. Das Design der Studie (randomized, cross-over) sieht vor, dass die Hälfte 
der Freiwilligen zuerst mit der p.o. Applikation beginnen (Session 1 gefolgt von einer wash 
out Phase), während die andere Hälfte zunächst i.v. (Session 2 gefolgt von einer wash out 
Phase) behandelt wird. Nach der wash out Phase wird der Proband mit der jeweils noch 
verbleibenden Applikationsart behandelt. Die Probanden werden mittels Los in die 
entsprechenden Gruppen eingeteilt. 
Abbildung 1 und Tabelle 1 veranschaulichen den genauen Studienverlauf für Probanden, 
die mit p.o. Applikation beginnen. 
 
Basislinienmessungen 
Der Proband erhält am Morgen des Versuchstages 7,5 mg Midazolam (Dormicum®) p.o. auf 
nüchternen Magen. Zu folgenden Zeitpunkten werden Blutproben (jeweils 5,5 ml) zur 
Bestimmung der Midazolamkonzentration über einen Venenkatheter entnommen: 0, 10, 20, 
30, 40, 60, 90, 120, 180, 240, 480, 600 min nach Applikation. Eine zusätzliche Blutprobe 
wird 24 Stunden nach Applikation von Midazolam entnommen. 
Speichel (jeweils 2-5 ml) zur Bestimmung der Midazolamkonzentration wird in 
Speichelröhrchen 0, 15, 30, 40, 60, 80, 100, 120, 150, 180, 240, 360 und 480 min nach 
Applikation gesammelt.  
Zur Bestimmung des Verhältnisses 6-β-Hydroxycortisol/Cortisol wird der Morgenurin, für 
das Verhältnis 1’-Hydroxymidazolam/Midazolam der Urin zwischen 0-8 und 8-24 Stunden 
nach Midazolamapplikation gesammelt. 
Eine zweite Basislinienmessung wird nach einer i.v. Dosis von 2 mg Midazolam 
durchgeführt. Blutproben werden am contra-lateralen Arm zu folgenden Zeitpunkten 
entnommen: 0, 5,10, 20, 30, 40, 60, 90, 120, 240, 480 und 600 min. Eine zusätzliche 
Blutprobe wird 24 Stunden nach Applikation von Midazolam entnommen. Alle weiteren 
Konditionen folgen dem p.o. Protokoll. 
 
Induktionsphase 
Zur Induktion von CYP3A4 erhalten die Probanden an 6 aufeinanderfolgenden Tagen 600 
mg Rifampicin (Backman et al., 1998; Eeckhoudt et al., 2001; Kharasch et al., 2004; Niemi 
et al., 2003) einmal täglich morgens 30 min vor der Mahlzeit, beginnend am Studientag 2 
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(bzw. 44). Am Studientag 8 (bzw. 50) wird der gleiche Vorgang analog zur 
Basislinienmessung wiederholt (jeweils für i.v. und p.o.). 
 
Wash out Phase 
Zur Wiederherstellung der ursprünglichen CYP3A4 Aktivität (vor der Induktion) schließt sich 
eine wash out Phase an (Backman et al., 1998; Fromm et al., 1996; Niemi et al., 2003; 
Villikka et al., 1999). Da keine konkreten Daten vorhanden sind, wie lange die Induktion von 
CYP3A4 in vivo anhält, wird bei allen Probanden nach 7, 14, 21 und 28 Tagen nach 
Absetzen der Rifampicintherapie nochmals 7,5 mg MDZ p.o bzw. 2 mg MDZ i.v. verabreicht 
(je nachdem in welcher Gruppe sich der Proband befindet), und aus Plasma eine reduzierte 
Kinetik aufgenommen. Blut- und Speichelproben werden zu den Zeitpunkten t=30, 60, 90 
und 120 min entnommen. Zudem wird zur Bestimmung des Verhältnisses 6-β-
Hydroxycortisol/Cortisol der Morgenurin gesammelt. 
Die verbleibende Applikation erfolgt frühestens 4 Wochen nach Absetzen der 
Rifampicintherapie abhängig von den gewonnenen Daten. 
 
Applikation po 
 
 
 
 
 
 
 
Applikation iv 
 
 
 
 
 
 
 
 
 
Abbildung 1. Schematische Darstellung des geplanten Studienablaufs Studiendesigns für die 
Gruppe, welche mit der p.o. Applikation beginnt (* abhängig von Andauer der Induktion). 
Tag 1 
MDZ 7,5 mg Tabl. 
2 
Baseline po 
measurement 
8 
Rifampicin 600 mg po 
Induction phase 
MDZ 7,5 mg Tabl. 
Measurement po 
after induction 
9 
Wash out 
42* 
Tag 43* 
MDZ 2 mg Infusion 
44* 
Rifampicin 600 mg po 
50* 
MDZ 2 mg Infusion. 
Baseline iv 
measurement 
51* 
Induction phase 
Measurement iv 
after induction 
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Tabelle 1. Zusammenfassung des Studiendesigns für die Gruppe, welche mit der p.o. Applikation 
beginnt (* abhängig von Andauer der Induktion) 
 
Studienphase Tag Medikation Maßnahmen 
Besprechungstag   Information 
Basislinienmessung 
nach p.o. Applikation 
1  Sammeln des Morgenurins für Cortisolmessungen 
  Entnahme von Blankspeichel, -plasma und -urin 
Kinetik p.o.  7.5 mg p.o. 
Midazolam 
Blutentnahme für MDZbestimmung zu t=10, 20, 
30, 40, 60, 90, 120, 180, 240, 360, 480, 600 min 
   Speichelentnahme für MDZbestimmung zu t= 10, 
30, 40, 60, 80, 100, 120, 150, 180, 240, 360, 480 
min 
   Sammeln des Urins zwischen 0-8h, 8-24h  
 2  MDZ Plasmakonzentration nach 24h 
Induktion 2-7 600 mg p.o. für 
6 Tage 
 
 8 Sammeln des Morgenurins für Cortisolmessungen 
Entnahme von Blankspeichel, -plasma und –urin,  
Kinetik p.o. nach 
Induktion 
 7.5 mg p.o. 
Midazolam 
Blut-, Speichel- und Urinentnahmezeitpunkte für 
MDZbestimmung analog p.o. Basislinienmessung 
 9  MDZ Plasmakonzentration nach 24h 
 
Wash out  
Überprüfen der Andauer 
der CYP3A4 Induktion im 
Abstand von je einer 
Woche 
8-42* 7.5 mg MDZ 
p.o. oder 2 mg 
i.v. (abhängig 
von der Proban-
dengruppe)  
Sammeln des Morgenurins für Cortisolmessungen 
Blut- und Speichelentnahme für MDZbestimmung 
zu t=30, 60, 90, 120 min 
 
Basislinienmessung 
nach i.v. Applikation 
43*  Sammeln des Morgenurins für Cortisolmessungen 
  Entnahme von Blankspeichel, -plasma und -urin 
Kinetik i.v.  2 mg i.v. 
Midazolam 
Blutentnahme für MDZbestimmung zu den 
Zeitpunkten: 5, 10, 20, 30, 40, 60, 90, 120, 240, 
360, 480, 600 min 
   Speichelentnahme für MDZbestimmung zu den 
Zeitpunkten: 10, 20, 30, 40, 60, 80, 100, 120, 150, 
180, 240, 360, 480 min 
   Sammeln des Urins zwischen 0-8h, 8-24h  
 44*  MDZ Plasmakonzentration nach 24h 
Induktion 44-
49* 
600 mg p.o. für 
6 Tage 
 
  Sammeln des Morgenurins für Cortisolmessungen 
Entnahme von Blankspeichel, -plasma und –urin  
Kinetik i.v. nach Induktion 50* 7.5 mg i.v.. 
Midazolam 
Blut-, Speichel- und Urinentnahmezeitpunkte für 
MDZbestimmung analog i.v. Basislinienmessung 
   MDZ Plasmakonzentration nach 24h 
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Der Proband erhält während des Studientages ein standardisiertes Frühstück (2 Stück Brot, 
20 g Butter, Schinken, Marmelade, Früchtetee) 2,5 Stunden nach Midazolam-applikation 
und ein standardisiertes Mittagessens (mageres Stück Fleisch, Salat, Brot, Wasser oder 
Früchtetee) 5 Stunden nach Medikamentengabe. 
 
 
Probanden 
Einschlusskriterien 
• Vorgesehen sind 8 gesunde männliche Freiwillige  
• Unterzeichnete Einverständniserklärung 
 
Ausschlusskriterien 
• Überempfindlichkeit gegenüber den Wirkstoffen Midazolam oder Rifampicin 
• Einnahme von Arzneistoffen, welche zu einer Induktion und/oder Inhibition von 
CYP3A führen könnten 14 Tage vor Beginn und während Andauer der Studie 
• Einnahme von grapefruithaltigem Essen oder Getränken 5 Tage vor und während 
des Studientages 
• Bekannte Leber- oder Nierenfunktionsstörungen, sowie respiratorische Insuffizienz 
• Patienten, welche in der Vergangenheit und aktuell alkohol- oder drogenabhängig 
waren oder sind 
• Überdurchschnittlicher Alkoholkonsum (> 2 Gläser Wein/d) 
• Rauchen  
• Alter über 50 
 
Eingangsuntersuchung 
Die Eingangsuntersuchung wird folgende Maßnahmen umfassen: 
• Aufnahme der Krankengeschichte, aktuelle Medikation, Erfassung des Gewichts 
• Laboranalyse: Hb, Albumin, Serumglucose, Quick, Bilirubin, ALAT, alkalische 
Phosphatase, GGT, Kreatinin 
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Probenahme und Aufbewahrung der Proben 
Blutproben werden in heparinisierten Monovetten (je 5,5 ml) gesammelt, zentrifugiert und 
das separierte Plasma bei –70°C in Polypropylen(PP)gefässen bis zur Analyse gelagert. 
Speichelproben (je 2-5 ml) werden in Speichelröhrchen gesammelt, zentrifugiert und der 
klare Überstand bei –70°C in PPgefässen bis zur Analyse gelagert. 
Urinproben (10ml) werden bei –70°C in PPgefässen bis zur Analyse gelagert. 
 
Eigenschaften der Wirkstoffe 
Dormicum® ist ein rasch wirksames Einschlafmittel, das zur Kurzzeittherapie von 
Schlafstörungen eingesetzt wird. Daneben besitzt das Medikament auch angstlösende und 
muskelentspannende Eigenschaften. 
Rimactan® ist ein Antibiotikum, das zur Therapie von Tuberkulose sowie Lepra eingesetzt 
wird. 
Beide Medikamente werden seit Jahren verwendet und deren erwünschte, sowie 
unerwünschte Wirkungen sind gut bekannt (s.a. Patientensicherheit). 
 
Pharmakokinetik 
Zur Berechnung der Fläche unter der Konzentrations-Zeit-Kurve (’area under the curve, 
AUC 0-24h für Plasma und 0-8h für Speichel) wird die Trapezregel angewendet. Die 
maximale Konzentration (cmax) im Plasma und im Speichel, sowie deren Zeitpunkt (tmax) wird 
direkt aus der Konzentrations-Zeit-Kurve abgelesen. Ebenso von Interesse ist die 
Eliminationshalbwertszeit (t1/2) von Midazolam, die hepatische und intestinale Midazolam 
Plasmaclearance, sowie die systemische und orale Bioverfügbarkeit. Ausserdem wird das 
Verhältnis Midazolam/1’-Hydroxymidazolam bestimmt. 
 
 
Analytische Methoden 
Midazolam und Metabolite 
Midazolam und dessen Metabolite werden aus Plasma und Speichel (und evt. Urin) mittels 
flüssig-flüssig Extraktion extrahiert und gemäß eines in unserem Labor erstellten und 
validierten Protokolls mit HPLC-MS/MS analysiert. 
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Cortisol 
Cortisol und 6-β-Hydroxycortisol im Urin werden nach Festphasenextraktion mittels HPLC-
UV gemessen (Vrtic et al., 2003). 
 
 
Statistik 
Die Daten werden vom Investigator selbst ausgewertet. Die Statistik wird mittels SPSS- 
Software für PC’s durchgeführt. Untersucht wird primär die Aktivität von CYP3A4 mittels 
metabolischer (MDZ) und endogener Testsubstanz (Cortisol) sowohl nach p.o. als auch 
nach i.v. Applikation jeweils vor und nach Induktion mit Rifampicin. Die Änderungen werden 
mittels paired Tests untersucht mit einer Signifikanzschwelle von 5%.  
 
 
Ethische Überlegungen 
Patientensicherheit  
Die in der Studie verwendeten Wirkstoffe Midazolam (Dormicum®) und Rifampicin 
(Rimactan®) werden seit vielen Jahren verwendet. Die erwünschten und unerwünschten 
Wirkungen sind gut bekannt.  
Hohe Blutkonzentrationen von Midazolam können zu Müdigkeit und Schläfrigkeit führen. 
Selten wurde bei Patienten Amnesie beobachtet, die jedoch rasch reversibel verläuft. Bei 
besonders empfindlichen Menschen oder bei Überdosierung kann es zu einer verminderten 
Atemtätigkeit kommen, welche jedoch während der Studie überwacht wird. Falls sie unter 
einen bestimmten Wert fallen sollte, wird als Gegenmassnahme ein zweites Medikament 
(Flumazenil, Anexate®) verabreicht, welches den Effekt von Dormicum® aufhebt. 
Unter der Gabe von Rifampicin können sich Körperflüssigkeiten wie Speichel, Urin oder 
Tränenflüssigkeit rötlich anfärben. Dieser Effekt ist völlig ungefährlich und verschwindet 
nach Absetzen des Medikaments vollständig. Weiterhin können Beschwerden wie 
Appetitlosigkeit, Übelkeit, Müdigkeit, asymptomatische Veränderung der Leberenzyme und 
Kopfschmerzen sowie Juckreiz und vorübergehende Veränderungen des Blutbildes 
auftreten. In seltenen Fällen werden auch grippeähnliche Symptome beobachtet, die dem 
Studienarzt gemeldet werden sollten. Besondere Vorsicht ist geboten bei Polymedikation, 
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da Rifampicin aufgrund seiner induzierenden Wirkung, die Wirksamkeit vieler Arzneimittel 
herabsetzen kann. 
Das Legen der Venenkanüle(n), sowie die Blut-, Speichel- und Urinentnahmen sind mit 
keinem nennenswerten Risiko verbunden. 
 
Versicherung 
Die Probanden sind über eine Haftpflichtversicherung des Universitätsspitals Basel 
versichert. 
 
Entschädigung und Nutzen 
Der Proband hat von der Studie keinen direkten Nutzen, abgesehen von einer 
Entschädigung in Höhe von Fr 500. Im Falle eines vorzeitigen Studienabbruchs, wird diese 
Entschädigung anteilsmäßig ausbezahlt. 
 
Teilnahme und Gründe für einen vorzeitigen Studienabbruch 
Die Teilnahme an der Studie ist freiwillig. Der Proband hat jederzeit das Recht, die 
Studienteilnahme ohne Angabe von Gründen abzubrechen, ohne dass ihm dadurch ein 
Nachteil für seine weitere medizinische Betreuung entsteht. Jeder Teilnehmer bekommt 
sowohl eine mündliche als auch schriftliche Erklärung zur Studie. Außerdem wird ihm eine 
schriftliche und unterschriebene Einverständniserklärung ausgehändigt. 
Der Prüfarzt kann, falls er es für nötig erachtet, den Probanden im Interesse seiner 
Gesundheit aus dieser Studie auschliessen. 
 
Vertraulichkeit und Schutz der Daten 
Alle in dieser Studie gewonnenen Informationen und Aufzeichnungen über den Probanden 
werden vertraulich behandelt. Die Resultate, die aus der Studie gewonnen werden, werden 
nur ohne Namensnennung in einer wissenschaftlichen Publikation veröffentlich werden.  
 
Finanzierung 
Die Studie wird finanziert über die Klinik für Pharmakologie und Toxikologie des 
Universitätsspitals Basel. 
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